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Abstract 
Aims: Poorly designed, analyzed and reported preclinical in vivo experiments (inVivoExp) raise 
ethical as well as scientific concerns. It could be hypothesized that the recurring failure of apparently 
promising interventions to improve outcome in clinical trials has been partially caused by poor 
quality of statistical design and analysis (QoStat) of inVivoExp. This project aimed to assess and 
correlate QoStat with clinical activity, and to improve the statistical framework used in inVivoExp. 
Methods: A systematic search of Medline and EMBASE databases was carried out to identify 
epithelial ovarian cancer clinical trials assessing the antitumor activity of candidate compounds (CC) 
as monotherapy. For each eligible CC, a systematic search was carried out to identify scientific 
papers reporting inVivoExp on rats and mice, in which the CC was administered as monotherapy. An 
ad hoc checklist was used to assess QoStat of inVivoExp. QoStat was correlated to the clinical 
activity. 
Results: Fifty-two eligible CCs and 121 inVivoExp were identified. In 45 out of 120 (37.5%) inVivoExp 
the method of treatment assignment was not specified. The randomization type was specified in 3 
out of 74 (4.1%) inVivoExp and sample size was justified in 9 (7.4%) inVivoExp. If the primary 
outcome was tumor volume, the antitumor activity endpoint was declared in 14 out of 106 (13.2%) 
inVivoExp. The length of follow-up was specified in 43 (35.5%) inVivoExp. Outcome assessor was 
blinded in 5 (4.1%) inVivoExp. Inefficient statistical methods were often applied to analyze tumor 
growth data. A new statistical framework based on the Mann-Whitney statistic was proposed and 
applied to a specific tumor model. 
Conclusions: QoStat of inVivoExp was so poor that the correlation with clinical activity was 
impossible. The magnitude of the biological signal was poorly estimated. The new statistical 
framework should be considered for the design and analysis of in vivo tumor growth studies. 
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Chapter 1 
Introduction 
1.1 Drug development in Oncology 
Drug development is the process of bringing a new pharmaceutical drug to market once a candidate 
compound (CC, i.e. new chemical entity) has been identified. This process is essentially a set of 
applied methodologies that cover a wide range of objectives: the identification of targets, the 
identification of drug concentrations required for targets’ inhibition and modulation, the 
assessment of drug pharmacokinetics and pharmacodynamics, the assessment of safety, activity 
and favorable or negative effects on clinical endpoints. This process is an interdisciplinary endeavour 
involving a multitude of professional figures from biologists, chemists, computer scientists, medical 
staff, statisticians, and regulatory experts. This process is time consuming and expensive. It can take 
10 to 15 years and an average estimated cost exceeding USA $1 billion (Morgan et al., 2011; Rick, 
2015; DiMasi et al., 2016). This process is also competitive. The purpose of drug development is to 
select from millions of CCs those that most effectively and safely offer clinical benefit. Finally, this 
process is made up of a preclinical testing phase, in which in silico, in vitro and in vivo models are 
used, and a human testing phase, in which studies are conducted on human beings (i.e. clinical 
trials).  
What advantages are there to use preclinical models? First of all, simplifications and 
controllability are obtained. Hence, a mechanistic insight into the impact of CC on the evolution of 
a disease could be obtained. Second, biological science provides explicit justification to study 
diseases abstracted from the entire human organism. For example, it is well known that the 
essential elements of tumor growth lie within cells. Cancer cells have defects in regulatory circuits 
that govern normal cell proliferation and homeostasis (Hanahan et al., 2000). Hence, isolated cells 
or cell cultures are suitable objects for cancer research. As a third and last point, ethical and 
economic considerations request the use of preclinical models. Preliminary information about CCs’ 
safety and efficacy profile must be collected before a CC could be reasonably administered to a 
human being. Without this preliminary information obtained from preclinical models, it would be 
unethical to test unproven chemicals in humans (Garattini et al., 2017). Of course, these models 
must not be separated so far from reality that relevance to the ultimate goals of being better able 
to prevent the disease or improve treatment is lost, remembering that relevance of a result may not 
be evident initially. 
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In Oncology, the classic approach taken to identify chemotherapy drugs, requires that the CC 
is first evaluated against a panel of malignant cell lines, such as those used by USA National Cancer 
Institute (NCI-60, refer to the web site: https://dtp.cancer.gov/discovery_development/nci-
60/cell_list.htm. Developmental Therapeutics Program. National Cancer Institute. Last Updated: 8 
May 2015. Retrieved 01 September 2019). If the CC shows antitumor activity in the panel of cell 
lines, other in vitro studies are performed to determine its mechanism of action. New methods 
develop CCs in a different manner, namely targeting specific molecules or pathways known to have 
a role in tumor growth. These CCs can be identified in different ways, such as the screening of small-
molecule libraries or by computer-assisted protein-structured-based design. A biochemical or 
cellular assay is then required to evaluate the effects on the molecular target and those CCs that 
should undergo further development are selected. 
Biological differences between primary tumors and the cancer cell lines derived from them, 
limit the value of in vitro studies for the evaluation of CCs (Szakács et al., 2004). Once the target and 
mechanism of action have been identified using in vitro models, in vivo experiments are undertaken 
to ensure that inhibition of the target can be achieved at tolerated doses in vivo and to identify and 
validate predictive biomarkers of response. Chemotherapy drugs can be considered ‘targeted’ in 
that they inhibit DNA synthesis and the cell division apparatus. The theory behind the preclinical in 
vivo experimentation is to look for activity in in vivo models which would translate into some 
likelihood of activity in human disease. In vivo models are also required to evaluate CCs’ 
pharmacokinetics, CCs’ effects on biological processes such as invasion into neighboring tissues, 
angiogenesis, metastasis, and the relative effects of CCs against tumor cells compared to their 
toxicity in normal tissues (Ocana et al., 2010).  
Once preclinical in vivo experiments have been successfully performed, CCs could be 
administered in humans for the first time. When CCs reach the clinical setting, drug development 
proceeds through a series of sequential clinical phases designed to assess their safety and efficacy. 
The standard clinical paradigm for the evaluation of CCs consists of a phase I trial to establish the 
optimal dose, a phase II trial to obtain preliminary evidence of activity and a phase III trial for 
comparison with the standard therapy. In this approach, the phases I and II (exploratory trials) are 
for gathering information and screening the CC; the phase III (confirmatory trial) is for a definitive 
comparison with the standard therapy.  
In Oncology, phase II trials are an essential bridge between the small phase I trials, which 
determine the dose of antitumor CCs, and the large-scale and confirmatory phase III trials. The 
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primary aim of phase II trials is to screen CCs for their biologic antitumor activity. Secondary aims 
are the preliminary evaluation of CCs’ safety profile and predictive biomarkers.  
CCs’ antitumor activity is assessed using standardized response criteria. In solid tumors, the 
first international standardized response criteria were written and disseminated by the World 
Health Organization (WHO) in 1979 [World Health Organization. WHO Handbook for Reporting 
Results of Cancer Treatment Offset Publication No. 48. (WHO press, Geneva, 1979)]. Of primary 
relevance, the authors defined exactly what constitutes a response to treatment or progression of 
disease by standardizing the amount of tumor shrinkage necessary to qualify a patient for each of 
four categories: complete response (CR: disappearance of all known disease by two observations at 
least 4 weeks apart), partial response (PR: 50% or more decrease in total tumor size of the lesions 
that have been measured. No new lesions. No progression of any lesion), stable disease (SD: it 
cannot be established that the total size has decreased by at least 50%, nor has a 25% increase in 
the size of one or more measurable lesions been demonstrated) and progressive disease (PD: a 25% 
or more increase in the size of one or more measurable lesions or the appearance of new lesions). 
This answered an urgent need of medical oncology. Because single-arm, uncontrolled, Phase II trials 
were used to assess CCs’ antitumor activity, standards to compare responses across trials were 
urgently needed. Widespread application of the WHO criteria, however, brought to light some 
deficiencies/discrepancies. The reliability of the methodology both in terms of intraobserver as well 
as in terms of interobserver variability was questioned (Warr et al., 1984; Tonkin et al., 1985; Warr 
et al., 1985; Thiesse et al., 1997). Cooperative groups and pharmaceutical companies often 
‘modified’ original WHO criteria to accommodate new technologies for human cancer imaging or to 
address areas that were unclear in the original document. For example, the South West Oncology 
Group (SWOG) published their version of the WHO criteria in 1992 (Green et al, 1992). As a major 
change, a larger increase in tumor size (50%) was requested to define PD. In the same year, the 
European Organization for Research and Treatment of Cancer (EORTC) published its own version of 
the WHO criteria (Tumor eligibility and response criteria for phase II and III studies. Brussels: EORTC 
Data Center Manuel 1992), defining minimum sizes for lesions from different organs to be 
considered as measurable. Because different versions of the original WHO criteria were used in 
clinical trials, the comparison of results of clinical trials became very unreliable. In 1994, several 
clinical research organizations began updating the WHO standards and, 6 years later, published a 
new version, under the acronym RECIST (Response Evaluation Criteria In Solid Tumors, Therasse et 
al., 2000). The WHO and RECIST standards share the same principles, that is standardizing the 
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amount of tumor shrinkage necessary to qualify a patient for each of the previous four 
classifications. In RECIST criteria, the assessment of tumor lesions was simplified and better 
specified in order to address apparent deficiencies and lack of details of the WHO criteria. RECIST 
requires that certain lesions are identified as the key lesions that will track disease change; RECIST 
alters the definition of PR and PD and changes the way that lesions are measured (unidimensional 
versus bidimensional in the WHO criteria); the RECIST standards also update which imaging 
modalities are acceptable for measuring tumor size. In 2009, RECIST criteria were updated in the 
version 1.1 (Eisenhauer et al., 2009). Major changes were the reduction of the number of lesions to 
be assessed,  how to assess pathological lymph nodes was specified, the definition of PD was better 
specified, the confirmation of response was not requested anymore in randomized trials and, finally, 
what constitutes ‘unequivocal progression’ of non-measurable/non-target disease was explained. 
Whereas the RECIST criteria address many shortcomings of previous attempts to classify 
tumor response, they have limited utility in the evaluation of ovarian cancer. In recurrent ovarian 
cancer, a significant proportion of patients have only micro-nodular peritoneal carcinomatosis and 
ascites, which are non-measurable according to RECIST criteria. Because the RECIST criteria define 
tumor response on the basis of evaluation of measurable disease, it precludes its use in almost 50% 
of ovarian cancer patients (Rustin et al., 2004). To allow the inclusion of these patients, it was 
proposed that the CA-125 serum tumor marker could be utilised as a tumor response criterion. 
CA125 is a high molecular weight glycoprotein which is raised in approximately 90% of patients with 
advanced epithelial ovarian cancer (Bast et al., 1983). Many more patients are evaluable according 
to CA-125 than those assessed by computed tomography scanning used to assess standard (WHO 
or RECIST) response criteria (van der Burg et al., 1993; Pearl et al., 1994; Rustin et al., 1996;). 
Moreover, measurement of CA-125 is less expensive and more comfortable for patients than 
computed tomography scanning. Characterized in 1981, the CA-125 antigen has several important 
roles in the routine management of ovarian cancer patients and could be used as a prognostic 
marker (Rustin et al., 2004).  In 1996, Rustin et al. defined criteria for evaluating 50% and 75% 
response according to CA-125. Based on retrospective studies, the Gynecologic Cancer Intergroup 
(GCIG) proposed that a definition of ovarian tumor progression based on CA-125 doubling should 
be used in clinical trials of first-line therapies (Vergote et al., 2000). In addition to increasing the 
number of eligible patients for a given trial, it was suggested that utilisation of a composite 
definition of progression based on both RECIST and CA-125 criteria (instead of only one or the other) 
would increase the statistical power for tests of differences between trial arms regarding PFS (Rustin 
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et al., 2006). Thus, a public workshop sponsored by the US Food and Drug Administration, American 
Society of Clinical Oncology, and American Association for Cancer Research (FDA-ASCO-AACR) 
recommended CA-125 to be used as a surrogate marker of disease progression (Bast et al., 2007). 
They also proposed that CA-125 should be included as a part of a composite endpoint that includes 
radiological and clinical evaluation. 
There are two main types of endpoints based on standardized response criteria: binary and 
time-to-event. Binary endpoints include the Objective Response Rate (ORR, i.e. the proportion of 
patients whose tumor exhibits a PR or CR), and the Disease Control Rate (DCR, i.e. the proportion of 
patients whose tumor exhibits SD, PR or CR). Time-to-event endpoints include the progression-free 
survival (PFS) and the time-to-progression (TTP): the former measures time-to-tumor progression 
or death whichever occurs first, while the latter treats death as a censoring event. Based on 
antitumor mechanism, different endpoints could be used to detect CC’s antitumor activity. Broadly, 
ORR is considered suitable for cytotoxic drugs but less suitable for cytostatic agents (Adjei et al., 
2009; Sharma et al., 2012). PFS is said to be more informative for cytostatic agents (Seymour et al., 
2010).  
A recent survey (Hay et al., 2014) demonstrated that Oncology has one of the highest attrition 
rates in the drug development process. Oncology drugs have the lowest likelihood of success from 
phase I; only around 1 in 15 drugs (6.7%, n = 1.803) of all indication development paths in phase I 
were approved by FDA. In particular, the phase II success rate (i.e. the probability of a drug moving 
from phase II to phase III) was estimated at 28.3%. The unsatisfactory positive predictive value of 
phase II trials (i.e. the low probability of reaching market approval from the phase II) is explained by 
the following reasons: 
o The strength of activity signal obtained in phase II Oncology trials is often too low to cause a 
clinical benefit in large-scale and confirmatory phase III trials 
o The methodology applied to phase II Oncology trials is generally low-level. First, there is a 
lack of surrogate biomarkers that can be measured earlier than survival, and that can predict 
phase III outcome more reliably than conventional response criteria based on tumor size 
variations. Correlation with clinical endpoints does not mean surrogacy. Exactly 30 years ago, 
Prentice formulated the criteria to demonstrate the surrogacy of a biomarker (Prentice, 
1989). These criteria require thousands of patients enrolled in different clinical trials. To 
date, there are only a handful of accepted biomarkers that are established surrogate 
endpoints. In prostate cancer, for example, the prostate specific antigen (PSA) decrease has 
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been reasonably well validated in Phase III studies of cytotoxic agents, although there is 
debate on using this biomarker in exploratory trials (Stadler, 2002; Williams, 2018). Second, 
poor quality statistical designs have been traditionally used in phase II Oncology trials. The 
traditional single-arm phase II Oncology trial uses a historical response rate as the reference 
point by which improved response rate is judged. Outcomes of single-arm phase II trials 
reflect some combination of treatment effect, random effect, and unknown differences 
between treated and historical control patients. Recommendations have been produced to 
use randomization to protect against selection bias in phase II Oncology trials (Booth et al., 
2008; Ratain et al., 2009). Also dose-ranging, controlled phase II trials should receive 
considerable attention in order to determine the relationship between dose and CCs’ 
antitumor activity (Ratain, 2005; Michaelis et al., 2006). Finally, blinding techniques could be 
useful to prevent different types of biases (i.e. performance, assessment, and attrition 
biases. Table 1.2.1.1 reports their definition), especially for time-to-event endpoints such as 
PFS and TTP. Unfortunately, it is often difficult to apply blinding techniques in Oncology. For 
example, to mask devices, routes of administration and side effects such as myelosupression 
or nausea is often impossible and unethical  
o CCs are wrongly selected in the preclinical drug development or, at least, the positive 
predictive value (i.e. the probability of reaching market approval from the preclinical testing 
phase) of methodologies applied in the preclinical drug development, is unsatisfactory. 
1.2 Principles of methodology of preclinical in vivo experiments 
Animal experiments remain essential to understand the fundamental mechanisms underpinning 
malignancies and to discover and screen methods to prevent, diagnose and treat them. Given the 
limited usefulness and predictive capability of in silico and in vitro models, the use of animal models 
must continue (Garattini et al., 2017). In Europe, animal research is tightly controlled under the 
European Directive 2010/63/EU; ethical validity is usually judged in relation to the “three Rs” (i.e. 
Replacement, Reduction and Refinement) introduced by Russell and Burch in their book, “The 
Principles of Humane Experimental Technique”, first published in 1959 (Russell et al., 1992).  
Michael Festing, one of the most prominent statistician involved in animal research, reminds 
us that “the use of animals in biomedical research generates strong emotions, but everyone will 
surely agree that if they are used the experiments should be properly designed and cause the 
minimum amount of pain and distress” (Festing, 2010). And yet, a recent survey of 271 papers from 
academic organisations in the UK and USA involving work on live laboratory mice, rats or non-human 
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primates, has found that the design, analysis and reporting of animal experiments could be 
improved (Kilkenny et al., 2009). The survey’s major findings are reported in Table 1.2.1 (Festing, 
2010). That survey has spawned a follow-up paper introducing the ARRIVE guidelines (Kilkenny et 
al., 2010). ARRIVE stands for Animal Research: Reporting In Vivo Experiments. ARRIVE guidelines 
were published first in PLoS Biology and then in several other journals. These guidelines consist of a 
checklist of 20 items describing the minimum information that all scientific publications reporting 
research using animals should contain. 
Survey finding Percentage 
of studies 
Purpose of the study not clearly stated in the introduction 5 
Did not clearly indicate how many separate experiments were done 6 
Failed clearly to identify the experimental unit 13 
Failed to state the sex of the animals 26 
Reported neither age nor weight of animals 24 
Failed to record the exact number of animals used (although in several cases an 
approximate number could be estimated) 
36 
Failed to justify the sample sizes used 100 
Reports of the numbers of animals used differed between materials and methods 
and results sections 
35 
Random allocation of animals reported 12 
Studies reporting blinding when qualitative scoring was used 14 
Studies where the statistical methods used were not clear or not reported 4 
Studies with numerical data which failed to present a measure of variation such 
as a standard deviation, standard error, or confidence interval 
17 
Papers judged not to have used the correct statistical methods, or where the 
methods used were not clear 
12 
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Table 1.2.1 Primary findings of the survey of the quality of experimental design, statistical 
analysis and reporting of research using animals. 271 papers from academic organisations in the UK 
and USA were assessed (Festing, 2010) 
The poorly designed, analysed and reported preclinical in vivo experiments raise ethical and 
scientific concerns about proper use of animals and reproducibility, respectively. Key 
methodological issues of preclinical in vivo experiments are shown in Figure 1.2.1. All these issues 
are put into doubt by variability of experimental results, measurements and biological models. They 
are summarised in the following sections.  
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Figure 1.2.1 Methodological issues of preclinical in vivo experiments
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1.2.1 Internal validity 
Internal validity is the core issue. A preclinical in vivo experiment with poor internal validity implies 
poor reproducibility. Due to poor reproducibility, its results are suspiciously accepted by the 
scientific community. The situation is worse still. Systematic reviews and meta-analyses of all 
available evidence from preclinical in vivo experiments produce low weight of evidence if single in 
vivo experiments have poor internal validity. Adequate internal validity of a preclinical in vivo 
experiment means that the differences observed between groups of animals allocated to different 
interventions may, apart from random error, be attributed to the treatment under investigation 
(Jüni et al., 2001). By definition, random error is totally controlled by the calculus of probability. 
Neither the calculus of probability nor other statistical tools can handle systematic error (bias) 
without unverified assumptions. 
Four types of bias threaten internal validity. Their definition and possible solution are reported in 
Table 1.2.1.1. 
Type of bias  Definition Solution 
Selection bias Treated and control groups differ prior to 
treatment in ways that matter for the 
outcomes under study 
Randomization; allocation 
concealment; intention-
to-treat analysis 
Performance bias Systematic differences in care between the 
treatment groups apart from the 
intervention under study 
Blinding 
Assessment/detection 
bias 
Systematic differences between treatment 
groups in the assessment of study 
outcomes 
Blinding 
Attrition bias Systematic differences between treatment 
groups in the number and the way animals 
are lost or exit from the experiment 
Blinding; intention-to-
treat analysis 
Table 1.2.1.1 Types of bias threatening internal validity 
To prevent selection bias, treatment allocation should be based on randomization. This means that 
an a priori determined probability of enrollment in a specific treatment or control group should be 
assigned to each animal. This is not enough. To prevent selection bias, concealing the allocation 
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sequence from those assigning animals to intervention groups, until the moment of assignment, 
should be applied. In few words, picking animals ‘at random’ from their cages has the risk of 
conscious or subconscious manipulation, and does not represent a true and satisfactory method of 
randomization. To prevent performance, detection, and attrition bias, caregivers, researchers and 
outcome assessors should be blinded from knowing which intervention each animal received during 
the experiment. Blinding may not always be possible in all stages of an experiment, for example 
when the treatment under investigation concerns a surgical procedure or the treatment safety 
profile unmasks the administered treatment. However, blinding of outcome assessment is almost 
always possible. In a retrospective review, 290 animal studies with intervention were classified by 
the use of randomization and blinding (Bebarta et al., 2003). The Odds Ratio (OR) of reporting a 
significant difference was 3.4 (95%CI: 1.7 to 6.9) for the studies in which randomization was not 
used compared to those in which randomization was used. The OR of reporting a significant 
difference was 3.2 (95%CI: 1.4 to 7.7) for the studies in which blinding was not used compared to 
those in which blinding was used. Finally, the OR of reporting a significant difference was 5.2 (95%CI: 
2.0 to 13.5) for the studies in which both experimental techniques were not used compared to the 
studies in which both techniques were used. These results suggest that failure to blind and 
randomize may lead to bias.  
Intention-to-treat analysis is the analysis of data of all animals included in the group to which 
they were randomly assigned, regardless of whether they completed the intervention. This 
statistical procedure is useful to prevent selection and attrition bias. For instance, suppose that 
animals dead for treatment toxicity are removed from the final analysis. It could be argue that only 
animals with specific characteristics are retained in the final analysis and the measure of treatment 
effect respect to control group is biased. Risk of bias tools (SYRCLE’s RoB tool) for animal 
intervention studies are useful to evaluate the level of internal validity of in vivo experiments 
(Hooijmans et al., 2014).  
1.2.2 Reproducibility 
The ability to reproduce experiments is at the heart of science. Goodman et al. (2016) decline this 
term in three different ways, that are reported in Table 1.2.2.1. 
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Type of 
reproducibility 
Definition 
Methods Methods reproducibility refers to the provision of enough detail about 
study procedures and data so the same procedures could, in theory or in 
actuality, be exactly repeated 
Results Results reproducibility refers to obtaining the same results from the 
conduct of an independent study whose procedures are as closely 
matched to the original experiment as possible 
Inferential Inferential reproducibility refers to the drawing of qualitatively similar 
conclusions from either an independent replication of a study or a 
reanalysis of the original study. Inferential reproducibility is not identical 
to results reproducibility or to methods reproducibility, because scientists 
might draw the same conclusions from different sets of studies and data 
or could draw different conclusions from the same original data, 
sometimes even if they agree on the analytical results 
Table 1.2.2.1 Types of reproducibility 
Scientists in the Haematology and Oncology department at the biotechnology firm Amgen in 
Thousand Oaks, California, tried to confirm published findings of ‘landmark studies’ in Oncology 
(Begley et al., 2012). Fifty-three papers were deemed ‘landmark’ studies (i.e. something completely 
new, such as fresh approaches to targeting cancers or alternative clinical uses for existing 
therapeutics). Scientific findings were confirmed in only 6 (11%) cases! This disappointing result 
could be due to the following reasons: poor internal validity, lack of good reporting and 
transparency, and poor control of biological variability. Lack of reproducibility in other laboratories 
may also be caused by treatment x environment interactions. For example, animal houses may differ 
in the physical environment, management, or microflora in such a way as to alter the relative 
treatment differences. These are the reasons threating reproducibility in science. A similar finding 
was reported by Prinz et al. (2011). The scope of the Prinz et al. study was to compare in-house 
results with published results for wet-lab experiments related to drug target identification and 
validation. Sixty-seven in-house projects within the oncology (47 projects, 70%) , women’s health 
(12 projects, 18%) and cardiovascular (8 projects, 12%) indications were used to reproduce pub-
lished data. Only in 20 to 25% of the projects in-house findings were completely in line with 
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published data. In almost two-thirds of the projects, there were inconsistencies between in-house 
data and published data that either considerably prolonged the duration of the target validation 
process or, in most cases, resulted in termination of the projects because the evidence that was 
generated for the therapeutic hypothesis was insufficient to justify further investments into these 
projects. 
1.2.3 Control of biological and experimental variability 
Russell and Burtch’s chapter on reduction, written in 1959, is largely concerned with the control of 
inter-individual biological variation through the use of inbred strains (Russell et al., 1992). The 
control of variability delivers enormous advantages in in vivo experimentation, that are reported in 
Table 1.2.3.1. 
Type of benefit Explanation 
Power Uncontrolled biological variability leads to increased numbers of false 
negative results. The noise (i.e. biological variability) prevails over the 
biological signal  
Reproducibility Uncontrolled biological and experimental variability leads to lack of 
methods and results reproducibility 
Reduction Controlling biological and experimental variability, the signal (i.e. 
treatment effect) / noise (i.e. variability) ratio is increased and less animals 
are necessary to detect the same treatment effect 
Table 1.2.3.1 Benefits derived from the control of biological and experimental variability 
One of the methods largely suggested to control biological variability has been the use of blocks. 
Simple randomization requires substantial numbers of animals in order to fully randomly balance 
all possible confounding factors (e.g. animal strain, age, gender, weight, housing). In randomized 
block designs different sources of variability are distributed in a controlled manner to the individual 
block entities to which individual animals are assigned at random. Blocks could be useful to 
guarantee reproducibility. Suppose that an experiment is executed in different times or 
laboratories. Times or laboratories could be used as blocks. If there is good agreement between 
these blocks, then this gives some assurance that the experiment is reproducible. Other useful 
statistical designs to control biological variability include Latin square, crossover designs and 
repeated measure design (Festing et al., 1998; Festing et al., 2002). 
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1.2.4 External validity 
External validity could be defined as the extent to which the results of a preclinical in vivo 
experiment provide a correct basis for generalisations to the human condition. Ideally, a disease 
model should fully reproduce the clinical condition in a system that can be used for research and 
drug discovery. But all preclinical models are an imperfect replication and simplified models of the 
clinical condition. The following reasons could explain the failed translation of in vivo experiments 
to the clinic: 
o Differences between in vivo models and humans, testing the same treatment (e.g. 
pathophysiology of disease, comorbidities, age) 
o Differences between the treatment administered in an in vivo experiment and that 
administered in humans e.g. (timing of the administration, dosing of the study treatment, 
using of co-medications) 
o Differences in the outcome measures (e.g. in in vivo antitumor activity studies, tumor growth 
curves are usually used to detect CCs’ treatment effect. In clinical trials time-to-progression 
could be used to detect CCs’ treatment effect) 
o Shortcomings of the clinical trial. For instance, clinical trials may have had insufficient 
statistical power to detect a true benefit of the treatment under study or the same treatment 
was administered at at later time points when the window of opportunity has passed 
(Gladstone et al., 2002; Grotta, 2002). 
If the issues regarding internal validity are almost the same in all in vivo experiments, regardless of 
the disease under study, the external validity of an in vivo experiment will largely be determined by 
disease-specific factors. 
1.2.5 R as reduction 
The number of animals used should be reduced to the minimum consistent with achieving the 
objectives of the preclinical in vivo experiment. Reduction, of course, lies squarely in the field of 
statistics. Table 1.2.5.1 reports the statistical techniques available to reduce sample size in in vivo 
experiments. 
Statistical technique Explanation 
Increasing the signal/noise 
ratio 
The number of animals is smaller if a larger treatment effect is 
targeted and/or the biological and experimental variability is 
reduced 
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Multi-arm designs 
 
Multiple treatments could be evaluated in the same experiment. 
Control arm is the same for all active arms. Interactions between 
treatment factors could be fairly evaluated using a factorial 
design 
Choosing appropriate 
endpoints 
 
For instance, continuous endpoints are more powerful than 
categorical endpoints; repeated measures instead of single 
measures increase the power of common statistical tests 
Using indirect evidences 
 
Historical data could be combined to in vivo experiment’s data 
using, for example, bayesian techniques (Gelman et al., 2004). 
Moreover, historical data should be used to guide statistical 
design 
Increasing statistical errors 
 
The number of animals could be reduced by accepting more false 
positive (i.e. type I) and negative (i.e. type II) errors (refer to 
Section 5.1.1 for their explanation). For instance a type I error of 
0.05 could be substituted by a type I error of 0.10 and a type II 
error of 0.20 could be substituted by a type II error of 0.22. 
Moreover, in case of in vivo experiments screening CCs, two-
tailed tests could be substituted by one-tailed tests 
Adaptive designs 
 
If data are analyzed at interim, decision rules such as stopping 
rules or sample size re-estimation could be applied. Hence, the 
the number of animals used in in vivo experiments is better 
justified and, stopping early the experiment, is reduced 
Table 1.2.5.1 Statistical techniques to reduce sample size in in vivo experiments 
Excluding multi-arm designs, other statistical techniques are rarely applied in in vivo experiments. 
For example, randomized block designs are scarcely used (Festing, 2014). Adaptive designs are 
almost never applied in preclinical in vivo experimentation. 
1.2.6 Publication bias 
Systematic review and meta-analysis are techniques developed for the analysis of data from clinical 
trials. They may be helpful also in preclinical research. For instance, a systematic review and meta-
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analysis of all available evidence from preclinical studies should be performed before clinical trials 
are started. 
If studies are published selectively on the basis of their results, even a meta-analysis based 
on a rigorous systematic review will be misleading. In a meta-analysis of 525 publications included 
in systematic reviews of 16 interventions tested in animal studies of acute ischaemic stroke, it was 
estimated that publication bias might account for around one-third of the efficacy reported in 
systematic reviews of animal stroke studies and that a further 214 experiments, in addition to the 
1,359 identified through rigorous systematic review (non publication rate: 14%), have been 
conducted but not reported (Sena et al., 2010). 
Nonpublication of the results of animal studies is unethical because the included animals are 
wasted. They do not contribute to accumulating knowledge.  As a consequence, ‘wrong ways’ could 
be taken in preclinical and clinical research:  
o overstated biological effects may lead to further unnecessary in vivo experiments testing 
poorly founded hypotheses 
o publication bias deprives researchers of the accurate data they need to estimate the 
potential of novel therapies in clinical trials. 
The recognition of substantial publication bias in the clinical literature has led to the introduction of 
clinical trial registration systems to ensure that those summarising research findings are at least 
aware of all relevant clinical trials that have been performed (De Angelis et al., 2004). A central 
register of preclinical in vivo experiments performed should be kept along with their respective 
reference publications (van der Worp et al., 2010). 
1.3 Statistical analysis of in vivo tumor growth curves 
In preclinical in vivo experiments, antitumor activity is usually evaluated by estimating the tumor 
volume at different times after drug administration. In a typical experiment, rodents, usually mice 
or rats, are inoculated subcutaneously with tumor cells that are either isogenic, if the rodent is 
immunocompetent, or xenogenic (i.e. human tumor cells are inoculated), if the rodent is 
immunodeficient. Alternatively, tumor cells can be injected ortothopically, into the organ from 
which they originate. Tumors could also be induced by administration of carcinogens or genetic 
manipulations (Zitvogel et al., 2016). Rodents that develop tumors reaching a predetermined 
volume are randomized into different treatment and control groups and drugs are administered. 
Those rodents injected with tumor cells but with no sign of tumor burden are usually sacrificed after 
inoculation. The volume of each tumor is measured at the start of treatment and periodically 
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throughout the experiment. Rodents are sacrificed either when their tumor volume reaches a 
maximum target volume, or when a humane endpoint (i.e. the earliest, predetermined. 
physiological or behavioral sign used to avoid or stop the distress, discomfort, or potential pain and 
suffering) is reached or at the end of follow-up (administrative censoring). The resulting dataset 
consists of incomplete, repeated measures of tumor volume at common time points, from the start 
of treatment until the time in which the last rodent has been sacrificed. An example of tumor growth 
curve is reported in Figure 1.3.1. 
 
Figure 1.3.1 Antitumor effects of AZD2171 (, 0.75 mg per kg per day; , 1.5 mg per kg per day; 
, 3 mg per kg per day; , 6 mg per kg per day) or vehicle () on growth of MDA-MB-231 human 
breast tumor xenografts. Xenografts were established s.c. in athymic mice and allowed to reach a 
volume of 0.2 + 0.01 cm3 (mean + standard error) before treatment. Once-daily oral administration 
of AZD2171 or vehicle then commenced and was continued for the duration of the experiment. 
Points, mean from 10 to 11 mice; bars, standard error in one direction (Wedge et al., 2005)  
 
Limitations of this method include lack of information about the effects of the CCs on metastases, 
or the process of metastatic spread. Also, in order to evaluate the mechanism(s) of action of a drug, 
rodents must be killed to allow molecular analysis of the resected tumor. In addition, although 
tumor growth curves with and without treatment reflect tumor response or delay in progression, 
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these end points may not reflect selective effects against those tumor cells with high reproductive 
potential (e.g. putative stem cells) that are important in determining the long-term benefits of 
treatment (Ocana et al., 2010).  
Tumor volumes are measured on a weekly basis using a caliper on determined days. Imaging 
techniques, such as bioluminescence imaging, may be used to record changes in the volume of 
tumors that are not restricted to superficial sites and/or to provide information about drug-
influenced biological processes (e.g. metastatic spread, expression of proteins). Details about 
imaging techniques and their use are reported in Ocana et al., 2010.  
To analyse data series of tumor volumes at different time points, the common statistical 
practice is first to demonstrate that the treatment influences them, then to estimate the treatment 
effect. To solve the former problem, statistical tests are used (Lehmann et al., 2005), while to solve 
the latter problem, unbiased estimators are used (Lehmann et al., 1998). Details about hypothesis 
testing and statistical estimation are reported in Section 4.3.1. The statistical approaches currently 
used to analyse data series of tumor volumes at different time points, could be classified in the 
following categories: 
o Data analysis at a selected time point 
o Use of summary statistics to estimate treatment effect 
o Substitution of data series with the time required to reach a target volume 
o Use of multivariate methods 
An overview of these statistical approaches is shown below. 
1.3.1 Comparison of tumor growth curves at a selected time point 
Control and treatment arms are compared at a selected time point; usually the time point at the 
end of follow-up. The statistical test at each time point could be parametric, namely t test for two 
arms or ANOVA test for more than two arms, or non-parametric, namely Mann-Whitney test for 
two arms or Kruskal-Wallis test for more than two arms. The T/C ratio, calculated at the selected 
time point, is a common measure of treatment effect (Corbett et al., 2003; Houghton et al., 2007). 
T and C are the means, or medians, of the tumor volumes of the treatment (T) and control (C) arms, 
respectively, at the selected time point. From a statistical point of view, this approach is inadequate 
as explained in the following three points: 
1) comparing control and treatment arms at a selected time point is a weaker comparison than that 
of the tumor growth curves over all times. It neither captures all the data nor addresses the 
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different biological mechanisms underlying tumor growth. The suboptimal use of data series is 
well represented by the following examples:  
1a. suppose that at the end of follow-up control and treatment arms have the same tumor 
volume distribution but previously, tumor growth was constant in the control arm while tumor 
volume was greatly reduced and then quickly increased in the treatment arm, as reported in 
Figure 1.3.3.1. Treatment effect is not formally recognized by this statistical approach 
1b. suppose that, at the start of treatment, there is a tumor volume reduction in the treatment 
arm but, after few days, tumor growth curves of control and treatment arms remain parallel to 
each other over all the rest of follow-up. At the end of follow-up, treatment effect could be 
formally recognized by this statistical approach although its biological relevance is poor 
2) the choice of the time point could be data driven (e.g. most of rodents in the control arm are just 
sacrificed) or a priori (e.g. based on the planned treatment administration). In the first case, 
comparison is constrained by specific events, such as animal sacrifice in the control arm, that 
weaken and rather render ambiguous the interpretation of this comparison. In the second case, 
the a priori choice of the time point creates difficulty because unreliable assumptions are needed 
(e.g. exponential growth with a determined growth rate in the control arm) to design and 
determine sample size 
3) attrition bias due to censoring animals (e.g. rodents previously sacrificed) could affect the formal 
comparison at the selected time point.  
A worst method is to repeat this approach at different time points, indicating all the times at which 
differences were significant. This procedure may be naively considered better because it uses all the 
data series. On the contrary, due to its very bad procedure caused by the inflation of type I error 
due to the multiple comparisons problem, post-hoc tests are difficult to apply because repeated 
measures are correlated and comparisons are usually underpowered. 
1.3.2 Summary statistics  
Per-experiment and per-animal summary statistics are commonly used to estimate treatment 
effect. Examples of per-experiment summary statistics are the minimal T/C ratio, which reflects the 
maximal tumor growth inhibition achieved (Hendriks et al., 1992), and the adjusted AUC ratio (aAUC 
ratio; Wu et al., 2010). The minimal T/C ratio is the minimum of the T/C ratios calculated at all time 
points. aAUC ratio is defined as the ratio of the means of the aAUCs of the treatment and control 
groups, where aAUC is the per-animal area-under-the-curve (AUC) calculated up to the last time 
point available for the rodent, divided by the length of the interval between the start of treatment 
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and the last time point with existing tumor volume measurements. Another example of per-animal 
summary statistics is the Tnadir. It is defined as the minimum of the growth curve of a treated tumor 
relative to the tumor volume at the start of treatment (Ubezio, 2019). 
Per-experiment and per-animal summary statistics are usually easy to calculate and 
informative. However, their sampling distribution could be highly skewed and average values such 
as the aAUC ratio could suffer from suboptimal power with respect to multivariate methods. 
1.3.3 Time-to-event endpoints 
Control and treatment arms are compared in terms of time in days for the tumors to reach a 
predefined target volume (tumor growth delay). For instance, it could be the doubling time of tumor 
volume, defined as the earliest day on which the tumor volume is at least twice as large as on the 
first day of treatment. The non-parametric log-rank test and the semi-parametric Cox regression 
model are available to detect and estimate treatment effect, respectively, in the presence of right-
censored data. However, there are two major disadvantages when using this approach. First, the 
choice of the target volume at which to assess the delay is critical for this comparison (Begg, 1980). 
Second, it neither captures all of the data nor addresses the different biological mechanisms 
underlying tumor growth, as reported in Figure 1.3.3.1.  
 
Figure 1.3.3.1 Repeated measures of tumor volume on two rodents, at the start of treatment until 
the doubling time. Tumor growth delay is the same but biological mechanisms are different 
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1.3.4 Multivariate methods 
The methods are called “multivariate” because they treat the series of tumor volumes on an animal 
as a single multivariate observation (Heitjan et al., 1993). They use the entire data series and permit 
detailed modelling of tumor growth curves and intra-animal correlation patterns, substantially 
improving the efficiency of testing and reducing sample size requirements. Furthermore, they 
provide more descriptive features that address mechanisms underlying tumor growth inhibition and 
maximize the biological information obtained from in vivo studies. Repeated-measures ANOVA, or 
Friedman repeated-measures ANOVA on ranks, can compare tumor growth curves after accounting 
for the correlation of measurements on the same tumor. Other multivariate models are reported in 
Heitjan et al. (1993). On the other hand, these multivariate methods could be criticized for the 
following reasons: 
o in case normality or homoscedasticity (i.e. same variance in all groups and at all times) are 
assumed, they are often unreliable and, due to small samples, usually unverifiable 
o in case a correlation structure between repeated measures is assumed, it is often unreliable 
and, due to small samples, usually unverifiable 
o in case of missing values, either data series are excluded, or imputation is used, or a 
correlation structure should be specified. Due to informative missing and small samples, 
imputation techniques could introduce biases into the analyzed data. 
Sophisticated regression models have been proposed to fit tumor growth curves; a biexponential 
model (Demidenko, 2004; Liang et al., 2004), a linear exponential model (Demidenko, 2006), a non-
parametric model (Liang, 2005) and a Bayesian model (Zhao et al., 2011). However, regression 
models to fit tumor growth curves have limits: due to a small sample size of preclinical in vivo 
experiments, assumptions are only verifiable with great difficulty and, if an excessive number of 
parameters are used, overfitting occurs. 
In addition to the statistical approaches reported in Sections 1.3.1-1.3.4, many statistical tests, 
unfortunately not combined with appropriate estimators (i.e. only p-values are obtained), have 
been proposed. Tan and colleagues (Tan et al., 2002) proposed a small-sample t-test via the EM 
(expectation maximization) algorithm. They assumed a multivariate normal distribution for the 
repeated log tumor volumes with a Toeplitz covariance matrix. Due to the strong model assumption, 
their method has limited application to preclinical in vivo experiments. Vardi et al. (2001) proposed 
a nonparametric two-sample U-test. The proposed methodology is a fully nonparametric approach. 
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Finally, Liang (2007) proposed a non-parametric approach to compare antitumor effects in two 
treatment groups. The approach yields a p-value only. 
In conclusion, different shortcomings are present in the current statistical methods used to 
analyse preclinical in vivo tumor growth curves: incomplete use of the entire data series, unreliable 
assumptions, poorly addressed biological mechanisms underlying different patterns of tumor 
growth, lack of statistical power and inferential estimators with inadequate statistical properties. 
This project would like to improve statistical methodology applied to preclinical in vivo tumor 
growth curves, overcoming previous shortcomings. 
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Chapter 2 
Aims 
There is no doubt that poorly designed, executed, analyzed and reported in vivo experiments raise 
ethical as well as scientific concerns. Briefly, on one side the weight of scientific evidence is reduced 
and no statistical method could completely fix this damage. On the other side, research 
reproducibility, the fundamental assumption of science, is definitely compromised. As a 
consequence of poor methodology applied to in vivo experiments, ‘wrong roads’ could be taken in 
preclinical research (Figure 2.1). Many laboratories spend time and money and use in vivo models 
in vain, trying to extend unreliable findings or apply them to different problems. The mean number 
of citations of the forty-seven landmark studies non-reproduced by the scientists in the 
Haematology and Oncology department at the biotechnology firm Amgen in Thousand Oaks, was 
about two hundred (range: 3-1.909 citations, Begley et al., 2012) . 
 
Figure 2.1 Consequence of poor methodology applied to in vivo experiments 
It could be worse still. Methodological flaws in in vivo experiments could ruin the drug development 
process. It could be hypothesized that the recurring failure of apparently promising interventions to 
improve outcome in clinical trials has been partially caused by these flaws. For instance, several of 
these errors could have led to bias with false positive (i.e. type I) errors. And false positive errors 
could have wrongly selected CCs for clinical evaluation.  
To the best of the author’s knowledge, the impact of methodological flaws in in vivo 
experiments on the drug development process has never been quantitatively investigated. In 
Oncology, the assessment of antitumor activity in in vivo experiments and clinical trials could be a 
useful way to detect and estimate this impact. CCs demonstrating better antitumor activity than no 
treatment or standard therapies (i.e. active controls) in preclinical cancer models (i.e. in silico, in 
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vitro and in vivo models), are advanced to confirmatory testing in early (i.e. Phase I and II) clinical 
trials. Antitumor activity detected in preclinical cancer models is a fundamental prerequisite for 
advancing a CC from preclinical testing in the laboratory to clinical testing and for prioritizing CCs’ 
progress to clinical cancer trials. This prerequisite is based on the assumption that CCs’ activity in 
preclinical cancer models translates into at least some efficacy in human patients. In drug discovery 
and development, in vivo models have the greatest complexity and, above all, the greatest similarity 
to human patients among preclinical cancer models. At the same time, the assessment of antitumor 
activity is the first test bench of the CCs’ clinical development after CCs’ dose has been defined. 
Therefore, detecting and estimating the correlation between methodological quality of in vivo 
experiments, whose primary objective is to assess CCs’ antitumor activity, and the level of CCs’ 
antitumor activity in phase II clinical trials, could be a direct way to estimate the impact of 
methodological flaws in preclinical in vivo experiments on the process of drug discovery and 
development. 
It is necessary to retrieve data about statistical design and analysis of preclinical in vivo tumor 
efficacy studies from scientific literature in order to address the previous issue. Hence, it is also 
possible to assess the methodological quality of in vivo tumor efficacy studies using the same data. 
To the best of the author’s knowledge, the methodological quality of preclinical in vivo tumor 
efficacy studies has never been qualitatively and quantitatively investigated. 
Finally, the statistical design and analysis of experiments to study in vivo tumor growth curves 
is a primary issue. A new methodological framework, based on the Wilcoxon-Mann-Whitney test, 
will be introduced for the statistical design and analysis of these experiments. 
More specifically, the project addresses the following interrelated aims: 
1. to correlate the quality of statistical design and analysis of preclinical in vivo tumor efficacy 
studies with the level of antitumor activity estimated in phase II clinical trials 
2. to evaluate the quality of statistical design and analysis of preclinical in vivo tumor efficacy 
studies 
3. to improve the statistical design and analysis of experiments to study tumor growth curves. 
Regarding the first and second aim, research will focus on epithelial ovarian cancer (EOC). EOC  was 
chosen as tumor type for the following reasons: 
1. EOC treatment has not been substantially changed in the last thirty years. A platinum-based 
chemotherapy is the mandatory first line treatment. Stability and simplicity of administered 
treatment has a favourable influence on the control of variability 
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2. this project refers to the Oncology Department, Istituto di Ricerche Farmacologiche Mario 
Negri IRCCS, Milan (Italy). A large number of EOC research studies has been performed in 
this department in the last thirty years. Specifically, good expertise and skills has been 
developed in animal models and translational research about this type of tumor. 
It was necessary to design a survey in order to achieve the first two aims of the project. This task 
has been difficult and time-consuming. Survey design has been profoundly amended. Two previous 
survey designs have been rejected because they could not be effectively applied. Their ineffective 
applicability was due to methodological limits of designs used for phase II trials in Oncology (e.g. 
phase II clinical trials in Oncology are generally single-arm trials) and publication bias (i.e. in vivo 
experiments are not clearly identifiable in public assessment reports published by the European 
Medicines Agency and the Food and Drug Administration). Failed survey designs will be described 
and discussed in Chapter 6. 
Regarding the third aim, the project proposes a new methodological framework to study tumor 
growth curves. It is a general framework because it focuses on both statistical hypotheses testing 
and the theory of estimation. 
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Chapter 3 
Methods 
3.1 Survey design 
To achieve the first two aims of the project, a systematic survey of previous clinical and preclinical 
research has been performed using a sequential two-stage design. In the first stage, eligible CCs 
have been identified and estimates of their antitumor activity has been retrieved from clinical 
research literature. In the second stage, in vivo experiments testing antitumor activity of identified 
CCs have been retrieved from biomedical research literature. The quality of experimental design 
and statistical analysis of each preclinical in vivo experiment has been evaluated using an ad hoc 
checklist. Finally, the quality of experimental design and statistical analysis of preclinical in vivo 
experiments has been correlated to the estimates of clinical antitumor activity. If methodological 
flaws impact the Oncology drug discovery and development process, a positive correlation between 
methodological quality of in vivo experiments and estimates of clinical antitumor activity could be 
expected. 
Details about this two-stage design follows. 
3.1.1 Stage 1: identification of eligible CCs and estimation of their clinical antitumor activity 
A systematic search of the Medline and EMBASE databases has been carried out to identify clinical 
trials whose primary objective was to assess antitumor activity of CCs. This systematic search was 
limited to clinical trials in EOC. Reasons of this choice have been reported at the end of chapter 2. 
Selection of EOC clinical trials and eligible CCs was based on the following criteria: 
α. Eligible criteria for clinical trials 
α1. Inclusion criteria 
 Histologically or cytologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube 
cancer, or primary peritoneal cancer 
 Assessment of CCs’ antitumor activity was the primary or co-primary objective. At least one 
antitumor activity endpoint was a primary or co-primary endpoint 
 Women aged 18 years or older 
 ECOG/WHO performance status (PS) 0-2 or GOG PS 0-2 (Oken et al., 1982; Rubin et al., 2004) 
 Patients must have failed at least one prior line of platinum-based chemotherapy 
 Study protocol approved by the independent ethics committees or institutional review 
boards of the participating institutions 
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 The final study report was published on 1st January 2010 or later 
 The final study report was written in English 
Note: if inclusion criteria of the EOC clinical trials were broader but all patients evaluated for 
antitumor activity satisfied all previous α1 criteria, the clinical trial was considered eligible. For 
instance, if eligible criteria admitted the enrollment of children and all effectively enrolled patients 
were adults, EOC clinical trial was considered eligible. 
β. Eligible criteria for CCs 
β1. Inclusion criteria 
 CC was evaluated in monotherapy as experimental treatment (i.e. active arm) 
β2. Exclusion criteria 
 Monoclonal antibodies, oncolytic viruses or reoviruses, vaccines, immunotherapeutic and 
endocrine CCs were excluded 
 CC was administered in maintenance therapy 
 CC was administered as standard treatment (i.e. control arm) 
The following search string was used in Medline: 
("Clinical Trial, Phase II"[Publication Type] OR “clinical trial phase 2” OR “clinical trial phase ii” OR 
“clinical study phase 2” OR “clinical study phase ii” OR “phase 2 clinical study” OR “phase 2 clinical 
studies” OR “phase ii clinical study” OR “phase ii clinical studies” OR “phase 2 clinical trial” OR “phase 
2 clinical trials” OR “phase ii clinical trial” OR “phase ii clinical trials” OR “phase 2 study” OR “phase 
2 studies” OR “phase ii study” OR “phase ii studies” OR “phase 2 trial” OR “phase 2 trials” OR “phase 
ii trial” OR “phase ii trials” OR “phase 1/2” OR “phase 2/3” OR “phase 1 2” OR “phase 2 3” OR “phase 
1-2” OR “phase 2-3” OR “phase i/ii” OR “phase ii/iii” OR “phase i ii” OR “phase ii iii” OR “phase i-ii” 
OR “phase ii-iii”) AND (“Ovarian Neoplasms”[Mesh] OR “ovarian cancer” OR “ovarian cancers” OR 
“ovarian tumor” OR “ovarian tumors” OR “ovarian tumor” OR “ovarian tumors” OR “ovarian 
carcinoma” OR “ovarian carcinomas” OR “ovarian neoplasm” OR “ovarian neoplasms” OR “ovary 
cancer” OR “ovary cancers” OR “ovary tumor” OR “ovary tumors” OR “ovary tumor” OR “ovary 
tumors” OR “ovary carcinoma” OR “ovary carcinomas” OR “ovary neoplasm” OR “ovary neoplasms”) 
Filters: Publication date from 2010/01/01 
The following search string was used in EMBASE: 
#8  #6 AND #7  
#7  [embase]/lim NOT [medline]/lim  
#6  #3 AND #4 AND [2010-2019]/py  
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#5  #3 AND #4  
#4  
'phase 2 clinical trial'/exp OR ‘clinical trial phase 2’ OR ‘clinical trial phase ii’ OR ‘clinical study 
phase 2’ OR ‘clinical study phase ii’ OR ‘phase 2 clinical study’ OR ‘phase 2 clinical studies’ OR 
‘phase ii clinical study’ OR ‘phase ii clinical studies’ OR ‘phase 2 clinical trial’ OR ‘phase 2 clinical 
trials’ OR ‘phase ii clinical trial’ OR ‘phase ii clinical trials’ OR ‘phase 2 study’ OR ‘phase 2 studies’ 
OR ‘phase ii study’ OR ‘phase ii studies’ OR ‘phase 2 trial’ OR ‘phase 2 trials’ OR ‘phase ii trial’ 
OR ‘phase ii trials’ OR ‘phase 1/2’ OR ‘phase 2/3’ OR ‘phase 1 2’ OR ‘phase 2 3’ OR ‘phase 1-2’ 
OR ‘phase 2-3’ OR ‘phase i/ii’ OR ‘phase ii/iii’ OR ‘phase i ii’ OR ‘phase ii iii’ OR ‘phase i-ii’ OR 
‘phase ii-iii’ 
 
#3  #1 OR #2  
#2  
‘ovarian cancer’ OR ‘ovarian cancers’ OR ‘ovarian tumor’ OR ‘ovarian tumors’ OR ‘ovarian tumor’ 
OR ‘ovarian tumors’ OR ‘ovarian carcinoma’ OR ‘ovarian carcinomas’ OR ‘ovarian neoplasm’ OR 
‘ovarian neoplasms’ OR ‘ovary cancer’ OR ‘ovary cancers’ OR ‘ovary tumor’ OR ‘ovary tumors’ 
OR ‘ovary tumor’ OR ‘ovary tumors’ OR ‘ovary carcinoma’ OR ‘ovary carcinomas’ OR ‘ovary 
neoplasm’ OR ‘ovary neoplasms’ 
 
#1  'ovary tumor'/exp  
A PRISMA flow diagram (http://prisma-statement.org/PRISMAStatement/FlowDiagram.aspx. 
Retrieved 09 May 2019) was created to summarize the systematic review process.  
After the identification of eligible EOC clinical trials, their following characteristics were 
retrieved: 
 CC evaluated      (e.g. sorafenib) 
 Phase of the clinical trial    (i.e. phase I/II; II; II/III) 
 Year of final report publication   (e.g. 2012) 
 Participating macro geographical regions  (i.e. USA; Europe; other countries) 
 Monocentric or multicenter trial 
 Single arm or controlled trial     
 Randomized trial, in case of controlled trial  (i.e yes; no) 
 Open-label or blind trial    (e.g. double-blind trial) 
 Start date and end date of recruitment  (e.g. October 2013) 
 Major eligibility criteria    (e.g. number of previous treatment lines) 
 Demographic and pathological characteristics of enrolled patients (e.g. age; histotype) 
 Characteristics of administered treatments  (i.e. schedule) 
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 Primary activity endpoint     (e.g. Disease Control Rate) 
 Tumor response criteria     (e.g. RECIST, version 1.0) 
 Blinded Independent Central Review of tumor response (i.e yes; no) 
 Objective Response Rate (ORR): point estimates and 95% CI, overall and by platinum-
sensitivity 
 Median progression-free survival (PFS): point estimates and 95% CI, overall and by platinum-
sensitivity 
3.1.2 Stage 2: systematic review of in vivo experiments and their methodological evaluation 
For each eligible CC, whose clinical antitumor activity has been estimated in stage 1, a systematic 
search of Medline and EMBASE databases was carried out to identify scientific papers reporting 
original antitumor activity research on live rats and mice. These rodents are the most widely used 
animals in antitumor activity studies. If other species were used, their inclusion would reduce the 
sensitivity of the survey for drawing inferences about quality of statistical design and analysis.   
Selection of in vivo experiments about each eligible CC was based on the following criteria: 
γ. Eligible biomedical research papers 
γ1.  Inclusion criteria 
 At least one in vivo experiment on mouse or rat models of EOC model was reported 
 Eligible CC was used in in vivo experiment on mouse or rat models of EOC 
 The study report was written in English 
δ. Eligible in vivo experiment on mouse or rat models of cancer 
δ1.  Inclusion criteria  
 The primary or co-primary objective was to assess antitumor activity of CC 
 eligible CC was evaluated in monotherapy 
δ2. Exclusion criteria 
 In vivo pharmacokinetics or toxicology experiments 
 Pharmacodynamics experiments  
A PRISMA flow diagram (http://prisma-statement.org/PRISMAStatement/FlowDiagram.aspx. 
Retrieved 09 May 2019) was created to summarize the systematic review process. 
Search strings used in Medline and EMBASE are reported in Appendix A. These strings were 
developed exploring four primary concepts: epithelial ovarian tumor, preclinical screening, rat or 
mouse species and CC’s name. 
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After the identification of eligible biomedical research papers, their following characteristics were 
retrieved: 
 Year of publication     (e.g. 2000) 
 CC evaluated      (e.g. Sorafenib) 
 Peer-reviewed journal    (i.e yes; no) 
 Conflict of interest     (i.e. declared; not declared) 
 Funding statement     (i.e. private; public; mixed; not declared) 
 Recommended clinical translation    (i.e. yes; no) 
After the identification of eligible in vivo tumor efficacy experiments, the following characteristics 
of each mouse or rat cancer model were retrieved: 
 Species   (i.e. mouse; rat; not declared) 
 Strain    (e.g. BALB/c Nude; not declared) 
 Genotype   (i.e. inbred; outbred; not declared) 
 Immune status  (i.e. competent; compromised; not declared) 
 Sex    (i.e. female; male; mixed; not declared) 
 Age (weeks)   (e.g. 5-7 wks; not declared) 
 Weight (grams)  (e.g. 17 grams on average; not declared) 
 Housing   (i.e. SPF; Conventional; not declared) 
 Animal source  (i.e. internal breeding; certified breeder; not declared) 
 Model type    (i.e. human xenograft PDX; human xenograft CDX; syngeneic;  
    genetically engineered; other, specify; not declared) 
 Human ovarian cancer cell line (e.g. SKOV3) 
Next, for each eligible in vivo tumor efficacy experiment, the quality of statistical design and analysis 
was assessed using the checklist described in the following section. 
3.2 Quality of statistical design and analysis checklist 
The checklist used to assess the quality of statistical design and analysis of in vivo tumor efficacy 
experiments is reported in Appendix B. The checklist consists of 46 items separated in 8 distinct 
sections. Separate sections are related to distinct methodological issues. The references Heitjan et 
al., 1993; Altman et al., 1995; Kilkenny et al., 2009; Kilkenny et al., 2010; Hooijmans et al., 2014; 
Henderson et al., 2015, were used to draft and finalise the checklist. The checklist has been tested 
in a small pilot study of 20 eligible papers. The judgement has been subjective. If the checklist missed 
something important in one of the twenty papers, the checklist was updated. 
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The contents of the checklist’s sections are summarised below. 
3.2.1 Repetition and external validity 
On one side, the repetition of the same animal experiment by the same laboratory setting is ethically 
and scientifically unsound. If a laboratory wants to repeat its own experiment, it probably means it 
was badly designed (e.g. underpowered study) or other methodological errors (e.g. lack of well-
defined and standard operating procedures) were performed. On the other side, evidence that leads 
to a single laboratory or a single model or species showing some benefit should not be used as the 
basis for proceeding to the clinic (van der Worp et al., 2010). Hence, for each eligible in vivo 
experiment, the following information was retrieved: the number of repetitions by a single 
laboratory, the number of species and models used for the EOC malignancy type, and the number 
of participating laboratories. 
3.2.2 Internal validity 
As shown in Chapter 1, internal validity is at the core of good experimentation. To prevent selection 
bias, the use of an internal control group, the random allocation of animals, and methods used to 
conceal the allocation sequence were recorded. Control of variability is fundamental in in vivo 
experiments. Russell and Burch’s chapter on reduction, that was written back in 1959, stressed the 
use of inbred strains to control inter-individual variation (Russell et al., 1992). Poor control of 
variability increases the probability of false positive and false negative results (Kernan et al., 1999). 
Hence, for each eligible in vivo experiment, type of randomization (i.e. simple, block, stratified and 
unequal randomization) and the use of randomization techniques for other sampling units other 
than individual animals, such as cages, was recorded. Correct identification of the experimental unit 
[i.e. the unit that is randomly assigned to a treatment (Casella, 2008)] and cases, where there was 
suspicion of pseudo-replication, was recorded. Finally, it was checked whether the CC monotherapy 
arm was primarily used as active or control comparator arm, for each eligible in vivo experiment.    
However, this was only for descriptive purposes. Whereas the survey of clinical trials was limited to 
those in which the CC was the active-treatment arm, in the survey of in vivo experiments the CC 
could be either arm. 
3.2.3 Statistical design 
As Casella G. taught brilliantly to us, there are two aspects to a design: treatment design and 
experiment design (Casella, 2008). A statistical design contains both. A treatment design is the 
manner in which the levels of treatment factors are arranged in an experiment. Typically, treatment 
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factors are either crossed or nested (refer to Figure 3.2.3.1 and 3.2.3.2), and this relationship can be 
either complete or incomplete. 
First treatment 
factor      A      
Level  1   2   3   4  
Second treatment 
factor  B   B   B   B  
Level 1 2 3 1 2 3 1 2 3 1 2 3 
Treatment group 1 2 3 4 5 6 7 8 9 10 11 12 
Figure 3.2.3.1 Treatment factor A and treatment factor B are completely crossed 
 
First treatment 
factor      A      
Level  1   2   3   4  
Second treatment 
factor  B   B   B   B  
Level 1 2 3 4 5 6 7 8 9 10 11 12 
Treatment group 1 2 3 4 5 6 7 8 9 10 11 12 
Figure 3.2.3.2 Treatment factor A and treatment factor B are completely nested 
 
For the first aspect of a statistical design (i.e. treatment design), the use of a factorial (i.e. treatment 
factors are completely or partially crossed) and dose-response (i.e. > 3 doses) design was recorded. 
It was checked if an active control group was used. The number of design factors (i.e. first and 
second treatment factors in Figure 3.2.3.1 and 3.2.3.2) and treatment groups were also recorded. 
An experiment design determines the way in which the randomization of experimental units 
to treatments is carried out and how the data are actually collected. The error structure of the 
experiment is a consequence of the experiment design. Examples of different experiment designs 
are: the completely randomized design, in which all the treatment combinations of factors A and B 
are randomly allocated to units throughout the design; the randomized complete block design, in 
which all the treatment combinations of factors A and B are randomly allocated to units within 
blocks; the strip plot design, in which the randomization of both treatment factors are restricted 
within block factors. In Figure 3.2.3.3 possible “field layout” for completely randomized (a), 
randomized complete block (b), and strip plot designs (c) are shown. 
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(a) Whole experiment with 2 reps shown  
A1B1 A1B1 A2B3 A2B1 A3B2 A1B3 
A1B2 A1B2 A3B2 A2B1 A2B2 A3B3 
A3B1 A2B2 A2B3 A3B1 A3B3 A1B3 
 
 
(b) One block shown 
 
 
(c) One complete block shown 
A2B1 A3B2 A1B3  A1B1 A1B2 A1B3 
A1B1 A2B2 A3B3  A3B1 A3B2 A3B3 
A3B1 A1B2 A2B3  A2B1 A2B2 A2B3 
Figure 3.2.3.3 Possible layouts for three different experiment designs 
In the completely randomized design (a), neither of the two rectangles of 9 units contains all 
combinations of A and B, so they are not complete blocks.  In the randomized complete block design 
(b), 9 units per block are necessary to accommodate all combinations of A and B.  In the strip plot 
design (c), the two block factors are rows and columns. All the designs, (a), (b) and (c), will then 
allow to estimate and test the main effects of A, the main effects of B, and the A × B interaction 
effects. 
For the second aspect of a statistical design (i.e. experiment design), it was checked if blocking 
was used and whether the experimental unit was assigned to more than one treatment group (i.e. 
crossover design or within units design). 
3.2.4 Sample size 
In in vivo experiments sample size is a critical factor in detecting a relevant biological signal, avoiding 
false negative results and observing ethical requirements. As the ANOVA framework teaches us, 
replication (i.e. the repetition of the experimental situation by replicating the experimental unit) is 
necessary in order that the biological signal prevails on the error structure of the experiment. From 
a scientific point of view, underpowered studies should be avoided, as they might lead to the false 
conclusion that the CC is ineffective and all included animals will have been used to no benefit. From 
an ethical point of view, overpowered studies should be avoided, as animals are wasted. For each 
in vivo experiment, it was checked if the sample size was justified and which method was used to 
justify the sample size. The number of animals per treatment group declared in the methods section 
of the eligible paper was also recorded. 
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3.2.5 Outcomes and their assessment 
First of all, it was checked whether the primary outcomes were clearly identified in the methods 
section of the eligible paper. Then the list of primary and secondary outcomes and how they were 
defined was recorded. As task difficulty was considered very high and results unreliable due to poor 
reporting of preclinical in vivo experiments, selective outcome reporting was not evaluated in this 
survey.  
In in vivo antitumor efficacy studies, tumor growth is followed from tumor inoculation to a 
particular event of interest, that is called the antitumor activity endpoint (e.g. tumors reach a 
predetermined target volume). However, the event of interest may not be observed for some 
animals because of end-of-study censoring or competing events, such as death due to toxic effects 
of antitumor therapies or animal sacrifice that is ethically necessary. If the antitumor activity 
endpoint or the competing events are not clearly defined, the interpretation of the tumor growth 
curve could be misleading. For example, a relatively slower growth rate could be due either to effect 
of treatment or to exclusion of animals that have been sacrificed because of a competing event. It 
was checked whether the antitumor activity endpoint and all the competing events were clearly 
defined.  
Then, it was recorded whether the caregivers, investigators and outcome assessors were 
blinded from knowledge which intervention each animal received during the experiment. Finally, to 
prevent detection bias, it was recorded whether animals were selected at random for outcome 
assessment. 
3.2.6 Statistical analysis 
Data analysis of in vivo antitumor efficacy studies was assessed in this section. First of all, it was 
checked whether inferential methods were used to demonstrate antitumor activity. Inferential 
methods were classified as hypothesis testing or estimation methods. If used, the inferential 
methods were recorded. If applicable, it was checked whether statistical assumptions used to 
analyze tumor growth data were justified and whether methods for correction of multiple 
comparison were used. Finally, descriptive methods used to demonstrate antitumor activity were 
recorded. 
3.2.7 Attrition bias about tumor growth curves 
Incomplete outcome data causes ambiguity in the interpretation of results. The number of animals 
assigned to each treatment arm and reported in the results section was recorded. It was checked 
whether and how many animals, assigned to each treatment arm, were excluded from statistical 
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analysis. It was checked whether the number of animals with right-censored data was clearly 
reported and, more specifically, whether, for each animal included in the statistical analysis, it was 
clearly reported which event determined the end of follow-up. In clinical trials, it is a common 
practice to report progressively the number of patients at risk in the plot of survival curves. It was 
checked, if applicable, whether the number of animals at risk were progressively reported in the 
plot of tumor growth or survival curves. It is not enough to report progressively descriptive or 
inferential measures of variability such as standard deviation or standard error, respectively. A 
correct interpretation of these measures needs to specify the number of animals to which these 
measures refer. Finally, it was checked whether the length of follow-up was clearly defined. 
Treatments effect varies greatly along time; for example, a cytotoxic CC could have an effect that is 
very different from a cytostatic CC, not only in its magnitude, but also in its pattern over time. Hence, 
the comparison of tumor growth or survival curves depends heavily on the length of follow-up 
chosen. 
3.2.8 Miscellanea 
The majority of statistical analyses are performed with the help of computer programs. It was 
checked if any information was given in the papers about the commercial software used to analyse 
the data. Further, to evaluate whether known statistical involvement improved the quality of a 
paper, it was checked if any author was a member of a department of statistics or epidemiology. 
Finally, any peculiarities which the assessor noticed in the papers and which were not covered in 
other sections of the checklist were recorded. 
3.3 Sample size 
The sample size was not based on formal statistical considerations. It was determined by the time 
period in which final reports of eligible phase II clinical trials were published. This time period had 
to satisfy the following criteria: 
1. it was the most recent time period to the project execution 
2. large enough to retrieve 50 to 100 eligible phase II clinical trials from clinical research 
literature. 
This upper limit was considered satisfactory in order to assess and extract information from each 
biomedical publication within the planned project timeframe. 
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3.4 Statistical analysis 
Non-parametric statistics (i.e. median and range for continuous variables, absolute and percentage 
frequencies for categorical variables) were used to describe eligible clinical trials and in vivo 
experiments. Antitumor activity of the eligible CCs was assessed in terms of ORR and median PFS. 
Separate analyses were performed for ORR and PFS endpoints. For each eligible CC identified in a 
specific cohort of patients, a point estimate and a standard error of ORR and median PFS was 
obtained. Point estimates and standard errors were then used as inputs for a random-effects meta-
analysis. The Q and I2 statistics were used to test and estimate, respectively, the percentage of total 
variation due to inter-cohort heterogeneity.  
For the ORR endpoint, in order to include cohorts with an estimated proportion equal to 0 or 
1, and since the coverage probability is closer to the nominal confidence level than that obtained 
from the exact likelihood approach, score test-based confidence intervals were used to estimate 
the percentage of patients with complete or partial response. The Stata metaprop command with 
random, cimethod(score) and ftt options was used (Nyaga et al., 2014).  
For the PFS endpoint, assuming an exponential distribution, the constant hazard rate was 
directly computed from the point estimate of the median PFS. The following formula was used: 
log(2) / median PFS                                                         3.4.1 
Standard error of the constant hazard rate was estimated using the following formula: 
 {[ log(2) / lower 95%CI median PFS ] - [ log(2) / upper 95%CI median PFS ] } / [2 ∙ Ф (0.975)]   3.4.2 
where Ф(z) is the Standard Normal Cumulative Distribution Function. The Stata metan command 
with random option was used to estimate the random effects model (Harris et al., 2010). 
The checklist used to assess the quality of statistical design and analysis of in vivo tumor 
efficacy experiments was analysed by item, using non-parametric statistics (i.e. median and range 
for continuous variables, absolute and percentage frequencies for categorical variables). The unit of 
analysis was each eligible in vivo experiment. 
A meta-regression approach was used to detect correlation between methodological quality 
of in vivo experiments and clinical antitumor activity. 
The following procedure was applied: 
o in the presence of multiple cohorts evaluating the same CC, a summary measure of the CC’s 
clinical antitumor activity was estimated using a fixed-effects meta-analysis model 
o in vivo experiments were classified as either experiments of good methodological quality 
(‘good’ in vivo experiment) or bad methodological quality (‘bad’ in vivo experiments). In vivo 
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experiments were considered of good methodological quality if the following checklist’s 
items were positively answered: β1, β1 a, δ1, ε1, ε3, ε5 c, ζ1, η5 and η6 (refer to Appendix B 
for the items specification). If at least one of these items was negatively answered, the in 
vivo experiment was classified as a ‘bad’ in vivo experiment 
o based on the number of their ‘good’ and ‘bad’ in vivo experiments, CCs were ordered and 
weighted 
o correlation between ordered CCs and their clinical antitumor activity was detected using a 
linear meta-regression model and was shown using a forest plot. 
Statistical analyses were generated using SAS software, version 9.4 of the SAS System for Windows. 
Copyright (c) 2016 by SAS Institute Inc., Cary, NC, USA. Fixed and random effects model were 
generated using  StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: 
StataCorp LLC. Forest plots were generated using SAS software, version 9.4, and Review Manager 
(RevMan), version 5.3. Copenaghen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014. 
  
49 
 
Chapter 4 
Results 
4.1 Selection of clinical trials and CCs 
On 1st January 2019 a systematic search of the Medline and EMBASE databases was carried out to 
identify eligible CCs and to estimate their clinical antitumor activity. The systematic database search 
yielded 2020 records. After 70 duplicates were removed, 1738 were excluded after reviewing the 
title and abstract. A total of 212 articles were selected for full-text review and closer inspection to 
determine whether they met eligibility criteria for clinical trials and CCs. 143 full-text articles were 
excluded, the major reasons being (1) duplicate abstract of an eligible and assessed trial (n = 44, 
31%), (2) on-going eligible trial (n = 31, 22%), (3) ineligible CC or therapy (n = 30, 21%) or antitumor 
activity endpoint was neither primary nor co-primary of the trial (n = 17, 12%; refer to Figure 4.1.1). 
Sixty-nine eligible clinical trials in total were included in this survey. They are listed in Appendix C. 
 
Figure 4.1.1 PRISMA flow diagram on selection of clinical trials 
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The major characteristics of eligible clinical trials are reported in Table 4.1.1. All the clinical trials 
except one (Tew et al., 2014; see Appendix C) did not use blinding. Fifty-seven out of 69 (83%) were 
open-label, single-arm phase I/II or II trials. Only 5 out of 69 (7%) trials were randomized in 
conjunction with a control arm to detect efficacy improvement of the experimental CC with respect 
to the standard therapy. All the clinical trials except one (Seetharamu et al., 2010; see Appendix C) 
started patients’ accrual in the 21st century. Eligible CCs were evaluated as monotherapy in 85 
cohorts of patients. In each cohort, the median number of patients evaluated for antitumor activity 
was 34.5 (IQR: 20.5-51.0). 49 out of 69 (71%) trials chose ORR as the primary endpoint. To assess 
tumor response, RECIST criteria, version 1.0 and version 1.1, were used respectively in 37 (54%) and 
27 (40%) out of 68 trials (Graziani et al., 2017, did not report which tumor response criteria were 
used; see Appendix C). GCIG CA125 criteria alone or in combination with RECIST criteria were used 
in 14 out of 68 (21%) trials. Sixty-four out of 69 (93%) trials did not use an Independent Review 
Committee to assess tumor response. 
 N % 
Year of final publication 
30 43 2010-2012 
2013-2015 16 23 
2016-2019 $ 23 33 
Phase of clinical trial 
65 94 II 
I/II 4 6 
Experimental design   
Blinding Open-label 68 99 
 Double-blind 1 1 
Single-arm Yes 57 83 
 No 12 17 
Randomized trial Yes  12 17 
  Controlled 5 42 
  Not controlled, multi-arm 7 58 
 No 57 83 
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Multicenter Yes 58 84 
 No 11 16 
Geographic location 
42 61 USA 
Europe 28 41 
Other location Canada 11 16 
 Australia 5 7 
 Israel 3 4 
 Japan 2 3 
 Brazil, China, South Korea 1 1 
Start of accrual, year 
2008  Median 
 Min-max 1999-2015 
 Missing data 2 3 
Efficacy population, number of patients by cohort §§  
 N  84 
 Median 34.5 
 Q1-Q3 20.5-51.0 
 Min-max 4-193 
 Missing data §§§ 1 1 
Primary endpoint 
40 58 ORR 
PFS 15 22 
PFS AND ORR 9 13 
DCR 5 7 
  
52 
 
Tumor response criteria 
31 45 RECIST Version 1.0 
RECIST Version 1.1 20 29 
RECIST Version 1.1 AND/OR GCIG CA125 criteria 7 10 
RECIST Version 1.0 AND/OR GCIG CA125 criteria 6 9 
WHO criteria 2 3 
MASS criteria (Smith et al., 2010) 1 1 
GCIG CA125 criteria 1 1 
 Missing data 1 1 
Tumor response assessment 
64 93 Investigator-determined response 
Unblinded Independent Review Committee 5 7 
Table 4.1.1 Major characteristics of eligible clinical trials 
Legend 4.1.1: $ Two articles in press on 1st January 2019 were considered eligible; $$ antitumor 
activity was evaluated in 85 cohorts of patients analyzed in the 69 eligible clinical trials; $$$ for one 
cohort, the number of patients evaluated for antitumor activity was not available (Drew et al., 2016; 
see Appendix C)  
 
Fifty-two eligible CCs were identified in the 69 eligible clinical trials. They are listed in Table 4.1.2. 
Of these, 34 (65%) and 18 (35%) could be broadly classified as targeted and chemotherapeutic CCs, 
respectively. Forty-three out of 52 (83%) CCs were identified in a single clinical trial. 
Classification of 
eligible CCs 
CCs’ names (number of eligible clinical trials in which the CC was 
administered as monotherapy) 
Targeted therapy Olaparib (4), Sunitinib (4), Cabozantinib (3), Rucaparib camsylate (3), 
Sorafenib (3), ENMD-2076 (2), Temsirolimus (2), Veliparib (2), Aflibercept 
(1), Alisertib (1), Apatinib (1), Birinapant (1), BI 2536 (1), Cediranib (1), 
Dalantercept (1), Danusertib (1), Dasatinib (1), Enzastaurin (1), Iniparib (1), 
Imatinib Mesylate (1), Lapatinib (1), L-asparaginase (1), Lenalidomide (1), 
Motesanib (1), Nintedanib (1), Pazopanib (1), Perifosine (1),  Prexasertib 
(1), RO4929097 (1), Selumetinib (1), Tasquinimod (1), Urokinase-derived 
peptide (A6) (1), Vandetanib (1), Volasertib (1) 
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Chemotherapy Topotecan (3), Belinostat (1), Bendamustine Hydrochloride (1), 
Elacytarabine (1),  Eribulin Mesylate (1), Etirinotecan pegol (1), Gimatecan 
(1), Irofulven (1), Ixabepilone (1), Liposomial cisplatin (1), Lurbinectedin 
(1), Nab-paclitaxel (Abraxane) (1), Non-pegylated liposomal doxorubicin 
(1), Paclitaxel in non-protein lipid core nanoparticles (1), Patupilone (1), 
Sagopilone (1), Trabectedin (1), Zoptarelin Doxorubicin Acetate (1) 
Table 4.1.2 List and broad classification of eligible CCs 
4.2 Patient characteristics and assessment of clinical antitumor activity 
One out of the 69 (1.4%) eligible trials was excluded from quantitative analysis of clinical antitumor 
activity because neither ORR nor PFS endpoints were available (Drew et al., 2016). A total of 3455 
patients were enrolled in the remaining 68 trials. The major characteristics of these patients are 
reported in Table 4.2.1. The mean age of patients was 60 years. The majority of enrolled patients 
had ECOG PS equal to 0-1. Despite the high percentage of missing data, it could be said that ovary 
and serous were the most common primary sites of tumor origin and cell type, respectively. Patients 
were mainly platinum resistant. Platinum resistant patients are those in whom the disease has 
progressed during (i.e. more precisely, refractory patients) or within 6 months of completing a 
platinum-based therapy. Platinum-sensitive are those with a platinum-free interval of six months or 
longer. At least 1547 (67%) patients had more than the one line of chemotherapy for recurrent 
disease. 
   N % 
Age (years)  
 N  3455 
 Mean (Standard error) 60 (0.4) 
ECOG Performance Status   
0-1  3002 96 
2  112 4 
 Missing data 341 10 
54 
 
 
Table 4.2.1 Major characteristics of enrolled patients 
Legend 4.2.1: § Platinum resistant patients are those in whom disease has progressed during (i.e. 
refractory) or within 6 months of completing a platinum-based therapy 
 
Antitumor activity of the 52 eligible CCs was assessed in terms of ORR and median PFS endpoints, 
in 82 and 72 cohorts, respectively. Statistical analysis of these endpoints is graphically shown in 
Figure 4.2.1 and Figure 4.2.2 respectively, and could be summarized by the following considerations: 
o Most patients had a poor prognosis. Average summary ORR and median PFS were 13% 
(95%CI 10-16) and 3.3 (95%CI 2.9-3.9) months, respectively. These average estimates could 
not be attributable to the presence of few cohorts with very unsatisfactory prognosis. In fact, 
as shown in Figure 4.2.1 and Figure 4.2.2, these average estimates were obtained with an 
Malignancy 
1933 89 Ovarian cancer 
Primary peritoneal carcinoma 183 8 
Fallopian tube carcinoma 58 3 
 Missing data 1281 37 
Cell type 
2060 79 Serous 
Adenocarcinoma 132 5 
Endometrioid 126 5 
Clear cell 120 5 
Other 186 7 
 Missing data 831 24 
No. of prior chemotherapy regimens   
1 760 33 
>1 1547 67 
 Missing data 1148 33 
Platinum sensitivity § 
2064 65 Resistant  
Sensitive 1095 35 
 Missing data 296 9 
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approximately equal weight assigned to each cohort. ORR was less than 10% in 42 out of 82 
(51%) cohorts and median PFS was less than 4 months in 40 out of 72 (56%) cohorts 
o Cohorts’ prognosis was highly heterogeneous. The proportion of variance not explained by 
random error was 85.9% and 95.7% for the ORR and median PFS endpoints, respectively. 
Although it is impossible to estimate the proportion of this unexplained variance due to 
heterogeneous distribution of prognostic and predictive factors, the great contribution of 
prognostic and predictive factors was shown by a couple of subgroup-analyses. In the first 
subgroup-analysis, the impact of platinum sensitivity on patients prognosis was estimated 
(refer to Figure 4.2.3 and 4.2.4). Cohorts evaluating platinum sensitive patients had a better 
prognosis compared to cohorts with platinum resistant patients, in terms of both ORR  
[average ORR: 31% (95%CI 23-41%) vs 10%(95%CI 7-14%), p-value<0.001] and median PFS 
[average median PFS: 5.8 (95%CI 4.8-7.4) vs 3.2 (95%CI 2.8-3.8) months, p-value<0.001]. 
However, platinum sensitivity did not fully account for the variance not explained by random 
error, suggesting that many, some of them unknown, prognostic/predictive factors cause 
the detected heterogeneity. In the second subgroup-analysis, CCs administered in more than 
one cohort were identified. In each subgroup of cohorts, the proportion of variance not 
explained by random error was estimated (refer to Table 4.2.2). Although the same CC was 
administered in the cohorts’ subgroups, the cohorts’ prognosis continued to be highly 
heterogeneous. However, there were exceptions to this, as clearly shown in Table 4.2.2. 
In Figure 4.2.5 estimates of treatment effects in all eligible randomized and controlled clinical trials 
(RCTs) are shown. Because prognostic factors do not contribute to these estimates, the high 
heterogeneity between treatment effects observed in this group of trials supports our objective of 
correlating preclinical methodological quality to estimates of clinical antitumor activity. But the 
sample of available RCTs is too small to perform any meaningful analysis. 
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Figure 4.2.1 ORR distribution 
57 
 
 
Figure 4.2.2 Median PFS distribution 
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Figure 4.2.3 ORR distribution by platinum sensitivity 
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Figure 4.2.4 Median PFS distribution by platinum sensitivity 
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CC ORR  Median PFS  
 N° of 
cohorts Q (p-value), I
2(%) N° of cohorts Q (p-value), I
2(%) 
Olaparib 7 6.19 (0.402), 3.0 7 32.00 (<0.001), 81.2 
Sunitinib 5 3.65 (0.456), 0 5 6.71 (0.152), 40.4 
Rucaparib 5 24.53 (<0.001), 83.7 3 37.64 (<0.001), 94.7 
Topotecan 5 11.16 (0.025), 64.2 2 2.21 (0.137), 54.7 
Sorafenib 3 2.73 (0.256), 26.7 3 16.11 (<0.001), 87.6 
Cabozantinib 3 8.56 (0.014), 76.6 2 0.57 (0.450), 0 
Veliparib 2 3.11 (0.078), 67.8 2 3.38 (0.066), 70.4 
ENMD-2076 2 0.002 (0.962), 0 2 0.01 (0.913), 0 
Temsirolimus 2 0.022 (0.883), 0 2 0.02 (0.883), 0 
Table 4.2.2 Heterogeneity in different cohorts treated with the same CC 
 
ORR endpoint 
PFS endpoint 
Figure 4.2.5 Heterogeneity of treatment effects in RCTs 
Legend 4.2.5:  Chi2 values in the figure are the same as the Q statistic used previously. Forest plots 
were automatically generated using RevMan, version 5.3 
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4.3 Selection of preclinical in vivo antitumor activity studies 
On 9th May 2019 a systematic search of the Medline and EMBASE databases was carried out to 
identify eligible preclinical in vivo antitumor activity studies and to assess their methodological 
quality. The systematic database search yielded 823 records. No additional records were identified 
by hand searching. After 58 duplicates were removed, a total of 765 articles remained. Due to poor 
reporting standards of preclinical in vivo antitumor activity studies, it was decided to screen articles 
based upon the full-text review. Six hundred ninety full-text articles were excluded on this basis, the 
major reasons being (1) no eligible CC was used in an in vivo EOC model, as monotherapy (n = 417, 
60%), (2) no EOC model was used (n = 199, 29%), (3) the paper was requested to the Institute Library 
but it was not available (n = 43, 6%) and the paper was written in languages other than English (n = 
28, 4%; refer to Figure 4.3.1). Seventy-five articles in total were included in this survey. They are 
listed in Appendix D. 
 
Figure 4.3.1 PRISMA flow diagram on selection of preclinical in vivo antitumor activity studies 
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Characteristics of eligible preclinical research articles are reported in Table 4.3.1. Fifty-three out of 
75 (71%) eligible papers were published in the last ten years. One hundred twenty-one eligible in 
vivo experiments and 176 eligible in vivo EOC models were identified. Only 14 (19%) papers reported 
more than two eligible in vivo experiments. In 94 out of 121 (78%) eligible in vivo experiments, the 
CC was administered as monotherapy in a single eligible EOC model. The conflict of interest was 
declared in 40 (53%) papers. In 60 (80%) papers, the translation of preclinical results to the clinical 
setting was recommended or at least it was considered possible. 
 N % 
Year of publication 
10 13 1998-2003 
2004-2008 12 16 
2009-2013 24 32 
2014-2018 29 39 
Number of eligible in vivo experiments, by eligible paper 
49 65 1 
2 12 16 
3 10 13 
4 3 4 
5 0 0 
6 1 1 
Number of eligible in vivo models, by eligible experiment   
1 94 78 
2 20 17 
3 1 1 
4 4 3 
11 1 1 
12 1 1 
Conflict of interests   
Declared Yes 40 53 
  Conflicts of interest are reported 13 32 
  None 27 68 
 No 35 47 
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 N % 
Recommended clinical translation   
 Yes  32 43 
 Possible  28 37 
 No  15 20 
Table 4.3.1 Major characteristics of eligible preclinical research papers 
In Table 4.3.2, the list of eligible CCs, administered as monotherapy in at least one eligible EOC 
model, is reported.  For 28 out of  52 (54%) eligible CCs, no eligible preclinical in vivo experiment 
was identified.  
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 N § % §§ 
Topotecan 28 23 
Olaparib 14 12 
Cediranib 8 7 
Gimatecan 8 7 
Dasatinib 7 6 
Nab-Paclitaxel 7 6 
Pazopanib 7 6 
Sunitinib 7 6 
Vandetanib 6 5 
Sorafenib 5 4 
Irofulven 4 3 
Eribulin Mesylate 4 3 
Trabectedin 4 3 
Belinostat 3 2 
Aflibercept 3 2 
Selumetinib 3 2 
Perifosine 3 2 
Alisertib 2 2 
Rucaparib 2 2 
Lapatinib 2 2 
Etirinotecan pegol 2 2 
Ixabepilone 1 1 
Imatinib Mesylate 1 1 
Non-pegylated liposomal doxorubicin 1 1 
Table 4.3.2 List of CCs evaluated in preclinical in vivo experiments 
Legend 4.3.2: § Number of preclinical in vivo experiments §§ Does not sum to 100% as in 6 out of 121 
(5%) preclinical in vivo experiments two eligible CCs were administered as monotherapy [topotecan 
and pazopanib (2); sorafenib and sunitinib (1); cediranib and olaparib (1); nab-paclitaxel and 
topotecan (1); gimatecan and topotecan (1)] 
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4.4 Tumor models used in preclinical in vivo antitumor activity studies 
The characteristics of eligible in vivo tumor models are reported in Table 4.4.1. All models were 
immunocompromised. Unexpectedly and without explanation, 2 out of 140 (1.4%) tumor models 
were male mice (Alvero et al., 2007; Nagengast et al., 2011; refer to Appendix D). Poor reporting or 
methodological mistake could explain this data. One hundred thirty-nine out of 176 (79.0%) tumor 
models were CDX. The most common types of cells were A2780 and the derived cells (n = 37, 26.6%), 
and SKOV3 and the derived cells (n = 30,  21.6%). Athymic nude mice were the most commonly used 
strain (n = 98, 57.0%). 
 N % 
Species   
Mouse 175 99 
Rat 1 1 
Age (weeks)   
 Min-max 3-14  
 Missing data 52 30 
Sex   
Female  138 98.6 
Male  2 1.4 
 Missing data 36 20.5 
Weight (grams)   
 Min-max 14-28  
 Missing data 171 97 
Immune status   
Immunocompromised 176 100 
Immunocompetent 0 0 
Model type   
Cell derived xenograft (CDX) 139 79.0 
Patient derived xenograft (PDX) 37 21.0 
CDX, type of cell   
A2780 and derived cells 37 26.6 
SKOV3 and derived cells 30 21.6 
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 N % 
HEY and derived cells 13 9.4 
IGROV-1 9 6.5 
OVCAR-3 7 5.0 
RMG-II 7 5.0 
PEO1 and derived cells 4 2.9 
RMG-I 4 2.9 
ES-2 3 2.2 
MA148 3 2.2 
OVCAR-5 and derived cells 3 2.2 
Caov-3 2 1.4 
EFO-27 2 1.4 
Pat-7 2 1.4 
PEO4 and derived cells 2 1.4 
RMUG-S and derived cells 2 1.4 
TOV-21G 2 1.4 
C13 1 0.7 
HO-8910 1 0.7 
OVTOKO 1 0.7 
OV-2008 1 0.7 
OV-90 1 0.7 
OW1 1 0.7 
Tumor-initiating cells derived from A2780/HEY cell lines 1 0.7 
Strain   
Athymic nude 98 56.0 
CD-1 nude  8 4.6 
Swiss nude   19 10.9 
BALB/c Nude 15 8.6 
CB17 SCID 4 2.3 
SCID-beige 4 2.3 
NOD/Scid 8 4.6 
NOD/SCID gamma 18 10.3 
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 N % 
RNU Nude (Rat species) 1 0.6 
Missing data 1 0.6 
Table 4.4.1 Major characteristics of eligible in vivo tumor models 
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4.5 Assessment of the quality of statistical design and analysis 
Results of the assessment of the quality of statistical design and analysis are reported in Tables 4.5.1-
4.5.8, by ad hoc checklist’s sections. All preclinical in vivo experiments used mice, expect one that 
used rats. Ninety-four out of 121 (77.7%) preclinical in vivo experiments used a single cancer model. 
All preclinical in vivo experiments were monocenter. Forty-five out of 120 (37.5%) preclinical in vivo 
experiments did not specify the method of treatment assignment and 71 out of 74 (95.9%) 
preclinical in vivo experiments did not specify the type of randomization. The technique of allocation 
concealment and the use of randomization for housing animals within the animal room and for 
assessing study outcomes were totally missing. As reported in Table 4.5.2, CC was the active arm in 
64 out of 121 (52.9%) preclinical in vivo experiments. Twenty-three (19.0%) preclinical in vivo 
experiments used a dose-response design (i.e. > 3 doses were administered including the placebo 
arm). Fifty-seven (47.1%) preclinical in vivo experiments used a factorial design but interaction 
between design factors was never formally tested. The technique of blocking was never used, 
neither in statistical design nor in statistical analysis. Sample size was justified in only 9 (7.4%) 
preclinical in vivo experiments. In these few cases, sample size was determined using a power 
analysis but the magnitude of the targeted biological signal was never justified. Moderate 
heterogeneity was observed in the number of animals enrolled by arm (IQR: 6-10; min-max: 3-29). 
The primary outcome measure was tumor volume in 64 (52.9%) preclinical in vivo 
experiments. Tumor volume was measured in different ways (mono, bi and tridimensional ways). 
Lack of standardization was detected in tumor volume determination and in the definition of tumor 
response (i.e. PR/CR) and definition of cure of animal. In only 14 out of 106 (13.2%) cases the 
antitumor activity endpoint (i.e. the target tumor volume after which the rodent is sacrificed and 
hence tumor growth is not observed anymore) was clearly reported. Outcome assessor was blinded 
in only 5 (4.1%) cases.  
Hypothesis testing, which is necessary to detect treatment effects, was used in 99 (81.8%) 
cases, while treatment effect’s estimates were reported in only 61 (50.4%) cases. In the analysis of 
tumor growth curves, parametric methods were preferred over non-parametric methods but their 
statistical assumptions were questioned in only 9 out of 67 (13.4%) cases. On the other hand, non-
parametric methods such as the log-rank test were preferred in survival analysis. The inefficient 
one-way ANOVA was preferred over the efficient linear mixed-effects models for repeated 
measures. The analysis and reporting of tumor growth curves were definitely poor. It was never 
possible to review the process, starting from treatment assignment to the rodents that were actually 
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analyzed. The number of animals on which the plotted point was based was never reported in the 
plot of tumor growth curves. Hence it was impossible to estimate the variability of the biological 
signal. In only 5 (4.1%) cases, the event that determined the end of follow-up was clearly reported 
for each rodent. The length of follow-up, a key element to debate the magnitude of biological signal, 
was specified in only 43 (35.5.%) cases. The statistician could be identified in 14 (11.6%) cases and 
the use of a statistical software was reported in 58 (47.9%) cases. 
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Item Category Statistics  
α1. Is the same experiment repeated more than once by a single lab? Yes N (%) 3 (2.5) 
 No N (%) 118 (97.5) 
 N° of repetition 2 N (%) 3 (100) 
 Reasons for repetition, 
specify 
Poor statistical design; randomization 
was introduced in the repeated 
experiment 
N (%) 1 (100) 
  Unknown N (%) 2 (66.6) 
α2. N° of different species in which the EOC experiment has been repeated 1 (i.e. mouse) N (%) 120 (99.2) 
 2 (i.e. mouse and rat) N (%) 1 (0.8) 
α3. N° of different cancer models in which the EOC experiment has been repeated 1 N (%) 94 (77.7) 
 2 N (%) 20 (16.5) 
 3 N (%) 1 (0.8) 
 4 N (%) 4 (3.3) 
 11 § N (%) 1 (0.8) 
 12 § N (%) 1 (0.8) 
α4. N° of participating laboratories Monolab N (%) 121 (100) 
 Multilab N (%) 0 
Table 4.5.1 Repetition and external validity 
Legend 4.5.1: § Patient-derived xenograft models have been used 
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Item Category Statistics  
β1. Is an internal control group used? Yes N (%) 120 (99.2) 
 No N (%) 1 (0.8) 
 β1 a. If yes, are animals randomly allocated to treatment? Yes N (%) 74 (98.7) 
 No N (%) 1 (1.3) 
  Unknown N (%) 45 (37.5) 
  Alternative method to randomization Matching N (%) 1 (100) 
 β1 b. If randomization is used, is the randomization method stated? Yes N (%) 3 (4.1) 
  No N (%) 71 (95.9) 
 Specify randomization method  Stratified randomization N (%) 3 (100) 
 β1 c. If randomization is used, is allocation concealment employed? Unknown N (%) 74 (100) 
 β1 d. Are the animals randomly housed within the animal room? Unknown N (%) 121 (100) 
 β1 e. Are there equal numbers per treatment group? Yes N (%) 82 (75.2) 
  No N (%) 27 (24.8) 
  Unknown N (%) 12 (9.9) 
 β1 f. If not, is this justified?   No N (%) 27 (100) 
β2. Is the experimental unit clearly identified? Yes N (%) 121 (100) 
 No N (%) 0 
 Specify experimental unit Single animal N (%) 121 (100) 
 Suspicious case of pseudo-replication Drug was dissolved in cage’s water N (%) 1 (0.8) 
β3. Role of CC monotherapy arm Active N (%) 64 (52.9) 
 Only control arm N (%) 57 (47.1) 
Table 4.5.2 Internal validity 
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Item Category Statistics  
γ1. Is an active control group used? Yes N (%) 83 (68.6) 
 No N (%) 38 (31.4) 
γ2. Number of design factors 1 N (%) 64 (52.9) 
 2 N (%) 53 (43.8) 
 3 N (%) 4 (3.3) 
γ3. Number of treatment (design) groups    N 121 
  Median 4 
  IQR 3-5 
   Min-max 2-12 
γ4. Is a factorial (complete or incomplete) design used? Yes N (%) 58 (47.9) 
 No N (%) 63 (52.1) 
γ5. Is dose-response (i.e. > 3 doses) evaluated? Yes N (%) 23 (19.0) 
  No N (%) 98 (81.0) 
γ6. Is blocking used? Yes N (%) 0 
  No N (%) 121 (100) 
γ7. Type of experiment  Between units N (%) 121 (100) 
 Within units N (%) 0 
  Both N (%) 0 
Table 4.5.3 Statistical design 
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Item Category Statistics  
δ1. Is the sample size justified? Yes N (%) 9 (7.4) 
 No N (%) 112 (92.6) 
 δ1 a. If yes, specify method Common sense N (%) 0 
 Power analysis N (%) 9 (100) 
  Resource equation N (%) 0 
  Other method to determine sample size  N (%) 0 
δ2. Total number of enrolled animals per arm § N N 116 
 Median Median 9 
  IQR 6-10 
  Min-max 3-29 
  Unknown N (%) 5 (4.1) 
Table 4.5.4 Sample size 
Legend 4.5.4: § Both methods and results sections were considered to calculate the total number of enrolled animals per arm 
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Item Category Statistics  
ε1. Can the primary outcome measure of antitumor activity clearly be identified? § Yes N (%) 121 (100) 
 No N (%) 0 
ε2a. Specify primary outcome measure Tumor volume N (%) 64 (52.9) 
 Tumor weight N (%) 30 (24.8) 
 Overall survival N (%) 15 (12.4) 
 Photon counts per area N (%) 8 (6.6) 
 Volume of ascites N (%) 2 (1.7) 
 Number of metastases N (%) 1 (0.8) 
 Number of cured animals N (%) 1 (0.8) 
ε2b. Specify primary or secondary outcome measures Tumor volume N (%) 68 (56.2) 
 Tumor weight N (%) 37 (30.6) 
 Overall survival N (%) 20 (16.5) 
 Number of tumor nodules N (%) 18 (14.9) 
 Time to reach a target volume N (%) 14 (11.6) 
 Photon counts per area N (%) 9 (7.4) 
 Volume of ascites N (%) 5 (4.1) 
 Number of metastases N (%) 2 (1.7) 
 Number of cured animals N (%) 2 (1.7) 
 Tumor burden §§ N (%) 1 (0.8) 
 Definition of tumor volume §§§ Monodimensional (length)3 x (π/6) N (%) 1 (0.02) 
 (length)3 x (π/6) N (%) 1 (0.02) 
  Bidimensional (length x width2) / 2 N (%) 24 (48.0) 
   (length x width2) x (π/6) N (%) 7 (0.14) 
   (length x width)/2 N (%) 2 (0.04) 
 (length)3/2 x width)2 x (π/6) N (%) 1 (0.02) 
 (length x width)(3/2) x (π/6) N (%) 1 (0.02) 
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 (length x width) x (π/3) N (%) 1 (0.02) 
 [(length + width)/4]3 ∙ (0.67 ∙ π) N (%) 1 (0.02) 
  Tridimensional (length x width x height) / 2 N (%) 6 
   (length x width x height) x (π/6) N (%) 4 (0.1) 
   (length x width x height) x (4 ∙ π/3) N (%) 2 (0.04) 
  Missing data  N (%) 20 (28.2) 
 Definition of cured animals Animals without tumor at the end of the study N (%) 1 (50.0) 
  Recovery of the initial weight N (%) 1 (50.0) 
 Measures of treatment effect Tumor volume T/C N (%) 30 (44.1) 
   CR/PR §§§§ N (%) 14 (20.6) 
   % change respect to treatment start N (%) 4 (5.9) 
  Time to reach a target volume §§§§§ Log Cell Kill (LCK) N (%) 4 (28.6) 
   Tumor Growth Delay (TGD) N (%) 3 (21.4) 
ε3. Is the antitumor activity endpoint (i.e. event)  Overall survival as primary Yes N (%) 13 (86.7) 
clearly defined? outcome measure No N (%) 2 (13.3) 
 Tumor volume and other Yes N (%) 14 (13.2) 
 primary outcome measures No N (%) 92 (86.8) 
ε4. Are the competing events clearly defined?     Yes N (%) 3 (2.5) 
 No N (%) 118 (97.5) 
ε5. Outcome assessment    
ε5 a. Are the caregivers and/or investigators blinded? Yes N (%) 1 (0.8) 
 No N (%) 120 (99.2) 
ε5 b. Are animals selected at random for outcome assessment? Unknown N (%) 121 (100) 
ε5 c. Is the outcome assessor blinded?  Yes N (%) 5 (4.1) 
 No N (%) 116 (95.9) 
Table 4.5.5 Outcomes and their assessment 
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Legend 4.5.5: § Only one eligible paper defined clearly the primary outcome (Decio et al., 2015; refer to Appendix D). In all other cases, assessor’s 
judgement deduced which was the primary outcome based on the report and the biological relevance. Reporting bias about primary/secondary outcomes 
could be present although it was impossible to detect it §§ An arbitrary score was used to estimate tumor dissemination §§§ 71 preclinical in vivo experiments 
used as outcome measure the tumor volume, measured by caliper, or the time to reach a target volume §§§§ CR/PR: Complete Response/Partial Response;  
CR and PR were defined differently by eligible papers §§§§§ 14 preclinical in vivo experiments used the time to reach a target volume as secondary outcome. 
LCK is defined as [(T-C) /3.32] x DT, where T and C are the mean times (days) required for treated (T) and control (C) tumors, respectively, to reach the 
target volume, and DT is the doubling time of control tumors. TGD is defined as T-C, where T and C are the mean times (days) required for treated (T) and 
control (C) tumors, respectively, to reach the target volume 
 
 
  
77 
 
Item Category Statistics  
ζ1. Are inferential methods used to demonstrate antitumor activity? Yes N (%) 106 (87.6) 
 No N (%) 15 (12.4) 
 ζ1 a. Hypothesis test Yes N (%) 99 (93.4) 
 No N (%) 7 (6.6) 
  Specify hypothesis test One-way parametric ANOVA N (%) 56 (56.6) 
   Log-rank N (%) 20 (20.2) 
   One-way non-parametric ANOVA N (%) 13 (13.1) 
   Two-way parametric ANOVA for repeated measures N (%) 11 (11.1) 
   Other hypothesis tests § N (%) 5 (5.1) 
   Not specified hypothesis test N (%) 2 (2.0) 
 ζ1 b. Estimation Yes N (%) 61 (57.5) 
  No N (%) 45 (42.5) 
 Specify estimator Mean plus SE or 95%CI N (%) 60 (98.4) 
  Hazard Ratio plus 95%CI N (%) 1 (1.6) 
ζ2. Are descriptive methods used to demonstrate antitumor activity?  Yes N (%) 109 (90.1) 
 No N (%) 12 (9.9) 
 Specify methods §§ Tumor growth curve N (%) 54 (49.5) 
  Mean plus STD N (%) 23 (21.1) 
  Kaplan-Meier N (%) 17 (15.6) 
ζ3. Are methods for correction of multiple comparison used? Yes N (%) 20 (22.7) 
  No N (%) 68 (77.3) 
  Not applicable N (%) 33 (27.3) 
 Specify methods Post-hoc tests §§§ N (%) 19 (95.0) 
  Holm’s procedure N (%) 1 (5.0) 
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ζ4. Are statistical assumptions used to analyze tumor growth data 
justified? 
Yes N (%) 9 (13.4) 
  No N (%) 58 (86.6) 
  Not applicable N (%) 54 (44.6) 
 Specify methods Normality tests §§§§ N (%) 7 (77.8%) 
  Log-transformation  2 (22.2%) 
Table 4.5.6 Statistical analysis 
Legend 4.5.6: § Wilcoxon matched-pairs signed test (3 preclinical in vivo experiments); Fisher's exact test (1 preclinical in vivo experiments), Q test for 
heterogeneity (1 preclinical in vivo experiment) §§ Only descriptive methods used by a number of preclinical in vivo experiments greater or equal to 5 are 
reported §§§ Tukey (9 preclinical in vivo experiments); Bonferroni (5 preclinical in vivo experiments); Dunnett (5 preclinical in vivo experiments) §§§§ 
Kolmogorov-Smirnov test (6 preclinical in vivo experiments), Shapiro-Wilk test (1 preclinical in vivo experiment)  
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Item Category Statistics  
η1. Number of animals assigned to each treatment arm (results section) Exact N (%) 67 (55.4) 
 Estimate N (%) 16 (13.2) 
 Unknown N (%) 38 (31.4) 
η2. Are there animals assigned to each treatment arm and excluded  Unknown N (%) 121 (100) 
from statistical analysis? Specify reasons for exclusion  N (%) - 
η3. Are there animals at risk progressively reported in the plot  Yes N (%) 0 
of tumor growth curves? No N (%) 54 (100) 
 Not applicable § N (%) 67 (55.4) 
η4. Is the number of animals with right-censored data clearly reported? Yes N (%) 5 (4.1) 
 No N (%) 116 (95.9) 
η5. For each animal, is it clearly reported which event determined the end of  Yes N (%) 5 (4.1) 
follow-up? No N (%) 116 (95.9) 
η6. Is the length of follow-up clearly defined? Yes N (%) 43 (35.5) 
 No N (%) 78 (64.5) 
 Specify definition Based on treatment schedule N (%) 33 (76.7) 
  Control group reached critical conditions N (%) 7 (16.3) 
  The target volume was reached N (%) 2 (4.7) 
  Historical growth rate of the tumor model N (%) 1 (2.3) 
Table 4.5.7 Attrition bias about tumor growth curves 
Legend 4.5.7: § Tumor growth curves were reported in 54 preclinical in vivo experiments (refer to Table 4.5.6) 
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Item Category Statistics  
θ1. State any important concerns about statistical design and analysis not covered 
by other sections in the checklist § 
   
 Interaction was not formally evaluated in a factorial design N/Tot (%) 56/57 (98) 
 One-way parametric/non-parametric ANOVA was repeated for all time points N/Tot (%) 9/54 §§ (17) 
 Mice were grafted bilaterally. Statistical analysis was not explained N/Tot (%) 5/6 (83) 
 Different number of animals reported in methods and results sections N/Tot (%) 5/116 (4) 
 In survival analysis, lead time bias was detected using the day of tumor 
transplant, instead of the day of randomization, as the starting day  
N/Tot (%) 3/20 §§§ (15) 
θ2. Was any author a member of a department of statistics or epidemiology? Yes N (%) 14 (11.6) 
 No N (%) 107 (88.4) 
θ3. Was mentioned the use of a statistical software for data analysis? Yes N (%) 58 (47.9) 
  No N (%) 63 (52.1) 
 Specify statistical softwares §§§§ GraphPad Software, La Jolla, CA, USA N (%) 38 (65.5) 
  SPSS Inc, Chicago, IL N (%) 14 (24.1) 
  Excel  4 (6.9) 
  STATA  3 (5.2) 
  SAS N (%) 2 (3.4) 
  JMP N (%) 1 (1.7) 
  Python N (%) 1 (1.7) 
  R N (%) 1 (1.7) 
Table 4.5.8 Miscellanea 
Legend 4.5.8: § Only statistical pitfalls regarding a number of preclinical in vivo experiments greater or equal to 3 are reported §§ Tumor growth curves were 
reported in 54 preclinical in vivo experiments §§§ Overall survival was the primary or secondary outcome in 20 preclinical in vivo experiments §§§§  Two statistical 
softwares were used in 6 preclinical in vivo experiments
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4.6 Correlation between preclinical quality and phase 2 activity 
There were no preclinical in vivo experiment eligible to be classified with good methodological 
quality. Even if two of the items defining a ‘good’ in vivo experiment are not considered, no 
preclinical in vivo experiment could be classified with good methodological quality. Different 
preclinical in vivo experiments had ‘good’ scores on different aspects. But different aspects could 
not be used confidently to rank the quality of preclinical in vivo experiments. 
In conclusion, due to poor methodology applied, it was impossible to correlate quality of 
preclinical in vivo experiments with clinical activity.  
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Chapter 5 
Improving statistics of in vivo tumor growth curves 
5.1 Concepts 
This section reviews the concepts of hypothesis testing and estimation. Readers who are familiar 
with these concepts can skip to the Section 5.2. 
5.1.1 Testing statistical hypotheses 
The researcher is primary interested in detecting a treatment effect. The definition of ‘no effect’ is 
as follows: each animal exhibits a response (i.e. outcome) that is observed some time after 
treatment. To say that the treatment has no effect on this response is to say that each animal would 
exhibit the same value of the response whether assigned to active or control arm. If changing the 
treatment assigned to an animal changed that animal’s response, then certainly the treatment has 
at least some effect. Because it is usually impossible to observe animal’s response under both 
conditions (i.e. each animal is treated according to the active and control arm), animals are 
randomized to the active and control arm and their responses are collected. A test statistic (e.g. 
mean difference or the Mann-Whitney statistic) is then calculated from the data. The primary 
usefulness of the randomization procedure is that the probability distribution of the test statistic 
when the null hypothesis (i.e. no treatment effect) is true is known. Based on this probability 
distribution, a ‘p-value’ is assigned to the test statistic. The p-value is the probability of obtaining a 
test statistic as extreme or more extreme when the null hypothesis is true. If the p-value is less than 
a sufficiently small value, called alpha (i.e. the significance level of the test; for example, 0.05), the 
investigator can ‘reject the null hypothesis’ and conclude that the treatment really does have an 
effect. A rejection of the null hypothesis when it is true is an error of inference, known as a type I 
error or ‘false positive’ result. An alpha (α) of 0.05 means that the investigator is willing to accept a 
type I error 5% of the time if the null hypothesis (i.e. no treatment effect) is actually true. If the 
treatment has no effect on the chosen outcome and the researcher replicates the same experiment 
100 times, we can expect that the significance level of the test is reached in 5 replications. The 
significance level of the test should be determined in advance, in the same manner that the rules of 
a card game are defined before the gamblers play with dealers. 
The p-value does not provide any information about how large or important the treatment 
effect is. Although the p-value does not provide any information about the treatment effect’s 
estimate, it is strictly related to the accuracy of the treatment effect’s estimate. Increasing sample 
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size, even tiny and unimportant effects can be discovered and accuracy of treatment effect’s 
estimate is improved.  
There is a second type of error of inference. A type II error occurs when one fails to discover 
a treatment effect when the null hypothesis is false (i.e. ‘false negative’ result). The probability of 
type II error is denoted as β. The complement of type II error, the power (i.e. 1 - β), is the probability 
that the null hypothesis will be rejected correctly given that there is a treatment effect. The power 
is a function of the treatment effect and sample size, as shown in Figure 5.1.1.1. 
 
Figure 5.1.1.1 Power as a function of treatment effect, expressed as effect size d (i.e. difference 
between means divided by standard deviation) and total sample sizes (i.e. “N Total”) in a 2-tailed t 
test with 2 independent groups, allocation ratio 1:1 and α = 0.05 
An in vivo experiment is underpowered if the power is inadequate (e.g. power = 0.50 or 0.60) to 
detect a valuable treatment effect. As consequence of underpowered in vivo experiments, animals 
could be wasted because the probability of type II error is high. An in vivo experiment is 
overpowered if power is too large. As consequence of overpowered in vivo experiments, trivial 
effects could be detected and too many animals are used. For example, as shown in Figure 5.1.1.1, 
if an effect of 1 standard deviation (STD) is the smallest interesting effect, designing the experiment 
to detect this effect with high power, such as 99%, could waste animals (total sample size is 76 
animals), because the test continues to detect trivial effects, such as 0.5, with a high frequency 
(57%). Setting a power of 90% for the smallest interesting effect, with a total sample size of 46 
animals, causes the detection of trivial effects to decline more steeply. 
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5.1.2 Point and interval estimates 
Once the treatment effect has been detected, a researcher is usually interested to estimate it. To 
solve this problem, the observations collected from an in vivo experiment are postulated to be the 
values taken by random variables which are assumed to follow a joint probability distribution. 
Eisenhart (1964) attributes the crucial step of considering observed data as generated by random 
variables to Simpson (1755).  
The probabilistic model that generates in vivo experiment’s observations is usually indexed by 
a set of parameters. The aim of the analysis is then to specify a plausible value for each parameter 
(this is the problem of point estimation), or at least to determine a subset of plausible values for 
each parameter (estimation by confidence intervals or credible intervals).  
For example, the probabilistic model of the one-way ANOVA is the following: 
Yij = μ + τi + εij, i=1,…,t; j=1,…,ri                                               5.1.2.1 
where Yij is the outcome and the parameters μ and τi are the overall mean and the effect of 
treatment i, respectively. εij is the error (i.e. the deviation of the particular unit j from the average 
of the set of units assigned to treatment i), often taken to be independent, identically and normally 
distributed with mean equal to zero. Casella’s book (2008) brilliantly discusses this model. If the 
experimental data are generated by the ANOVA model, the researcher is interested to estimate the 
parameters μ + τi, with i=1,…t.  
An estimator of a parameter is said ‘unbiased’ if its expected value is equal to the true value 
of the parameter. For example, from 5.1.2.1 
E { (1 / ri) ∙ [∑j (μ + τi + εij)] } = μ + τi                                            5.1.2.2 
showing that the parameter μ + τi is estimable and that the sample mean is an unbiased estimator. 
Confidence intervals and credible intervals are common measures used to specify subsets of 
plausible values for a probabilistic model’s parameter. Confidence and credible intervals are 
estimates of an interval that may contain the true value of the parameter. The interval is generally 
defined by its lower and upper bounds. A confidence or credible interval is usually expressed as a 
percentage (the most frequently quoted percentages are 90%, 95%, and 99%). The percentage is 
called the confidence and credible level, respectively. The confidence interval is constructed in the 
following way: parameter values that when postulated as the null hypothesis produce a p-value 
greater than 1 - percentage / 100 (e.g., 1 - 90/100 = 0.10, 1 - 95/100 = 0.05 and 1 - 99/100 = 0.01), 
will typically define a range of values that would be considered more compatible with the data than 
values outside the range - if the probabilistic model generating in vivo experiment’s observations is 
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correct. This range of values corresponds to a percentage (e.g. 90%, 95% and 99%) confidence 
interval, and provides a convenient way of summarizing the results of hypothesis tests for many 
parameter values. A credible interval is constructed in a way so that an unobserved parameter value 
falls within this interval with a particular probability. In bayesian statistics, the parameter is itself a 
random variable with a known probability distribution. Hence, credible intervals are commonly used 
to summarize the posterior probability distribution.  
5.2 Non-parametric Two-Sample Tests 
5.2.1 Definition of statistical tests 
When the tumors have reached a designated target volume, tumor-bearing animals are randomly 
assigned to control and experimental arms. Inactive vehicle or antitumor therapies are delivered to 
them, respectively. Tumor volumes are then measured with a caliper at randomization (0 = t0) and 
periodically (e.g. twice a week) at common time points tr, r=1,…,K, until the tumors reach a 
predetermined target volume. 
For some animals, tumor volume does not reach the target size because competing events 
occurs. For instance, death due to toxic effects of antitumor therapies or aggressive behaviour 
among animals occurs, a humane endpoint (i.e. the earliest indicator used to avoid or stop the 
distress, discomfort, or potential pain and suffering) is reached and animal sacrifice is ethically 
necessary, or a planned time to complete the experiment is reached. Tumor-bearing animals, for 
whom the predetermined target volume have not been observed, are said to provide right-censored 
data.  
Formally, the null hypothesis of interest is that tumor volumes are equally distributed in 
control and treatment arms, for each time tr, r=0,…K. Notice that only animals, whose tumor does 
not reach the predetermined target volume, participate in the assessment of tumor volume 
distribution at time tr, r=1,…,K. To simplify statistical considerations, let us suppose that common 
time points are equidistant [i.e. tr - t0 = r x (t1 - t0), r=1,…,K]. Let vi (tr) be the tumor volume at time 
tr of the ith animal. Each couple of subsequent and nonmissing tumor volume data vi (tr), vi (tr+1), 
r=0,…,K-1 are summarized as gr.i, using a slope function that increases monotonically with the 
distance between vi (tr) and vi (tr+1). For instance, gr.i could be defined as { vi (tr+1) - vi (tr), } / (tr+1 - tr),  
{ vi (tr+1) - vi (tr) } / (tr+1 - tr)2, { log(vi (tr+1)) - log(vi (tr)) } / (tr+1 - tr) or { 1 + vi (tr+1) } /  { 1 + vi (tr) }  using 
respectively a linear, quadratic, exponential or ratio function. For each interval [tr, tr+1], r=0,…,K-1, 
the Mann-Whitney Wr statistic, its expected value (Er) and variance [var(Wr)] could be calculated on 
the samples of observations gr.i computed from the control and experimental arms. Let Xr.1,…,Xr.m(r) 
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be the sample of slopes gr.i computed from the experimental arm, identically and independently 
distributed with probability distribution function Tr(x), for all x Є (-∞, +∞), at time tr, r=0,…,K-1. Let 
Yr.1,…,Yr.n(r) be the sample of slopes gr.j computed from the control arm, identically and 
independently distributed with probability distribution function Cr(x), for all x Є (-∞, +∞), at time tr, 
r=0,…,K-1. Consider all possible pairs of slopes (Xr.i, Yr.j) consisting of one slope gr.i computed from 
experimental arm and one slope gr.j computed from control arm, at time tr, r=0,…,K-1. The Mann-
Whitney Wr statistic at time tr, r=0,…,K-1, is defined as 
[number of pairs (Xr.i, Yr.j) with Xr.i < Yr.j] + ½ ∙ [number of pairs (Xr.i, Yr.j) with Xr.i = Yr.j]   5.2.1.1 
As consequence of the central limit theorem, the null distribution of the Wr statistic is asymptotically 
normal. Assuming no ties in tumor volume data,   
 Er = mr ∙ nr  / 2                                                              5.2.1.2 
var(Wr) = mr ∙ nr ∙ (mr + nr +1) / 12                                             5.2.1.3 
where mr and nr are respectively the number of animals in the experimental and control arms at 
time tr, r=0,…,K-1.  In presence of tied slopes, Er is the same while var(Wr) changes in the following 
more complex formula:  
 { mr ∙ nr ∙ (mr + nr +1) / 12 }  - { (mr ∙ nr ∙  ( ∑j (dj 3 - dj) )) / (12 ∙ (mr + nr) ∙ (mr + nr – 1)) }   5.2.1.4 
for j =1,…e, where e is the number of distinct values taken by the mr + nr observations and dj is the 
number of observations equal to the jth distinct value. The first term of the formula is just the 
variance of Wr in absence of tied data; the second gives the correction for ties. When no ties are 
present, all the dj are equal to 1, and the correction term is zero as it should be. Refer to the 
Lehmann’s book (2006) for proofs of previous formulas. 
Once the previous statistics have been computed in each interval [tr, tr+1], r=0,…,K-1, they can be 
combined into an overall test. The overall standardized test statistic can be defined as  
                             { ∑r (Wr - Er) } 2 / var(∑r Wr)                                            5.2.1.5 
for r=0,…,K-1. This statistic is approximately distributed as chi-square with one degree of freedom. 
It follows from the subsequent result in probability theory: a random variable, which is the sum of 
correlated normal random variables, is also distributed according to a normal distribution, with its 
mean being the sum of the means, and variance being the sum of the elements of the covariance 
matrix. 
A one-sided test could be performed using the following statistic:  
   ∑r (Wr - Er) / (var(∑r Wr)) 1/2                                       5.2.1.6 
r=0,…,K-1. The previous statistic has an approximate standard normal distribution. 
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5.2.2 Censoring and missing data   
The family of statistical tests proposed in Section 5.2.1 are valid (i.e. statistical test distribution 
under null hypothesis is exactly known) in case of non-informative right-censoring. Formally, the 
condition of non-informative right-censoring observations in our in vivo tumor efficacy experiments 
could be defined as follows: at time tr, r=0,…,K-1, let  mr + nr be the number of animals with tumor 
volume measurement, where mr and nr are respectively the number of animals in the experimental 
and control arms. At time tr+1, r=0,…,K-1,suppose that c out of mr + nr animals lack a tumor volume 
measurement due to competing events. These c animals will provide non-informative right-
censoring observations if they are randomly selected from the mr + nr animals. 
An equivalent definition of non-informative right-censoring observations is the following: let 
Tr(x) and Cr(x) for all x Є (-∞, +∞), at time tr, r=0,…,K-1, be the probability distribution functions 
generating the sample of slopes computed respectively from the experimental and control arms. To 
the ith tumor-bearing animal, a couple of data (ti, δi) could be assigned, where ti is the observed 
time since start of inactive or active treatment and δi is an indicator of failure, assuming values δi = 
1 if the predetermined target volume has been reached and δi = 0 if it has not been reached. Then 
survival data of tumor-bearing animals could be represented by the following U, V and T random 
variables: U is the survival time to reach the predetermined target volume, which we cannot always 
observe, and V is the potential censoring time. The observed time T is: 
T = min(U,V) and δ = 1 if U < V or δ = 0 if U > V. T = U only when the observation is not right-censored. 
In our in vivo tumor efficacy experiments, right-censoring is non-informative if and only if both 
condition holds: 
o the random variables Tr(x) and V are independent, for all times tr, r=0,…,K-1                       5.2.2.1 
o the random variables Cr(x) and V are independent, for all times tr, r=0,…,K-1                      5.2.2.2 
However, random variables U and V could be dependent without contradicting the condition of non-
informative right-censoring. 
In practical terms, non-informative right-censoring means that the tumor growth experience 
of censored animals can be fairly estimated by using the data on the uncensored animals available 
at the time points following right-censoring. This is true also in case of non-informative missing data 
at common time points t0 < … < tK, until the censoring date. In case of non-informative right-
censoring or missing data at time tr, r=0,…,K, slope estimates are unbiased and statistical tests 
proposed in Section 5.2.1 are valid.  
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For specific competing events, such as administrative censoring, when V is the planned time 
to complete the experiment, the condition of non-informative right-censoring could be fairly 
assumed. For other competing events, this condition is doubtful or definitively questionable. For 
instance, suppose that a humane endpoint at time tr, r=1,…K, has been reached and a particular 
animal in the experimental arm must be sacrificed. One could argue that tumor growth slope of this 
animal could be very large in the time interval [tr, tr+1] and so, the independence between random 
variables Tr(x) and V is definitively questioned.  
If our interest is to test treatment effect in absence of certain biological conditions (e.g., the 
animal is moribund) the family of statistical tests proposed in Section 5.2.1 are again valid. Clearly, 
what permits us to apply the same statistical procedure is that our aim is to detect treatment effect 
conditional on specific biological conditions. Notice that measuring tumor volumes below the 
predetermined target volume is the first biological constrain that we apply to our in vivo tumor 
efficacy experiments. In conclusion, our family of statistical tests is valid not only in case of non-
informative right-censoring observations but also when the experimental models are constrained 
by more specific condition (e.g. tumor volume below the predetermined target volume, in vivo 
models not in moribund status). 
Conversely, if our interest is to test treatment effect incorporating competing events that 
cause informative right-censoring observations, the family of statistical tests proposed in Section 
5.2.1 does not hold. The useful null hypothesis to be investigated is that the cumulative probability 
functions F(tr), r=1,…,K, are the same in control and treatment arms. For each r=1,…,K, F(tr) is the 
probability distribution function generating the sample of tumor growth curves defined in the time 
interval [t0-tr], in presence of competing events. Animals affected by informative right-censoring at 
time tr*, r*=2,…,K, contribute to the definition of each function F(tr), r<r*. The study of this function 
is not the subject of this project. In survival analysis, we refer to Kalbfleisch and Prentice who 
suggested the study of an analogue cumulative probability function, the cumulative incidence 
function (Kalbfleish et al., 1980). This approach, that accounted for the presence of competing 
events, led to the formulation of the Gray’s test (Gray, 1988) and of the Fine and Gray regression 
model (Fine et al., 1999). 
5.2.3 Weighted non-parametric Two-Sample Tests 
A number of weighted tests can be generated from the basic tests defined in Section 5.2.1. These 
are generally defined as 
{ ∑r [wr ∙ (Wr - Er)] } 2 / [var(∑r wr ∙ Wr)]                               5.2.3.1 
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for r=0,…,K-1, where wr are positive constants. The weights wr can vary as time tr, r=0,…,K-1, 
changes. The statistic reported in Formula 5.2.3.1 is asymptotically distributed according to the chi-
square density function with 1 d.f. for the two group comparisons discussed here, under the null 
hypothesis that tumor volumes are equally distributed in control and treatment arms. 
If we set wr = 1 or broadly wr = constant, for r=0,…,K-1, then this assigns equal weight to each 
part of the growth curve. In this situation, Equation 5.2.3.1 becomes that of the unweighted test of 
Equation 5.2.1.5. Instead, if we set wr ≠ wr+1 for at least one r, r=0,…,K-1, we are implicitly stating 
that differences between certain parts of the growth curves being compared are of greater interest 
than others. For example, if it is anticipated that the active treatment reduces the tumor growth 
rate at the start of treatment delivery but thereafter holds no particular advantage, then higher 
weight may be assigned to the earlier parts of the growth curves. 
In survival analysis, weighted Mantel-Haenzel (M-H, log-rank) tests can be generated from the 
basic formula of the unweighted M-H test according to the same Equation 5.2.3.1. Expected value 
and variance of the Mann-Whitney Wr statistic are substituted respectively by expected value and 
variance of the M-H statistic. Two interesting types of weighted M-H tests have been proposed, 
according to the following values given to the weights wr, r=0,…,K-1: 
                                  wr =  mr + nr        (Gehan test; Gehan, 1965)                                      5.2.3.2 
 wr =  √ (mr + nr)     (Tarone and Ware test; Tarone et al., 1977)                    5.2.3.3 
where mr + nr, r=0,…,K-1 is the set of animals exposed to the risk of failing just before tr. Both 
weighted M-H tests place greater emphasis on earlier parts of the survival curves. Clearly, Tarone 
and Ware test is a less extreme means of weighting the earlier part of the survival curve than Gehan 
test. 
The methods of weighting survival curves suggested in Equations 5.2.3.2 and 5.2.3.3, could be 
applied to tumor growth curves, in order to test the null hypothesis of equal distribution of tumor 
volumes in control and treatment arms. One option is to let mr + nr be the number of slopes at time 
tr, r=0,…,K-1. mr + nr  and √(mr + nr) could be used as weights to be introduced in the Formula 5.2.3.1, 
according respectively to Gehan and Tarone and Ware test, respectively. Again, the former weights 
tend to place greater importance on the early differences among tumor volume distribution; the 
latter weights do the same but in a weaker way. The second option is counting the number of days 
between two consecutive time points tr and tr+1, r=0,…,K-1, in which tumor volumes are measured, 
instead of counting the number of slopes at time tr, r=0,…,K-1. The resulting weighted non-
parametric two-sample test could be useful in case of unequal distance between time points tr and 
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tr+1, r=0,…,K-1. These two options could be applied jointly, square rooting the product of the size of 
the sample at time tr with the number of days between the two consecutive time points tr and tr+1, 
for r=0,…,K-1, according to the following formula: 
 weightr =  √ [(mr + nr) ∙ (tr+1 - tr)]                                               5.2.3.4 
5.2.4 Stratified non-parametric Two-Sample Tests 
A straightforward extension of the statistical procedure given in Section 5.2.1 could be obtained in 
the presence of strata. Strata could be defined by confounding factors such as animal weight and 
sex, and by blocking factors such as cage placement within rooms in the animal house and different 
time periods in which the experiment is performed. Let m (m=1, 2, …, M) indicate the strata; within 
each stratum the Mann-Whitney mWr statistic, its expected value (mEr) and variance [varm(Wr)], 
r=0,…,mK-1, are computed. This compares like with like. These comparisons within each stratum are 
then combined to achieve an overall comparison of tumor growth curves by means of a stratified 
nonparametric two-sample test. The overall test statistic suitable for testing the null hypothesis that 
tumor volumes are equally distributed in control and treatment arms, for each time tr, r=0,…,K, is: 
                               { ∑m ∑r (mWr - mEr) } 2 / ∑m var(∑r m(Wr))                                    5.2.4.1 
for r=0,…,mK-1 and m=1, 2, …, M. This statistic is asymptotically distributed as chi-squared with one 
degree of freedom. 
Because animals compared in each stratum are matched for some characteristics, the stratified 
analysis tends to increase the power of the test by increasing the difference at the numerator and 
by decreasing the variance (denominator). In in vivo antitumor activity studies, the stratified analysis 
should be preferred in the following instances: 
o when making comparison between control and treatment arms, we need to ensure as much 
as possible that the differences observed in tumor volumes between arms is due to the 
treatments and not since the two groups of animals have inherently differing prognoses. We 
thus may wish to adjust for prognostic variables, such as animals’ sex or tumor weight at 
time t0. After the strata has been defined by different modalities of a prognostic variable or 
by combination of different levels of two or more such variables, a stratified analysis should 
be performed 
o in an randomized complete block (RCB) design, typically each observation can be classified 
by two factors, one “fixed” (usually called the treatment that is deliberately varied and is of 
scientific interest) and the other “random” (which may be called a “block” or replicate), 
which is of no scientific interest but which could cause noise if not removed in the statistical 
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analysis. Randomization is done separately within each block. Common examples of blocks 
in in vivo activity studies are: batches of animals, which could be of a slightly different age or 
weight with possible differences in the batches of diet; cages, which could be placed at 
different position in the enclosure and the period of time over which the experiment is 
executed. If a RCB design is chosen, a stratified analysis is mandatory. RCB designs are more 
powerful, have higher external validity, are less subject to bias, and produce more 
reproducible results than the completely randomized designs typically used in research 
(Festing, 2014) 
o in multicenter preclinical studies, multiple independent laboratories collaboratively conduct 
a research experiment using a shared protocol. The use of a multicenter design in in vivo 
experimentation is a recent and innovative approach. This kind of design has been suggested 
as a method to improve reproducibility, generalizability and clinical translation of preclinical 
work (Boltze et al., 2016; Chamuleau et al., 2018; Dirnagl et al., 2012; Langley et al., 2017; 
Maertens et al., 2017; O'Brien et al., 2013). Each participating center is a ‘block’ and a 
stratified analysis is required 
o a systematic review and meta-analysis of all available evidence from preclinical studies 
should be performed before clinical trials begin. Beneficial evidence obtained from a single 
laboratory or a single model or a species is probably not sufficient (van der Worp et al., 
2010). If raw data is available, each in vivo antitumor activity study should be treated as a 
‘block’ and a stratified analysis is required. 
It may so happen that treatment effect varies widely among strata. This may be evidence against 
pooling across strata to compute an overall test of difference in tumor volume distribution. Testing 
homogeneity across strata will be treated in Section 5.5. 
5.2.5 Paired data 
In some experiments mice may be grafted bilaterally, obtaining tumor growth on both flanks of the 
rodent. In this case, one has clustered data (i.e. data obtained from correlated observations in a 
single rodent). In the presence of clustering, true p-values will be overestimated or underestimated 
depending on the relationship between paired data and the confidence interval will be too narrow 
when using standard statistical procedures. In the case of balanced designs (i.e. the same number 
of replicates per rodent within each arm), a possible approach could be to rank all right tumor 
volume values and all left tumor volume values, separately, calculate the average rank or rank sum 
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within a cluster (i.e the rodent), and use our family of statistical tests on the cluster-specific mean 
rank or rank sum, using the cluster as the unit of analysis.  
This approach is inappropriate for unbalanced designs where paired data should be weighted 
more heavily than single data. In this case, a possible approach is to modify the variance of the 
Mann-Whitney statistic or the related Wilcoxon rank-sum statistic. Rosner et al. (1999) proposed a 
Mann-Whitney statistics for clustered data which corrects the variance of the test statistic for four 
types of intracluster correlation coefficients. These correlation coefficients could be estimated by 
experimental data. Rosner et al. (1999) did not provide a large sample theory, instead Rosner et al. 
(2003) proposed a modified Wilcoxon rank-sum statistic under the assumptions that all observations 
from the same cluster belong to the same treatment arm, observations within any cluster are 
exchangeable, and that the intracluster dependence does not vary across groups. They derived the 
asymptotic mean and variance that accommodates unequal cluster sizes and possible stratification. 
But above all, resampling techniques, such as those applied in SAS MACRO programs reported 
in Appendix E, could be used to obtain exact p-values and estimate credible intervals in presence of 
paired data (refer to Section 5.3.3). 
5.3 Statistical power and sample size determination 
5.3.1 Location shift model 
In in vivo experiments one of the most important issues is to determine the number of animals that 
need to be accrued in order to detect a difference, relevant at least from a biological viewpoint, 
between control and active arms, with high probability. This issue is fundamental for ethical, 
scientific and economic reasons. Unfortunately, a totally satisfactory solution has not yet been 
found (Festing, 2018). As R.A Fisher taught us (Fisher, 1935), the alternative hypothesis (i.e. tumor 
volumes are differently distributed in control and treatment arms in at least one time point tr, 
r=1,…K) is inexact. What this means is that because there are an infinite number of ways in which 
tumor volumes can be differently distributed, the distribution of test statistic under the alternative 
hypothesis is not exactly defined. It is necessary to reduce the myriad of possibilities within the 
alternative space to know precisely the distribution of the test statistic. It is worse than this. The 
task of determining the exact distribution of a test statistic under an alternative hypothesis is usually 
more difficult than under the null hypothesis. Generally, the null hypothesis simplifies the problem 
both mathematically and conceptually.  
For instance, in survival analysis, the hypothesis that survival distributions of control and 
active arms are the same implies that deaths are distributed randomly across control and active 
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arms, which gives the distribution of deaths occurring at a specific time point a relatively simple 
distribution (i.e. hypergeometric distribution). Based on this distribution, the distribution of the log-
rank statistic can be determined easily. Furthermore, if we reduce the myriad of possibilities within 
the alternative space to the proportional hazard assumption, it can be shown that the log-rank 
statistic is distributed asymptotically normal with a mean equal to the log hazard ratio and a variance 
equal to [d ∙ p1 ∙ (1-p1)](-1), where d is the number of deaths and p1 is the proportion of experimental 
units randomly assigned to the control arm (Schoenfeld, 1981; Schoenfeld, 1983). 
In our antitumor activity studies, one way to reduce the myriad of possibilities within the 
alternative hypothesis space, and to help gain a quantitative evaluation about the distribution of 
the test statistic, is to make the simplifying assumption of an additive effect. The model of an 
additive treatment effect (i.e. location shift model) assumes that animals do not interfere with each 
other and the administration of the experimental treatment decreases the slopes gr.i computed from 
the control arm, by a constant amount Δr > 0, for all animals in the time interval [tr, tr+1], r= 0,…,K-1. 
The parameter Δr then measures the effect of the experimental treatment in the time interval [tr, 
tr+1], r=0,…,K-1. The vector of parameters Δ = (Δ0,…,ΔK-1) to estimate is the additive treatment effect. 
Negative values of Δr, r=0,…K-1, correspond to the possibility that the experimental treatment has 
a detrimental effect on tumor growth curves. The case Δr = 0, for all r=0,…,K-1 corresponds to the 
case of no treatment effect. The case Δr = Δ, for all r=0,…,K-1, corresponds to the case of constant 
treatment effect in each time interval [tr, tr+1], r=0,…,K-1. 
Let Xr.1,…Xr.m(r) be the sample of slopes computed from the experimental arm, identically and 
independently distributed with probability distribution function Tr(x), for all x Є (-∞, +∞), at time tr, 
r=0,…,K-1. Let Yr.1,…Yr.n(r) be the sample of slopes computed from the control arm, identically and 
independently distributed with probability distribution function Cr(x), for all x Є (-∞, +∞), at time tr, 
r=0,…,K-1. Under the assumption of an additive effect, Tr(x) = Cr(x)- Δr, for all x Є (-∞, +∞), Δr Є (-∞, 
+∞) and r=0,…K-1. Let T = ∑r Tr, C = ∑r Cr, r=0,…,K-1 and Δ the vector (Δ0,…,ΔK-1). If Δr  > 0 for all 
r=0,…,K-1, Cr and C are random variables stochastically larger than Tr and T, respectively. 
The power function of the one-tailed test defined in Section 5.2.1 is given by 
∏(Δ) = PΔ (∑r Wr > c)                                          5.3.1.1 
where Wr is the Mann-Whitney statistic computed in the time interval [tr, tr+1], r=0,…,K-1, c is the 
critical value determined so that the area to the right of c is equal to the significance level of the 
one-sided test and finally, PΔ indicates that the probability is calculated for the location shift model. 
Since Δ = 0 corresponds to the case of no treatment effect, the value ∏(0) is just the significance 
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level of the one-sided test. In case of two-tailed tests (i.e. a detrimental effect of the experimental 
treatment on tumor growth curves is assessed), the power function ∏(Δ) is defined over the range 
(-∞, +∞) and the significance level is divided in half to account for the two tails of the sampling 
distribution of the test statistic, under the null hypothesis. 
Lemma 5.3.1.1, that is reported and demonstrated in the Lehmann’s book (2006), will be used 
to prove qualitative properties of ∏(Δ) in the following theorems. 
Lemma 5.3.1.1: Let K = 1. The power function ∏(Δ) defined by Equation 5.3.1.1 is a nondecreasing 
function of Δ. 
Proof. If K = 1, the vector of parameters Δ estimating the additive treatment effect reduce to 
the scalar Δ0. Let 0 < Δ0α < Δ0β. Let Y0.1,…Y0.n(r) be the sample of slopes computed from the 
control arm, independently and identically distributed with distribution C0(x) and X0.1,…X0.m(r) 
be the sample of slopes computed from the experimental arm, independently and identically 
distributed with distribution T0(x) = C0(x) - Δ0α. If S0.i = X0.i - (Δ0β - Δ0α), i=1,…,m(r), the 
distribution of the random variables S0.1,…S0.m(r) is C0(x) - Δ0β. It follows that ∏(Δ0α) = P (WYX 
> c) and ∏(Δ0β) = P (WYS > c), where WYX denotes the number of pairs (Y0.j, X0.i,) with Y0.j > X0.i 
and WYS the number of pairs (Y0.j, S0.i) with Y0.j > S0.i. Because S0.i < X0.i for all i=1,…,m(r), it is 
seen that WYX < WYS and hence that ∏( Δ0α) < ∏(Δ0β) as was to be proved. 
Lemma 5.3.1.1 says that if there is just one time interval, then the power of the significance test 
increases monotonically with respect to the size of the additive treatment effect. 
Theorem 5.3.1.1: Let K > 1. Let Δ = (Δ0,…,ΔK-1), the vector of parameters estimating the additive 
treatment effect. For each Δr > 0, r=0,…,K-1, the power function ∏(Δ) defined by Equation 5.3.1.1 is 
a nondecreasing function of Δr. 
Proof: If K = 1, the proof is furnished by Lemma 5.3.1.1. Let K > 1 and Δsα and Δsβ the vectors 
of parameters, respectively (Δ0α,…,ΔK-1α) and (Δ0β,…,ΔK-1 β), estimating the additive treatment 
effect, with Δrα > 0 and Δrβ > 0 for all r=0,…,K-1, 0 < Δsα < Δsβ for a specific s, 0 < s < K-1, and 
Δrα = Δrβ for all r=0,…,K-1, r ≠ s. Using the same argument of lemma 5.3.1.1, one can prove 
that Wrα  < Wrβ, for all r=0,…,K-1, where  
a) Wrα denotes the number of pairs (Yjα.r,Xiα.r) with Yiα.r > Xiα.r, where Yjα.r, j=1,…,n(r), is the 
slope calculated from the control arm, at time r, r=0,…,K-1, and Xiα.r, i=1,…,m(r), is the slope 
calculated from the experimental arm, at time r, r=0,…,K-1, under the additive treatment 
effect Δrα 
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b) Wrβ denotes the number of pairs (Yjβ.r,Xiβ.r) with Yiβ.r > Xiβ.r, where Yjβ.r, j=1,…,n(r), is the 
slope calculated from the control arm, at time r, r=0,…,K-1, and Xiβ.r, i=1,…,m(r), is the slope 
calculated from the experimental arm, at time r, r=0,…,K-1, under the additive treatment 
effect Δrβ. 
Therefore (∑r Wrα) < (∑r Wr β), r=0,…,K-1 and hence ∏(Δsα) < ∏(Δsβ) as was to be proved. 
Theorem 5.3.1.1 says that the power of the significance test increases monotonically with respect 
to the size of the additive treatment effect in a specified time interval, if the size in all the other time 
intervals is held constant. 
Theorem 5.3.1.2: Let K > 1. Let Δ = (Δ0,…,ΔK-1), the vector of parameters estimating the additive 
treatment effect. The power function ∏(Δ), defined by Equation 5.3.1.1, is a nondecreasing function 
of Δ. 
Proof.  If K = 1, the proof is furnished by lemma 5.3.1.1. Let K > 1 and Δα and Δβ the vectors 
of parameters, respectively (Δ0α,…, ΔK-1α) and (Δ0β,…,ΔK-1 β), estimating the additive treatment 
effect, with 0 < Δrα < Δrβ for all r=0,…,K-1 and 0 < Δsα < Δsβ for at least one s, 0 < s < K-1. Using 
the same argument of lemma 5.3.1.1, one can prove that Wrα  < Wrβ, for all r=0,…,K-1 (refer 
to the previous theorem for the meaning of Wrα  and Wrβ notation). Therefore (∑r Wrα) < (∑r 
Wr β), r=0,…,K-1, and hence ∏(Δα) < ∏(Δβ) as was to be proved. 
Theorem 5.3.1.2 says that the power of the significance test increases monotonically if the size of 
the additive treatment effect in every time interval is either increased or held constant, i.e. the size 
is not decreased in any time interval. 
Corollary 5.3.1.1: if ∏(0) = α is the significance level of the family of one-tailed tests defined in 
Section 5.2.1, it follows from Theorem 5.3.1.2 that for every continuous function Cr(x), for all x Є (-
∞, +∞), at time tr, r=0,…,K-1 
∏(Δ) > α, for all Δ > 0                                                       5.3.1.2 
Corollary 5.3.1.1 says that the power of the significance test is always greater than or equal to its 
false-positive rate, provided that the treatment effect is greater than or equal to zero in every time 
interval. A test whose power against a class of alternatives never falls below the significance level is 
said to be unbiased against these alternatives. The inequality 5.3.1.2 thus shows that our family of 
statistical tests is unbiased against the location shift alternatives. 
Corollary 5.3.1.2: Let K > 1. Let Δ = (Δ0,…,ΔK-1), the vector of parameters estimating the additive 
treatment effect, and Δr = Δ, for all r=0,…,K-1 (i.e. constant additive treatment effect in each time 
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interval [tr, tr+1], r=0,…,K-1. It follows from Theorem 5.3.1.2 that the power function ∏(Δ), defined 
by Equation 5.3.1.1, is a nondecreasing function of the constant additive treatment effect Δ. 
The previous properties describe how the power function depends qualitatively on the treatment 
effect Δ. When determining sample size, it is useful to describe how the power function depends on 
the number of slopes and the number of time intervals of our antitumor activity studies. For this 
aim, the following theorem is crucial, although it depends on the following strong assumption: 
o slopes in different intervals, in the same animal, are distributed independently (i.e. ρi.j = 0, 
where ρi.j is the correlation between slopes at time intervals [ti, ti+1] and [tj, tj+1], i≠j, i,j = 1 to 
0,…,K-1). 
This assumption (i.e. independence between time-intervals) will often not be valid in practice. 
Theorem 5.3.1.3: Let K > 2. Let Δ = (Δ0,…,ΔK-2) and Δ* = (Δ0,…,ΔK-1) the vector of parameters 
estimating the additive treatment effect in the time intervals [tr, tr+1], r=0,…,K-1, with Δr = Δ, for all 
r=0,…,K-1, Δ > 0 (i.e. constant treatment effect in each time interval [tr, tr+1], r=0,…,K-1). Let the 
continuous distribution Cr(x) = Co(x) and Tr(x) = C0(x) - Δ, x Є (-∞, +∞), for all r=0,…,K-1. Finally, 
assuming the independence between time-intervals and that the probability of a slope computed 
from the experimental arm, which is smaller than a slope computed from the control arm, is less 
than one (i.e. uncertain event), it follows that: 
1. the power function ∏(Δ) defined by equation 5.3.1.1 is an increasing function of the number 
of slopes computed from the experimental and control arm 
2. ∏(Δ) < ∏(Δ*) 
Proof.  Let Yr.0,…Yr.n(r) be the sample of slopes computed from the control arm, independently 
and identically distributed with distribution C0(x) and let Xr.0,…Xr.m(r) be the sample of slopes 
computed from the experimental arm, independently and identically distributed with 
distribution T0(x) = C0(x) – Δ, r=0,…,K-1. By definition, the test statistic Wr denotes the 
number of pairs (Yr.i,Xr.j) with Yr.i > Xr.j. From the fact that Cr(x) and Tr(x) do not vary across 
the time intervals and assuming the independence between time-intervals, the probability 
P(Yr.i > Xr.j) is constant across the time intervals with a value in the interval (0,1). Hence the 
test statistic ∑r Wr could be seen as the sum of independent and identically distributed 
Bernoulli trials with probability P(Yr.i > Xr.j). The number of Bernoulli trials are equal to the 
number of pairs (Yr.i,Xr.j), r=0,…,K-1. Based on the properties of the exact binomial 
distribution, the theorem is proved. 
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Corollary 5.3.1.3: Let K > 2. Let Δ = (Δ0,…,ΔK-2) and Δ* = (Δ0,…,ΔK-1) the vector of parameters 
estimating the additive treatment effect in the time intervals [tr, tr+1], r=0,…,K-1. Let the continuous 
distribution Cr(x) = Co(x) and Tr(x) = C0(x) - Δr, x Є (-∞, +∞), r=0,…,K-1, Δr > 0 for all r=0,…,K-1, Δr > 0 
for at least one r=0,…,K-1. If ΔK-1 > Δr for all r=0,…,K-1 then ∏(Δ) < ∏(Δ*) 
Proof.  Let Δ§ = (Δ0,…,ΔK-2), Δj = ΔK-1 for all j=1,…,K-2. From Theorem 5.3.1.3 it deduced that 
∏(Δ*) > ∏(Δ§). From Theorem 5.3.1.2 it deduced that ∏(Δ§) > ∏(Δ) and hence ∏(Δ*) > ∏(Δ) 
as was to be proved. 
Theorem 5.3.1.3 and its generalization, Corollary 5.3.1.3, say that, by assuming the independence 
between time-intervals, more animals or time intervals will always give us more power.   However, 
it is important to note that the assumption of independence between time-intervals in the same 
animal may be unrealistic. 
5.3.2 Asymptotic power 
Under the assumption of an additive treatment effect, the theorems on the power function ∏(Δ) 
proved in the preceding section were only qualitative. To calculate the power quantitatively, it is 
necessary to know the distribution of the ranks when the function Cr(x), x Є (-∞, +∞), at time tr, 
r=0,…,K-1, is continuous and Δr  > 0, for all r=0,…,K-1. Useful results can be obtained from the normal 
approximation to the power. Let [tr, tr+1] be a specific time interval, r=0,…,K-1. Under the alternative 
hypothesis, the distribution of the Mann-Whitney Wr statistic at time tr tends to a normal 
distribution as mr and nr tend to infinity, for any continuous distributions Cr(x) and Tr(x) = Cr(x) - Δr, 
x Є (-∞, +∞) and Δr  > 0, for which   
                                                                            0 < P ( X < Y ) < 1                                                           5.3.2.1 
where X and Y indicate two independent random variables with distribution Tr and Cr, respectively. 
If the probability of a slope, computed from experimental arm, being smaller than a slope, computed 
from control arm, is equal to 0 (impossible event) or 1 (certain event), the distribution Tr lies entirely 
to the right or to left of the distribution Cr, respectively. In either case, Wr statistic reduces to a 
constant. To prove asymptotic normality of Wr statistic under the assumption of an an additive 
effect, refer to the example 20 reported in the Appendix of Lehmann’s book (2006). 
Application of the normal approximation requires the expectation and variance of the Wr 
statistic under the hypothesis of an additive treatment effect. The expectation E(Wr) depends on 
the probability p1 = P(X < Y). It can be proved that  
E(Wr) = mr ∙ nr ∙ p1                                                                                      5.3.2.2 
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As a check, consider the case Δr = 0. The variables X and Y then have the same distribution, so that 
P(X < Y) = P(Y < X). From the fact that this common distribution is continuous, P(X = Y) = 0, and hence 
p1 = 1/2. The resulting value E(Wr) = mr ∙ nr  / 2 agrees with that given by Formula 5.2.1.2. The 
variance of the Wr statistic depends, besides p1, on the two following quantities: 
 p2 = P(X < Y and X < Y’)                                                      5.3.2.3 
where X, Y and Y’ indicate three independent random variables, X with distribution Tr, and Y and Y’ 
each with distribution Cr 
p3 = P(X < Y and X’ < Y)                                                      5.3.2.4 
where X, X’ and Y indicate three independent random variables, X and X’ with distribution Tr, and Y 
with distribution Cr.  
With this notation, it can be proved that 
var(Wr) = mr ∙ nr ∙ p1 ∙ (1-p1) + mr ∙ nr ∙ (nr-1) ∙ (p2- p1 2) + mr ∙ nr ∙ (mr-1) ∙ (p3- p1 2)            5.3.2.5 
Again, as a check, consider the case Δr = 0. Then p2 becomes the probability that of three 
independent random variables X, Y and Y’ with the same continuous distribution, X is the smallest. 
Since each of the three is equally likely to be the smallest, then p2 = 1/3 and by the same argument 
that p3 = 1/3. As previously proved, p1 is equal to 1/2. The resulting value var(Wr) = mr ∙ nr ∙ (mr + nr 
+1) / 12  agree with that given by Formula 5.2.1.3. To prove Formula 5.3.2.2 and 5.3.2.5, refer to the 
example 5 reported in the Appendix of Lehmann’s book (2006). It could be useful to note that p2 = 
p3, in the case where Cr is symmetric. 
In principle, the asymptotic power can be computed for any alternative Cr(x) and Tr(x) = Cr(x) 
- Δr, x Є (-∞, +∞) and Δr  > 0. In other terms, once Cr, Tr and Δr have been specified, the values of p1, 
p2 and p3 are determined and the expectation E(Wr) and variance var(Wr) can be computed using 
Formula 5.3.2.2 and 5.3.2.5. Note that the computations of p2 and p3 are typically more involved 
than that of p1. However, there are some important cases for which analytical forms are available:  
o Normal distribution [i.e. Cr(x) = N(ζ, σ2) and Tr(x) = N(ζ- Δr, σ2), x x Є (-∞, +∞)]: 
p1 = Ф[ Δr / (σ ∙ 2(1/2))], where Ф(z) is the Standard Normal Cumulative Distribution 
Function 
p2 = p3 = P (Z < , Z’ < z), where Z and Z’ are both normal with mean zero and unit variance 
and correlation coefficient equal to 0.5, z is equal to [ Δr / (σ ∙ 2(1/2)) ] 
For instance, if Δr = 5 and σ2 = 32, so that [ Δr / (σ ∙ 2(1/2)) ] = 0.625, p1, p2 and p3 are equal 
to 0.734, 0.600 and 0.600, respectively 
o Standard uniform distribution, defined in the interval (−1/2, 1/2), with 0 < Δr < 1: 
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p1 = (1 / 2) + Δr ∙ (1 - Δr / 2)  
p2 = p3 = (1 / 3) +  Δr - (Δr 3) / 3 
o Standard double exponential distribution: 
p1 = 1 - { (1 / 2) ∙ [1 + (Δr / 2) ] ∙ exp (-Δr) } 
p2 = p3 = 1 - [ (7 / 12) +  (Δr / 2) ] ∙ exp (-Δr) – [ (1 / 12) ∙ exp (-2 ∙ Δr) ] 
o Standard exponential distribution: 
p1 = 1 -  [ (1 / 2) ∙ exp (-Δr) ] 
p2 = 1 -  [ (2 / 3) ∙ exp (-Δr) ] 
p3 = 1 - exp (-Δr) +  [ (1 / 3) ∙ exp (-2 ∙ Δr) ] 
Because the distribution of the Wr statistic is discrete, a continuity correction should be applied to 
compute the asymptotic power. If the hypothesis Δr = 0 is rejected when Wr > c, the asymptotic 
power with continuity correction is 
PΔr (Wr > c) = 1 - Ф{ [c – (1 / 2) - E(Wr) ] / [ (var(Wr) (1/2)) ] }                         5.3.2.6 
where E(Wr) and var(Wr) are the expectation and variance computed in the specific time interval [tr, 
tr+1], under the alternative hypothesis Δr > 0.                
Previous results refer to a specific time interval [tr, tr+1], r=0,…,K-1. Based on these preliminary 
results, the asymptotic power of the family of statistical tests, defined in Section 5.2.1, could be 
computed. First af all, the following theorem is proved: 
Theorem 5.3.2.1: Let K > 1. Let Δ = (Δ0,…,ΔK-1) be the vector of parameters estimating the additive 
treatment effect. Let Wr be the Mann-Whitney statistic computed in the time interval [tr, tr+1], 
r=0,…,K-1, under the hypothesis of an additive treatment effect. Then the test statistic ∑r Wr, 
r=0,…,K-1, is asymptotically normally distributed. 
Proof.  If K = 1, the proof is furnished by the previous consideration reported in this section. 
Let K > 1. For each r, r=0,…,K-1, Wr is asymptotically normally distributed with expectation 
and variance given by Formula 5.3.2.2 and 5.3.2.5, respectively. Because it is the sum of 
correlated normal random variables, ∑r Wr, r=0,…,K-1, is asymptotically normally distributed. 
Its expectation is the sum of expectation of each Wr, r=0,…,K-1. Its variance is the sum of the 
elements of the covariance matrix. 
Hence, if the hypothesis Δ = 0 is rejected when ∑r Wr > c, the asymptotic power of the test against 
any fixed alternative hypothesis Tr(x) = Cr(x) - Δr, x Є (-∞, +∞) and Δr  > 0, Tr(x) ≠ Cr(x) for at least one 
r, r=0,…,K-1, is 
PΔ (∑r Wr > c) = 1 - Ф{ [c – ((1 / 2) + ∑r E(Wr)) ] / [ (var(∑r Wr)) (1/2) ] }                 5.3.2.7 
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where E(Wr) is the expectation computed in each time interval [tr, tr+1], r=0,…,K-1, and var(∑r Wr) is 
the sum of the elements of the covariance matrix, under the alternative hypothesis of an additive 
treatment effect. 
  
Asymptotic power is calculated in the following example: suppose that an in vivo experiment 
comparing a control and an active arm is performed, and the following assumptions are made: 
o 10 rodents are assigned to both arms 
o tumor volumes are assessed at consecutive time intervals from randomization. The number 
of time intervals vary between 3 and 6 
o tumor volumes increase over time according to an exponential growth in both arm. The 
growth rate of the control arm is equal to 0.07 
o slopes are distributed normally with standard deviation equal to 0.060 in both arms 
o slopes in different intervals, in the same animal, are distributed independently (i.e. ρi.j = 0, 
where ρi.j is the correlation between slopes at time intervals [ti, ti+1] and [tj, tj+1], i≠j, i,j = 1 to 
0,…,K-1). Hence, the following equality holds: var(∑r Wr) = ∑r var(Wr), r=0,…,K-1. 
In Table 5.3.2.1 asymptotic power is reported for different treatment effects Δ (i.e. difference in 
growth rate between control and active arm). Treatment effect is the same in different time 
intervals. The test is two-tailed with type I error equal to 0.05.  
Δ (day-1) N° of time intervals 
 3 4 5 6 
0.01 9.2 10.8 12.4 14.0 
0.02 23.1 29.3 35.3 41.1 
0.03 44.6 56.2 66.0 74.0 
0.04 68.3 80.9 88.9 93.8 
0.05 86.7 94.8 98.1 99.3 
Table 5.3.2.1 Asymptotic power for different treatment effects. Power is given as percent 
The values in the Table 5.3.2.1 show monotonic positive relationships between treatment effects Δ 
and power and between number of time intervals and power. This result is a direct illustration of 
Theorem 5.3.1.3 and its generalization, Corollary 5.3.1.3, as the assumption of independence 
between time intervals was used. Caution should be taken in generalizing this result because the 
101 
 
assumption of independence between time intervals in the same animal will often not be met in 
real cases. 
A SAS MACRO program to compute asymptotic power and sample size of an in vivo experiment is 
reported in Appendix E. Assumptions made by the SAS program are the following: 
o slopes are distributed normally 
o slopes in different intervals in the same animal are distributed independently. Hence, the 
following equality holds: var(∑r Wr) = ∑r var(Wr), r=0,…,K-1. This strong assumption does not 
usually hold for real cases 
o distribution of slopes and treatment effect does not vary over time intervals 
5.3.3 Other approximations and exact distribution of test statistic 
The distribution of the test statistic, under the null and alternative hypothesis, has been previously 
studied asymptotically. However, for ethical, economic and scientific reasons, in vivo experiments 
use small samples. To better approximate the distribution of the Mann-Whitney statistic and, hence, 
to better approximate the distribution of the test statistic proposed for studying tumor growth 
curves, an Edgeworth series could be used (Hall, 1992). Formulas are provided by Fix et al. (1955). 
They also provide a comparison of the accuracy of normal approximation with that derived from 
Edgeworth series. The approximations are studied further by Verdooren (1963) and Bickel (1974). 
The corresponding problem in the presence of ties is investigated by Klotz (1966). 
The exact distribution of the Mann-Whitney statistic, sometimes substituted by that of the 
equivalent Wilcoxon rank-sum statistic, is usually tabulated in books about non-parametric 
statistical methods. For example, Lehmann’s book (2006) tabulates the cumulative distribution of 
the Wilcoxon rank-sum statistic. The computation of the exact distribution of rank statistic under 
alternative hypotheses is difficult, and only such few computations have been carried out (Bell et 
al., 1966; Haynam et al., 1966; Milton, 1970). More than this, the computation of the exact 
distribution of the proposed test statistic, sum of dependent exact distributions of Mann-Whitney 
statistic, have never been carried out. Bootstrap methods and resampling techiniques could be 
easily used to compute the exact distribution. In Appendix E, two SAS MACRO programs compute 
both the asymptotic and exact p-values. The asymptotic p-value is calculated under the strong 
assumption that slopes in different intervals, in the same animal, are distributed independently. 
5.4 An example of statistical analysis of tumor growth curves 
The new family of statistical tests was applied to different in vivo experiments performed at the 
Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan (Italy). As an 
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example, the antitumor activity of the combination of trabectedin (Yondelis®) with the PPARγ 
agonist pioglitazone was evaluated in various patient-derived myxoid liposarcoma xenografts 
(PDXs), characterized by different sensitivity to trabectedin (Frapolli et al., 2019). The statistical 
analysis of a specific tumor model, the ML017/ET model, is reported. ML017/ET was obtained from 
the trabectedin sensitive ML017 PDX, through the exposition at repeated in vivo cycles of 
trabectedin until the acquisition of a resistant phenotype. When tumor burden reached about 300-
400 mg, athymic nude mice bearing ML017/ET xenografts were randomized in the following 
treatment groups: 
o control (i.e. placebo arm) 
o trabectedin 0.15 mg/kg i.v., every 7 days for three times (q7dx3) 
o pioglitazone 150 mg/kg p.o. daily for 28 days  
o combination of trabectedin and pioglitazone 
Tumor growth was measured using Vernier caliper, and the tumor burden was calculated by the 
formula: length x (width)2 / 2. Mice were sacrificed when tumor burden reached about 1500-2000 
mm3. The total number of mice evaluated in different days is reported in Table 5.4.1. Figure 5.4.1 
reports the tumor growth curves obtained. Mean tumor volumes and standard errors are shown in 
the same figure. The table of raw data is reported in Appendix F.  
 
Figure 5.4.1 Tumor growth curves 
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Arm 
Days after treatment 
0 4 7 12 15 18 21 26 29 34 36 40 43 46 
Control 12 12 12 12 12 12 12 0 0 0 0 0 0 0 
Pioglitazone 11 11 11 11 11 11 11 0 0 0 0 0 0 0 
Trabectedin 11 11 11 11 11 11 11 11 11 0 0 0 0 0 
Trab + Pio 11 11 11 11 11 11 11 11 11 11 11 11 11 11 
Table 5.4.1 Number of mice at risk 
In Table 5.4.2 the two-tailed asymptotic and exact p-values, used to detect differences between 
arms, are reported. Both types of p-value were calculated using SAS MACRO programs reported in 
Appendix E. 500 simulations have been used to calculate exact p-values. The level of agreement 
between the asymptotic and exact tests seems good.     
Comparison χ2 (Asymptotic p-value)° Exact p-value 
Pio vs Ctr 2.051 (0.152) 0.184 
Trab vs Ctr 10.669 (0.001) 0.010 
Trab vs Pio 3.130 (0.077) 0.080 
Trab + Pio Vs Ctr 25.001 (<0.001) <0.001 
Trab + Pio Vs Pio 16.823 (<0.001) 0.002 
Trab + Pio. Vs Trab 10.868 (<0.001) <0.001 
Table 5.4.2 Two-tailed asymptotic and exact p-values 
Legend 5.4.2:  ° Slopes in different intervals in the same animal are assumed to be distributed 
independently 
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5.5 Estimating the treatment effect 
5.5.1 Introduction 
Testing the hypothesis of no treatment effect is a necessary condition in the comparison of the 
experimental with the control arm. However, after the treatment effect has been detected, it could 
be relevant to give an estimate of this effect. Assuming the location shift model, the parameter Δ, 
by which the treatment shifts the tumor growth distribution, is the natural measure of the 
treatment effect. Let Xr.0,…,Xr.m(r) be the sample of slopes computed from the experimental arm, 
identically and independently distributed with probability distribution function Tr(x), for all x Є (-∞, 
+∞), at time tr, r=0,…,K-1. Let Yr.0,…,Yr.n(r) be the sample of slopes computed from the control arm, 
identically and independently distributed with probability distribution function Cr(x), for all x Є (-∞, 
+∞), at time tr, r=0,…,K-1. Under the assumption of an additive effect, Tr(x) = Cr(x)- Δr, for all x Є (-
∞, +∞), Δr Є (-∞, +∞), r=0,…,K-1. Δrmed and Δrmean, respectively the median and mean of the 
differences between control and experimental slopes, will be proposed as estimators of the 
parameter Δr. In case of constant treatment effect (i.e. Δr = Δ, for all r=0,…,K-1), estimators Δr med 
and Δr mean could be combined for all r=0,…,K-1 to estimate Δ. The choice of the estimator should 
always be made before the in vivo experiment is performed. 
5.5.2 Definition and properties of the estimator Δrmed 
Denote the ordered set of mr ∙ nr differences Yr.j - Xr.i, where j=1,…,nr and i=1,…,mr, by D(1) < D(2) 
<…<Dm(r).n(r). The definition of Δrmed depends on the parity of mr ∙ nr: 
o the product mr ∙ nr is even, say mr ∙ nr = 2 ∙ k. In this case the estimator Δrmed is the midpoint 
of the interval [D(k) - D(k+1)].  In other words, the estimator is the median of the D(s), s=1,…,  
2 ∙ k 
Δrmed = (1 / 2) ∙ (D(k) + D(k+1))                                                5.5.2.1 
o the product mr ∙ nr is odd, say mr ∙ nr = 2 ∙ k +1. Also in this case the estimator Δrmed is the 
median of the of the D(s), s=1,…, 2 ∙ k. The estimator is given by 
Δrmed = D(k+1)                                                             5.5.2.2 
Using statistical software such as SAS, Stata or R, it is very easy to calculate the point estimate of 
Δrmed in each time interval [tr, tr+1], r=0,…,K-1. A graphical shortcut method of calculating manually 
the point estimate of Δrmed is shown by Lehmann’s book (2006). 
Under the location shift model, the estimator Δrmed has the following important properties: 
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 The distribution of the difference Δrmed - Δr (i.e. the error of the estimator) is independent of 
Δr. Hence, the expected value and the standard error of the Δrmed estimator are independent 
from the real value of Δr. 
 The estimator Δrmed of the parameter Δr is distributed symmetrically about Δr if either of the 
following two conditions hold: 
1. The distribution Cr is symmetric about some point μ 
2. The two sample sizes are equal, that is, mr = nr 
Under the stated conditions, the estimator Δrmed of the parameter Δr is unbiased (i.e. the expected 
value of the estimator is exactly Δr). Proof of the previous properties are furnished by Lehmann’s 
book (2006). No closed formula is available for the variance of this estimator. Its variance depends 
on the Cr distribution. Instead, thanks to the following theorem, a credible interval could be 
associated to the point estimate of  Δrmed: 
Theorem 5.5.2.1: For each k=1,…,mr ∙ nr,  
 PΔ=δ ( D(k) < Δr < D(k+1) ) = PΔ=0 (Wr = k)                                                             5.5.2.3 
where δ=Δr. This theorem is fundamental because it links the probability that Δr lies between D(k) 
and D(k+1) to the distribution of the Mann-Whitney statistic under the null hypothesis (i.e. Δ=0). 
Hence, it permits to define a credible interval around the point estimate of Δr using merely the 
distribution of the Mann-Whitney statistic under the null hypothesis. Proof of this theorem is 
furnished by Lehmann’s book (2006). In appendix E, a SAS MACRO program permits to calculate the 
credible interval of each Δr, r=0,...,K-1. The SAS program was used to calculate point estimates and 
credible intervals of tumor growth rates of the example reported in Section 5.4. Tumor growth rates 
by time interval are reported in Table 5.5.2.1. 
5.5.3 Definition and properties of the estimator Δrmean 
Consider the set of mr ∙ nr differences Yr.j - Xr.i, where j=1,…,nr and i=1,…,mr. Then Δr mean is defined 
as the mean value of these differences, or equivalently, as the difference of the mean values of Yr.j, 
j=1,…,nr and Xr.i, i=1,…,mr. The asymptotic properties of this estimator are determined by the central 
limit theorem. Δrmean is an unbiased estimator and its variance could be calculated using the standard 
deviation of collected slopes {i.e. [σ2(Yr.j) + σ2(Xr.i)](1/2)}. Point estimates and 95% confidence intervals 
of tumor growth rates of Section 5.4 example are reported in Table 5.5.3.1. 
106 
 
Comparison Tumor growth rate 
(day-1) 
Time interval (days) 
  0-4 4-7 7-12 12-15 15-18 18-21 21-26 26-29 
Pio vs Ctr Point estimate 3.5 4.9 -1.2 -2.9 -5.5 -3.6 not defined not defined 
95% credible interval (-0.3) - 8.0  (-1.2) - 10.1   (-4.4) - 2.9  (-6.7) - 1.8 (-8.1) - (-1.9)  (-6.1) - 0.3    
Trab vs Ctr Point estimate -3.1 -1.3 -6.2 -2.0 -5.9 1.8 not defined not defined 
95% credible interval (-7.4) - 1.8 (-6.2) - 4.6 (-8.6) - (-3.1) (-6.4) - 1.6 (-10.4) - (-2.2) (-1.4) - 7.6   
Trab vs Pio Point estimate  -6.8 -6.1 -3.9 0.9 -0.9 5.8 not defined not defined 
95% credible interval (-10.4) - (-2.5) (-10.7) - (-0.4) (-8.2) - (-0.2) (-3.1) - 4.0 (-8.4) - 2.9 2.5 - 9.5   
Trab + Pio 
Vs Ctr 
Point estimate -4.8 6.2 -4.9 -6.6 -8.7 -4.8 not defined not defined 
95% credible interval (-8.8) - (-0.3) (-0.1) - 12.3 (-7.0) - (-2.8) (-10.6) - (-3.0) (-12.2) - (-4.9) (-7.6) - (-1.9)   
Trab + Pio 
Vs Pio 
Point estimate -8.6 1.1 -2.9 -4.2 -3.2 -1.3 not defined not defined 
95% credible interval (-12.6) - (-4.3) (-4.9) - 7.4 (-6.8) - (-0.2) (-7.1) - (-1.0) (-6.3) - 0.3 (-3.6) - 1.4   
Trab + Pio 
Vs Trab 
Point estimate -1.8 7.4 0.9 -4.7 -2.5 -7.0 -2.6 -5.3 
95% credible interval (-6.0) - 1.9 0.4 - 13.8 (-2.6) - 3.6 (-8.2) – (-1.8) (-6.1) - 3.7 (-10.8) - (-3.9) (-6.2) - (-0.4) (-8.4) - (-2.0) 
Table 5.5.2.1 Treatment effects using Δrmed as estimator 
Legend 5.5.2.1: Tumor growth rates are multiplied by 102
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Comparison Tumor growth rate* 
(day-1) 
Time interval (days) 
  0-4 4-7 7-12 12-15 15-18 18-21 21-26 26-29 
Pio vs Ctr Point estimate 4.0 4.5 -1.0 -2.0 -4.1 -2.9 not defined not defined 
95% confidence interval 2.9 - 5.1 3.1 - 5.9 (-1.9) - (-0.2) (-0.9) - (-3.2) (-5.3) - (-2.9) (-3.9) - (-2.0)    
Trab vs Ctr Point estimate -2.3 -1.3 -5.4 -1.9 -6.2 3.2 not defined not defined 
95% confidence interval (-3.5) - (-1.1) (-2.7) – (<0.1) (-6.1) - (-4.7) (-3.0) - (-0.7) (-7.7) - (-4.6) 2.2 – 4.3   
Trab vs Pio Point estimate -6.3 -5.8 -4.3 0.2 -2.1 6.2 not defined not defined 
95% confidence interval (-7.3) - (-5.3) (-7.1) - (-4.5) (-5.4) - (-3.3) (-0.8) – 1.1 (-3.4) - (-0.8) 5.2 – 7.1   
Trab + Pio 
Vs Ctr 
Point estimate -3.9 5.6 -4.8 -6.2 -7.2 -4.0 not defined not defined 
95% confidence interval (-5.0) - (-2.7) 4.0 - 7.3 (-5.3) - (-4.2) (-7.3) - (-5.1) (-8.4) - (-6.0) (-4.9) - (-3.2)   
Trab + Pio 
Vs Pio 
Point estimate -7.9 1.1 -3.7 -4.2 -3.1 -1.1 not defined not defined 
95% confidence interval (-8.9) - (-6.9) (-0.5) - 2.8 (-4.6) – (-2.8) (-5.0) - (-3.3) (-4.0) - (-2.2) (-1.8) - (-0.4)   
Trab + Pio 
Vs Trab 
Point estimate -1.6 7.0 0.6 -4.3 -1.0 -7.3 -3.2 -4.3 
95% confidence interval (-2.7) - (-0.5) 5.4 - 8.5 (-0.1) - 1.4 (-5.1) - (-3.5) (-2.3) - 0.3 (-8.1) - (-6.4) (-3.9) - (-2.4) (-5.3) - (-3.3) 
Table 5.5.3.1 Treatment effects using Δrmean as estimator 
Legend 5.5.3.1: Tumor growth rates are multiplied by 102
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5.5.4 Summary estimators and heterogeneity between time intervals 
Δrmed and Δrmean estimators are defined in each time interval [tr, tr+1], r=0,…,K-1. It could be useful to 
summarize estimates obtained in different time intervals, in a single average estimate. If the 
assumption that treatment effects in different time intervals are equal is reliable, this average 
estimate should represent the ‘true’ treatment effect. For the Δrmean estimator, fixed and random 
effects models for repeated measures could be used to estimate the average treatment effect and 
the heterogeneity between treatment effects in different time intervals. For the Δrmed estimator, it 
is not possible to apply the previous approach because expectation and variance of the estimator’s 
sampling distribution are unknown. Instead, the following estimator could be used: 
 (∑r Δrmed) / (K-1)                                                                               5.5.4.1 
Repeated simulations of ∑r Δr° / (K-1), r=0,…,K-1, where the distribution of the random variable Δr° 
is given by Formula 5.5.2.3, could be used to define credible intervals around the point estimate of 
Formula  5.5.4.1.   
The compatibility between the probability distribution of the estimator defined in 5.5.4.1 and 
estimates of each Δrmed, r=0,…,K-1, obtained in the in vivo experiment,  could be evaluated using re-
sampling techniques and summarized by p-values or graphical display.  
5.5.5 Estimating relative effects 
In the location shift model the administration of the experimental treatment decreases the slope 
gr.i of a constant amount Δr, for all animals in the time interval [tr, tr+1], r=0,…,K-1. The parameter Δr 
then measures the effect of the experimental treatment in the time interval [tr, tr+1], r=0,…,K-1. 
Optionally, researchers could prefer to express the effect size as a relative change. For instance, the 
administration of the experimental treatment reduce the slope gr.j of a relative amount Γr, for all 
animals in the time interval [tr, tr+1], r=0,…,K-1. This is no longer an additive model regulated by the 
parameter Δr, this is a multiplicative model regulated by the parameter Γr. Theoretical and calculus 
results of the location shift model could be simply transferred to the multiplicative model using 
logarithmic scale.  
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Chapter 6 
Discussion 
At the beginning of this project, the proposed survey design was very different to the current one. 
The initial survey design is shown in Figure 6.1. and can be summarized as following steps: 
Step 1. Database Search for published clinical studies 
A systematic search of Medline and EMBASE databases was to be carried out to identify antitumor 
activity studies in clinical research (i.e. phase II clinical trials) 
Step 2. Identifying CCs 
In each of the phase II clinical trials those CCs used as a single agent were to be identified. A random 
sampling procedure was to be used to retrieve and select CCs 
Step 3. Stratified case-control study 
CCs were to be classified as cases or controls based on positive (i.e. cases) or negative (i.e. controls) 
statistical demonstration of antitumor activity. Each case was to be matched to a maximum of three 
controls using the following variables: a) drug’s classification [i.e chemotherapy, targeted therapy] 
b) single-center or multicenter c) primary endpoint d) single-arm or controlled e) use of 
randomization. The strata were to be identified by the following variables: a) drug’s classification b) 
primary endpoint 
Step 4. Database Search for published animal studies 
A systematic search of Medline and EMBASE databases was to be carried out to identify preclinical 
in vivo antitumor activity studies in which CCs were used as monotherapy 
Step 5. Evaluation of the quality of statistical design and analysis 
For each preclinical in vivo experiment the quality of statistical design and analysis was to be 
assessed using the ad hoc checklist reported in Appendix B. Each checklist item was to be statistically 
correlated to cases and controls. 
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Figure 6.1 Initial survey design 
The project’s task, using this survey design, was terminated early because the classification of CCs 
as cases and controls was not reliable. Phase II clinical trials in Oncology are generally single-arm 
trials. The success rate for single-arm phase II clinical trials in Oncology is strongly influenced by 
patient selection bias, misclassification error in tumor response and choice of null and alternative 
hypotheses. 
Therefore it was decided to classify CCs as cases (i..e. authorized CCs) and controls (i.e. non-
authorized CCs) using the public assessment reports published by the European Medicines Agency 
and the Food and Drug Administration. But preclinical in vivo experiments were not clearly identified 
in the public assessment reports of the former agency and the public assessment reports of non-
authorized CCs were not available from the latter agency. Hence, the project’s task, using this 
modified survey design, was terminated. The survey design defined in Chapter 3 was finally 
considered. 
The first relevant result of this project was that poor methodology and reporting were applied 
to preclinical in vivo antitumor activity experiments. About 3 out of 4 assessed preclinical in vivo 
experiments were performed in the last ten years. Although the survey was limited to EOC models, 
it is reasonable to assume that the situation was identical for other tumors. These unsatisfactory 
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results are consistent with those obtained by other surveys not specifically focused in Oncology 
(Kilkenny et al., 2009). 
More than 3 out of 4 preclinical in vivo experiments were performed in a single laboratory, 
using only one species and model. This instills doubts about scientific reproducibility. Poor use of 
blinding techniques and absence of any reporting of allocation concealment call into question 
internal validity. Biological and experimental variability was scarcely controlled: if it was applied, 
randomization was limited to experimental units (i.e rodents); blocks were not used in treatment 
assignment or in the analysis of longitudinal data. Another interesting finding was that the number 
of animals allocated to each treatment arm was moderately heterogeneous (IQR: 6-10). This 
heterogeneity was not supported by a satisfactory justification of sample size. It is worse still. The 
statistical analysis, particularly that of tumor growth curves, was in the best cases inadequate (e.g. 
statistical assumptions were not justified, tumor growth curves were analyzed in a single and 
unjustified time point and confidence intervals were reported in less than half of the preclinical in 
vivo experiments) or even wrong (e.g. use of one-way ANOVA in multiple time points without 
controlling the statistical error or unequal number of animals assigned to different arms). Poor 
reporting of the number of animals at risk and lack of reasons of drop-outs render it impossible to 
fairly estimate biological signal and variability. For ethical reasons, scientific information should be 
maximized by each in vivo experiment. And yet, although factorial designs were greatly used, effects 
interaction between arms was never formally evaluated and confidence intervals were reported for 
less than half of in vivo experiments. Finally, due to rodent outcome measurement (e.g. tumor 
volume) and definition (e.g. tumor response, progression and cure) not being standardized, it is very 
unreliable to make comparison and perform meta-analyses of preclinical in vivo antitumor activity 
experiments.  
“The use of animals in biomedical research generates strong emotions, but everyone will 
surely agree that if they are used the experiments should be properly designed” said Michael Festing 
(2010) and our integrity requires this. My hope is that the result of this survey could be used by 
preclinical researchers to improve the quality of statistical design, analysis and reporting of the 
preclinical in vivo antitumor activity experiments. 
Particularly, this survey showed that the issue of estimating biological signals was poorly  
addressed and debated. If a biological signal (e.g. shrinkage of tumor volume at different time 
points) is formally detected, then its magnitude and pattern should be estimated and questioned. 
Poor methodological quality implies unreliable estimates of the biological signal. Broadly, it seemed 
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that researchers were interested to detect the biological signal but were less keen on or unable to 
debate its magnitude and pattern. In other words, reaching a statistically significant p-value was 
enough. It is time to overcome this simplification and get to the consequent and crucial step: to 
critically debate the magnitude and pattern of the biological signal. Better estimating the magnitude 
of the biological signal is necessary at least for the following reasons: 
o to improve preclinical reproducibility and compare in vivo antitumor activity experiments 
o to perform reliable systematic reviews and meta-analysis. For instance, without reliable 
data, attempts to correlate in vivo antitumor activity with clinical activity, which is the first 
aim of the project, produce doubtful results 
o to perform multicenter in vivo experiments 
o to critically debate tumor growth curves with complex biological patterns 
o to use adaptive designs with interim stopping rules in preclinical research (refer to Table 
1.2.5.1) 
o to use historical data to improve statistical designs of in vivo antitumor activity experiments 
(refer to Table 1.2.5.1). 
The first aim of the project aim was to correlate the quality of statistical design and analysis of 
preclinical in vivo experiments with estimates of clinical antitumor activity. In order to reach this 
aim, it would be necessary to identify a subgroup of in vivo experiments with good methodological 
quality. Instead, this survey showed that the quality of statistical design and analysis was 
systematically poor. Therefore, the first aim of the project failed. This aim of the project was 
probably too ambitious. Even if a subgroup of in vivo experiments was identified, the positive 
correlation between preclinical quality and clinical activity could not be detected for the following 
three reasons: 
1. the effect size of the biological signal prevails over the methodological quality (i.e. a large 
effect size may be detected even in the presence of poor methodological quality) 
2. only a very small part of the clinical effect is explained by the biological signal 
3. the heterogeneity of the clinical effect due to the choice of the drug schedule, the selection 
of patients, and the random error is so large that it prevails over the biological signal. 
Even if problems 1 to 3 did not exist, attempts to correlate in vivo antitumor activity with clinical 
activity will produce doubtful results without reliable data.  
Another disappointing result of this survey was that for more than half of CCs tested as 
monotherapy in EOC clinical trials, no eligible preclinical in vivo experiment was identified. Due to 
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the dramatic lack of data from preclinical in vivo experiments, testing these CCs in clinical trials is 
not supported by robust preclinical evidence.  
This project improved the methodology applied to tumor growth studies. An entirely 
innovative methodological framework to design and analyze preclinical in vivo tumor growth studies 
was proposed. This framework is complete because hypothesis tests are combined with coherent 
estimators of biological signal. Further studies comparing this framework with other statistical 
approaches are needed, but advantages of this new framework are evident: 
o the statistical approach takes into account the complete dataset of in vivo tumor growth 
data 
o the family of statistical tests is non-parametric. The parameter Δr, r=0,…,K-1, assume an 
additive effect at the time interval [tr, tr+1]. These parameters can vary between time 
intervals. There is a remarkable similarity between the framework proposed for the design 
and analysis of in vivo tumor growth studies and that framework usually used in survival 
analysis. The Mann-Whitney statistic and the family of statistical tests based on slopes 
computed from the experimental and control arms, corresponds to the Mantel-Haenzel 
statistic and the log-rank test, respectively. The parameter Δr, expressing the effect size as a 
relative change, corresponds to the parameter hazard ratio 
o in case of missing values or right-censoring, data series of tumor growth curves are fully 
included 
o if bootstrap methods and resampling techiniques are used to compute the exact 
distribution, it would not be required to assume or specify a correlation structure. Otherwise 
the covariance matrix could be estimated by experimental data 
o similar to the log-rank test, whose power is maximized if the proportional hazards 
assumption holds, the power of the proposed family of statistical tests is maximized under 
the alternative hypothesis of an additive effect 
o the proposed framework could address every biological mechanism underlying tumor 
growth curves. Partitioning the follow-up in time intervals [tr, tr+1], r=0,…,K-1, maximizes the 
biological information obtained from preclinical in vivo experiments   
o because test statistic and estimators are calculated using the slopes that join the values of 
tumor volumes at times r and r+1,  r=0,…,K-1, imbalances of tumor volumes at baseline are 
automatically adjusted. Moreover, because statistical tests are stratified by time interval [r, 
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r+1], r=0,..,K-1, each time interval is an experimental block. The power of our statistical tests 
benefits from the blocked analysis 
o patterns of tumor growth in the first days are well-balanced by patterns of tumor growth in 
the following days. Clearly, if tumor growth is reduced or just controlled by the experimental 
therapy in the first days, this advantage is formally lost if, in the following days, the pattern 
of tumor growth in the experimental arm is just the same as that in the control arm. In other 
words, the experimental therapy cannot maintain its initial advantage. This is important in 
the activity of screening CCs. 
In conclusion, 
o this project showed methodological limits and pitfalls of preclinical in vivo antitumor activity 
experiments performed in recent years. Preclinical researchers in Oncology should be aware 
of the limits and pitfalls shown in Tables 4.5.1-4.5.8, in order to improve statistical design, 
analysis and reporting of their preclinical in vivo experiments 
o this project showed that the issue of fairly estimating and then debating the magnitude and 
pattern of the biological signal is poorly addressed by preclinical researchers, at least in 
Oncology. It is time to shift the researcher’s interest from the mere presence of a treatment 
effect (i.e. the statistical significance is enough) to the estimation and judgement of the 
magnitude and pattern of the biological signal 
o a new, useful and practical methodological framework to design, analyze and report in vivo 
tumor growth studies is proposed. It should be considered by preclinical researchers in 
Oncology for their in vivo antitumor activity experiments. 
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Appendix A 
A.1 Preclinical search string used in the Medline database 
Search Query N° items 
#58 #1 AND #2 AND #3 AND #57 613 
#57 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR 
#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR 
#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR 
#41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR 
#53 OR #54 OR #55 OR #56 
169651 
#56 ("Paclitaxel"[Mesh] OR paclitaxel OR Abraxane OR ABI007 OR ABI-007 OR “ABI 007” OR abi007 
OR abraxane OR anzatax OR “bms 181339” OR endotag-1 OR genexol OR “genexol pm” OR 
infinnium OR intaxel OR “mbt 0206” OR “mitotax” OR “nab paclitaxel” OR “nanoparticle albumin 
bound paclitaxel” OR “nsc 125973” OR nsc125973 OR “oncogel” OR “onxol” OR “pacitaxel” OR 
“paclitaxel nab” OR padexol OR parexel OR paxceed OR “paxene” OR “paxus” OR “praxel” OR 
taxol OR yewtaxan) AND (“lipid nanoparticles” OR “lipid core nanoparticles”) 
92 
#55 "gemcitabine" [Supplementary Concept] OR gemcitabine OR dFdCyd OR “2’,2’-
difluorodeoxycytidine” OR “2’-deoxy-2’-difluorocytidine” OR “2’,2’-difluoro-2’- deoxycytidine” 
OR “LY 188011” OR LY-188011 OR Gemzar OR “2’ deoxy 2’, 2’ Difluorocytidine” OR “2’, 2’ 
Difluorodeoxycytidine” OR d07001 OR difluorodeoxycytidine OR gemcite OR gemzar OR “ly 
188011” OR ly188011 
15711 
#54 "Lenalidomide"[Mesh] OR lenalidomide OR “3-(4-Amino-1-oxoisoindolin- 2-yl)piperidine-2,6-
dione” OR “CC 5013” OR CC5013 OR CC-5013 OR Revlimid OR “Revimid” OR “cc 5013” OR cc5013 
OR “cdc 501” OR “enmd 0997” OR “imid 3” OR imid3 OR “revimid” OR revlimid 
4114 
#53 "birinapant" [Supplementary Concept] OR birinapant OR tl32711 68 
#52 "belinostat" [Supplementary Concept] OR belinostat OR beleodaq OR pdx101 OR “pxd 101” 231 
#51 "nintedanib" [Supplementary Concept] OR “nintedanib” OR “bibf 1120” OR bibf1120 OR 
intedanib OR ofev OR vargatef OR “BIBF 1120” OR BIBF1120 OR BIBF-1120 
716 
#50 "AZD 6244" [Supplementary Concept] OR “AZD 6244” OR AZD6244 OR AZD-6244 OR selumetinib 
OR “ARRY 142886” OR ARRY142886 OR ARRY-142886 OR “arry 142886” OR arry142886 OR “azd 
6244” OR azd6244 
563 
#49 "aflibercept" [Supplementary Concept] OR aflibercept OR “VEGF Trap - regeneron” OR “VEGF 
Trap-Eye” OR VEGF-Trap OR eylea OR Zaltrap OR “AVE 0005” OR AVE0005 OR AVE-0005 OR “AVE 
005” OR AVE005 OR AVE-005 OR ZIV-aflibercept OR “vascular endothelial growth factor trap” 
OR “VEGF Trap” OR “ziv aflibercept” 
1953 
#48 "N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin- 4-yl)methoxy)quinazolin-4-
amine" [Supplementary Concept] OR vandetanib OR "N-(4- bromo-2-fluorophenyl)-6-methoxy-
7-((1-methylpiperidin-4-yl)methoxy)quinazolin- 4-amine" OR “caprelsa” OR Zactima OR “ZD 
6474” OR ZD6474 OR ZD-6474 OR “caprelsa” OR “vandetinib” OR zactima OR “zd 6474” OR 
zd6474 
874 
#47 "prexasertib" [Supplementary Concept] OR prexasertib OR LY2606368 OR ly2606368 24 
#46 "Trabectedin"[Mesh] OR Trabectedin OR Yondelis OR “Ecteinascidin 743” OR ET-743 OR ET743 
OR “ET 743” OR “NSC 684766” OR “ecteinascidin 743” OR “et 743” OR et743 OR yondelis 
827 
#45 "ST 1481" [Supplementary Concept] OR “ST 1481” OR ST1481 OR LBQ707 OR 7-t-
butoxyiminomethylcamptothecin OR 7-t-butoxyiminomethyl-camptothecin OR gimatecan OR 
“7 tert butoxyiminomethylcamptothecin” OR lbq707 OR “st 1481” OR st1481 
52 
125 
 
#44 "Dasatinib"[Mesh] OR dasatinib OR Sprycel OR “BMS 354825” OR BMS354825 OR BMS-354825 
OR “bms 354825” OR bms354825 OR “n (2 chloro 6 methylphenyl) 2 [ [6 [4 (2 hydroxyethyl) 
piperazin 1 yl] 2 methylpyrimidin 4 yl] amino] thiazole 5 carboxamide” OR sprycel 
3193 
#43 "ixabepilone" [Supplementary Concept] OR ixabepilone OR “azaepothilone B” OR BMS247550 
OR “BMS 247550” OR BMS-247550 OR “azaepothilone B” OR “bms 247550” OR bms247550 OR 
ixempra 
426 
#42 "perifosine" [Supplementary Concept] OR perifosine OR “octadecyl-(1,1- dimethyl-4-
piperidylio)phosphate” OR “D 21266” OR D-21266 OR “d 21266” OR d21266 OR “krx 0401” 
353 
#41 "apatinib" [Supplementary Concept] OR rivoceranib OR apatinib OR YN968D1 OR YN-968D1 OR 
“apatinib mesylate” OR “aitan” OR apatinib OR “apatinib mesylate” OR yn968d1 
311 
#40 "BI 6727" [Supplementary Concept] OR BI-6727 OR volasertib OR “bi 6727” OR bi6727 121 
#39 "temsirolimus" [Supplementary Concept] OR temsirolimus OR “rapamycin, 42-(3-hydroxy-2-
(hydroxymethyl)-2-methylpropanoate)” OR “CCI 779” OR CCI-779 OR Torisel OR “cci 779” OR 
cci779 OR “cell cycle inhibitor 779” OR “nsc 683864” OR “rapamycin 42 [2, 2 bis (hydroxymethyl) 
propionate]” OR torisel OR “way-cci 779” 
1525 
#38 "Imatinib Mesylate"[Mesh] OR imatinib OR “Imatinib Methanesulfonate” OR STI571 OR STI-571 
OR “STI 571” OR Gleevec OR Glivec OR “ST 1571” OR ST1571 OR “CGP 57148” OR CGP57148B 
OR CGP-57148 OR CGP57148 OR Imatinib OR “Alpha-(4- methyl-1-piperazinyl)-3’-((4-(3-pyridyl)-
2-pyrimidinyl)amino)-p-tolu-p-toluidide” OR “cgp 57148” OR “cgp 57148b” OR cgp57148 OR 
cgp57148b OR “gleevac” OR gleevec OR glivec OR “glivic” OR “imatinib mesilate” OR “imatinib 
mesylate” OR “signal transduction inhibitor 571” OR “st 1571” OR st1571 OR “sti 571” OR sti-
571 OR sti571 
14892 
#37 "MLN 8237" [Supplementary Concept] OR “MLN 8237” OR MLN8237 OR MLN-8237 OR alisertib 
OR “mln 8237” OR mln8237 
271 
#36 "SPI-77, liposomal" [Supplementary Concept] OR “liposomal cisplatin” OR SPI-077 OR “SPI 077” 
OR “SPI 77” OR SPI-77 OR SPI077 OR “Stealth liposomal cisplatin” OR “cisplatin liposomal” OR 
(cisplatin AND (liposomes OR liposomal)) 
544 
#35 "PM 01183" [Supplementary Concept] OR “PM 01183” OR PM01183 OR PM-01183 OR 
lurbinectedin OR “pm 01183” OR pm01183 
39 
#34 "ALK1-Fc fusion protein, human" [Supplementary Concept] OR “ALK1-Fc fusion protein, human” 
OR ACE-041 OR dalantercept OR “ace 041” 
14 
#33 "olaparib" [Supplementary Concept] OR olaparib OR “AZD 2281” OR AZD2281 OR AZD-2281 OR 
AZD221 OR Lynparza OR “4 [3 (4 cyclopropanecarbonylpiperazine 1 carbonyl) 4 fluorobenzyl] 2h 
phthalazin 1 one” OR “4 [ [3 [ [4 (cyclopropylcarbonyl) piperazin 1 yl] carbonyl] 4 fluorophenyl] 
methyl] phthalazin 1 (2h) one” OR “azd 2281” OR azd2281 OR “ku 0059436” OR “ku 59436” OR 
ku0059436 OR lynparza 
1035 
#32 "Doxorubicin"[Mesh] OR doxorubicin OR Farmiblastina OR “Rubex” OR Adriamycin OR 
Adriblastin OR “Adriblastine” OR Adriblastina OR “Adriablastine” OR Adriablastin OR DOXO-cell 
OR “DOXO cell” OR “Myocet” OR “14 hydroxydaunomycin” OR adriablastin OR “adriablastina” 
OR “adriablastine” OR “adriacin” OR “adriamicina” OR “adriamicine” OR adriamycin OR 
“adriamycin hydrochloride” OR “adriamycin rdf” OR “adriamycina” OR adriblastin OR  
adriblastina OR “adriblastine” OR “adrim” OR “caelix” OR caelyx OR “caelyx/doxil” OR 
“doxorubicin” OR “dox sl” OR dox-sl OR doxil OR “doxil (liposomal)” OR “doxorubicin 
hydrochloride” OR “doxorubicin, liposomal” OR “doxorubicine” OR “doxorubin” OR “evacet” OR 
farmiblastina OR “fi 106” OR lipodox OR “liposomal doxorubicin” OR “mcc 465” OR mcc465 OR 
“myocet” OR “nsc 123127” OR “pegylated liposomal doxorubicin” OR “polyethylene glycol-
coated liposomal doxorubicin” OR “rubex” OR “tlc d 99” 
73070 
#31 "BI 2536" [Supplementary Concept] OR “BI 2536” OR BI2536 OR BI-2536 202 
#30 "Bendamustine Hydrochloride"[Mesh] OR Bendamustine OR “Bendamustin” OR Cytostasan OR 
“IMET 3393” OR Ribomustin OR Treanda OR “Zimet 3393” OR “5 [bis (2 chloroethyl) amino] 1 
1186 
126 
 
methyl 2 benzimidazolebutyric acid” OR “bendamustine hydrochloride” OR “bendeka” OR 
cytostasan OR “cytostasane” OR “imet 3393” OR “levact” OR ribomustin OR treanda OR “zimet 
3393” 
#29 "eribulin" [Supplementary Concept] OR eribulin OR “E 7389” OR E-7389 OR ER-086526 OR 
ER086526 OR “ER 086526” OR ER-86526 OR Halaven OR “NSC 707389” OR NSC707389 OR NSC-
707389 OR “B 1793” OR B-1793 OR “B 1939” OR B-1939 OR “eribulin mesylate” OR “eribulin 
mesilate” OR “e 7389” OR e7389 OR “er 086526” OR er086526 OR “eribulin mesilate” OR 
“eribulin mesylate” OR halaven 
594 
#28 "danusertib" [Supplementary Concept] OR danusertib OR “PHA 739358” OR PHA739358 OR 
PHA-739358 OR “pha 739358” OR pha739358 
63 
#27 "LHRH, lysine(6)-doxorubicin" [Supplementary Concept] OR "LHRH, lysine(6)- doxorubicin" OR 
“zoptarelin doxorubicin” OR ZEN-008 OR AN-152 OR AEZS-108 OR “aezs 108” OR “an 152” OR 
an-152 
62 
#26 "Sorafenib"[Mesh] OR sorafenib OR Nexavar OR “BAY 43-9006” OR “BAY 43 9006” OR “BAY 
439006” OR “Sorafenib N-Oxide” OR “Sorafenib N Oxide” OR BAY-673472 OR BAY-545-9085 OR 
BAY5459085 OR “Sorafenib Tosylate” OR “bay 43 9006” OR “bay 43-9006” OR “bay 439006” OR 
“bay43 9006” OR bay43-9006 OR bay439006 OR nexavar OR “sorafenib tosylate” 
7790 
#25 "cabozantinib" [Supplementary Concept] OR cabozantinib OR Cometriq OR “XL 184” OR XL-184 
OR “BMS 907351” OR BMS907351 OR BMS-907351 OR “bms 907351” OR bms907351 OR 
cabometyx OR “cabozantinib malate” OR “cabozantinib s malate” OR “cabozantinib s-malate” 
OR cometriq OR “xl 184” OR xl184 
684 
#24 "pazopanib" [Supplementary Concept] OR pazopanib OR GW786034B OR GW-786034B OR 
GW780604 OR GW-780604 OR Votrient OR “armala” OR “gw 786034” OR gw786034 OR 
gw786034b OR “pazopanib hydrochloride” OR votrient 
1542 
#23 "sagopilone" [Supplementary Concept] OR sagopilone OR DE-03757 OR EPO-477 OR SH-Y-03757 
OR ZK-epothilone OR SH-Y03757A OR ZK-219477 OR ZKEPO OR BAY-86-5302 OR “zk 219477” OR 
“zk epo” OR zk219477 
58 
#22 "Topotecan"[Mesh] OR topotecan OR 9-Dimethylaminomethyl-10- hydroxycamptothecin OR “9 
Dimethylaminomethyl 10 hydroxycamptothecin” OR “Topotecan Hydrochloride” OR “Nogitecan 
Hydrochloride” OR SKF-104864-A OR “SKF 104864 A” OR SKF104864A OR Hycamtin OR NSC-
609699 OR “NSC 609699” OR NSC609699 OR “9 dimethylaminomethyl 10 
hydroxycamptothecin” OR e89001 OR hycamptamine OR hycamtin OR “nsc 609699” OR 
nsc609699 OR “skf 104864” OR “skf 104864 a” OR “topotecan hydrochloride” OR “topotecane” 
3178 
#21 ("2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3- 
pentafluoropropyl)malonamide" [Supplementary Concept] OR RO4929097 OR RO-4929097) 
46 
#20 "epothilone B" [Supplementary Concept] OR “epothilone B” OR patupilone OR EPO906 OR “epo 
906” OR epo906 
458 
#19 "acetyl-lysyl-prolyl-seryl-seryl-prolyl-prolyl-glutamyl-glutamic acid amide" [Supplementary 
Concept] OR (“urokinase plasminogen activator” AND “136-143”) OR “urokinase derived 
peptide” OR “urokinase-derived peptide” OR (“A6” AND peptide) OR Ac-Lys-Pro-Ser-Ser-Pro-
Pro-Glu-Glu-NH2 OR Ac-KPSSPPEE-NH2 OR “acetyl- lysylprolyl- seryl-seryl-prolyl-prolyl-
glutamyl- glutamic acid amide” 
906 
#18 "tasquinimod" [Supplementary Concept] OR tasquinimod OR ABR-215050 OR “abr 215050” 64 
#17 "veliparib" [Supplementary Concept] OR veliparib OR “2-((R)- 2-methylpyrrolidin-2-yl)-1H-
benzimidazole-4-carboxamide” OR “ABT 888” OR ABT888 OR ABT-888 OR “abt 888” OR abt888 
338 
#16 "Sunitinib"[Mesh] OR sunitinib OR “Sunitinib Malate” OR Sutent OR “SU 11248” OR SU011248 
OR “SU 011248” OR SU-011248 OR SU11248 OR SU-11248 OR “su 011248” OR “su 11248” OR 
su011248 OR su11248 OR “sunitinib malate” OR suo11248 OR sutent 
5732 
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#15 "Albumin-Bound Paclitaxel"[Mesh]OR 130-nm albumin-bound paclitaxel [Supplementary 
Concept] OR (albumin AND paclitaxel) OR “130-nm albumin-bound paclitaxel” OR “Albumin-
Bound Paclitaxel” OR nab-paclitaxel OR “nab paclitaxel” OR “Albumin Bound Paclitaxel” OR 
“Protein-Bound Paclitaxel” OR “Protein Bound Paclitaxel” OR Abraxane OR ABI007 OR ABI-007 
OR “ABI 007” OR abi007 OR abraxane OR anzatax OR “bms 181339” OR endotag-1 OR genexol 
OR “genexol pm” OR infinnium OR intaxel OR “mbt 0206” OR “mitotax” OR “nab paclitaxel” OR 
“nanoparticle albumin bound paclitaxel” OR “nsc 125973” OR nsc125973 OR “oncogel” OR 
“onxol” OR “pacitaxel” OR “paclitaxel nab” OR padexol OR parexel OR paxceed OR “paxene” OR 
“paxus” OR “praxel” OR taxol OR yewtaxan 
37435 
#14 "motesanib diphosphate" [Supplementary Concept] OR motesanib OR “AMG 706” OR AMG706 
OR AMG-706 OR “amg 706” OR amg706 OR “motesanib diphosphate” 
97 
#13 "Lapatinib"[Mesh] OR lapatinib OR Tykerb OR GW282974X OR GW-282974X OR GW572016 OR 
GW-572016 OR “GW 572016” OR “Lapatinib Ditosylate” OR “gw 572016” OR gw2016 OR 
gw572016 OR “lapatinib ditosylate” OR tykerb OR “tyverb” 
2498 
#12 "Asparaginase"[Mesh] OR "monomethoxypolyethylene glycol-conjugated asparaginase" 
[Supplementary Concept] OR asparaginase OR "monomethoxypolyethylene glycol-conjugated 
asparaginase" OR “L asparaginase” OR L-asparaginase OR “PEG(2)-ASP” OR “asparaginase 2” OR 
“asparaginase a” OR “asparaginase ag” OR “asparaginase Erwinia chrysanthemi” OR 
“asparaginase ii” OR “asparagine amidohydrolase” OR “asparginase” OR “aspariginase” OR 
colaspase OR crasnitin OR crisantaspase OR “e.c. 3.5.1.1” OR elspar OR erwinase OR “erwinaze” 
OR “ery asp” OR “graspa” OR kidrolase OR krasnitin OR “l asparaginase” OR “l asparaginase a” 
OR “l asparagine amidohydrolase” OR “l asparginase” OR leunase OR “levo asparaginase” OR 
“nsc 109229” OR “Asparagine Deaminase” OR “Asparaginase II” OR Leunase OR “Asparaginase 
medac” 
5615 
#11 "rucaparib" [Supplementary Concept] OR rucaparib OR “AG 014699” OR AG014699 OR AG-
014699 OR PF-01367338 OR “8 fluoro 2 [4 [ (methylamino) methyl] phenyl] 1, 3, 4, 5 tetrahydro 
6h azepino [5, 4, 3 cd] indol 6 one” OR “ag 014699” OR “ag 14447” OR “ag 14699” OR ag014699 
OR ag14447 OR “co 338” OR “pf 01367338” OR “pf 1367338” OR rubraca 
225 
#10 ("5'-oleoyl cytarabine" [Supplementary Concept] OR “5’-oleoyl cytarabine” OR “5’-oleyl-ara-C” 
OR elacyt OR elacytarabine OR “CP 4055” OR CP4055 OR CP-4055) 
33 
#9 "iniparib" [Supplementary Concept] OR iniparib OR 4-iodo-3-nitrobenzamide OR “BSI 201” OR 
BSI201 OR BSI-201 OR “4 iodo 3 nitrobenzamide” OR “bsi 201” OR bsi201 OR “sar 240550” 
97 
#8 "cediranib" [Supplementary Concept] OR cediranib OR AZD2171 OR AZD-2171 OR “AZD 2171” 
OR “recentin” 
367 
#7 "irofulven" [Supplementary Concept] OR irofulven OR 6-hydroxymethylacylfulvene OR “6-
(hydroxymethyl)acylfulvene” OR “MGI 114” OR MGI.114 OR MGI-114 OR “6 
hydroxymethylacylfulvene” OR HMAF OR hydroxymethylacylfulvene OR “mgi 114” OR mgi114 
120 
#6 "etirinotecan pegol" [Supplementary Concept] OR etirinotecan OR NKTR-102 OR “NKTR 102” OR 
“nktr 102” 
29 
#5 "enzastaurin" [Supplementary Concept] OR enzastaurin OR LY317615.HCl OR “enzastaurin 
hydrochloride” OR “ly 317615” OR ly317615 
246 
#4 "ENMD 2076" [Supplementary Concept] OR “ENMD 2076” OR ENMD-2076 OR ENMD2076 20 
#3 "Rats"[Mesh] OR rat OR rats OR rattus OR "Mice"[Mesh] OR mouse OR mice OR mus OR murine 
OR xenograft OR xenografts OR heterograft OR heterografts OR xenogeneic OR xenogenic OR 
heterotransplant OR xenotransplant OR allograft OR allografts OR homograft OR homografts OR 
allogeneic OR allogenic OR allotransplant OR homotransplant OR alloplastic OR isograft OR 
isografts OR syngeneic OR “syngenic” OR isogeneic OR isogenic OR syngraft OR syngrafts OR syn-
graft OR syn-grafts OR isograft OR isografts OR iso-graft OR iso-grafts OR isotransplant OR 
"Animals, Genetically Modified"[Mesh] OR “genetically modified” OR “genetically engineered” 
OR “genetically manipulated” OR “genetically-modified” OR “genetically-engineered” OR 
“genetically-manipulated” OR transgenic OR transgene 
3450887 
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#2 "Drug Evaluation, Preclinical"[Mesh] 229642 
#1 “Ovarian Neoplasms”[Mesh] OR ovarian OR ovary 271440 
 
A.2 Preclinical search string used in the EMBASE database 
Search Query N° items 
#58 #1 AND #2 AND #3 AND #57 210 
#57 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR 
#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR 
#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR 
#41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR 
#53 OR #54 OR #55 OR #56 
503790 
#56 'paclitaxel'/exp OR paclitaxel OR 'abi 007' OR abi007 OR abraxane OR 'albumin bound paclitaxel' 
OR 'albumin-bound paclitaxel' OR anzatax OR apealea OR asotax OR biotax OR 'bms 181339' OR 
bms181339 OR 'bmy 45622' OR bmy45622 OR bristaxol OR britaxol OR coroxane OR 'dts 301' 
OR dts301 OR 'endotag 1' OR formoxol OR genexol OR 'genexol pm' OR hunxol OR ifaxol OR 
infinnium OR intaxel OR 'mbt 0206' OR mbt0206 OR medixel OR mitotax OR 'nab paclitaxel' OR 
'nanoparticle albumin bound paclitaxel' OR 'nsc 125973' OR 'nsc 673089' OR nsc125973 OR 
nsc673089 OR 'oas pac 100' OR oaspac100 OR oncogel OR onxol OR pacitaxel OR 'paclitaxel nab' 
OR pacxel OR padexol OR parexel OR paxceed OR paxene OR paxus OR praxel OR 'sb 05 
(terpenoid)' OR 'sb05 (terpenoid)' OR taxocris OR taxol OR 'taxus (drug)' OR taycovit OR 
yewtaxan) AND ('lipid nanoparticles' OR 'lipid core nanoparticles' 
251 
#55 'gemcitabine'/exp OR gemcitabine OR dfdcyd OR '2?,2?-difluorodeoxycytidine' OR '2?-deoxy-
2?-difluorocytidine' OR '2?,2?-dfdc' OR '2?,2?-difluoro-2?-deoxycytidine' OR '2?-deoxy-2?,2??-
difluorocytidine-5?-o-monophosphate' OR '2? deoxy 2?, 2? difluorocytidine' OR '2?, 2? 
difluorodeoxycytidine' OR 'd 07001' OR d07001 OR difluorodeoxycytidine OR 'ff 10832' OR 
ff10832 OR gemcite OR gemtro OR gemzar OR infugem OR 'ly 188011' OR ly188011 
53434 
#54 'lenalidomide'/exp OR lenalidomide OR '3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione' 
OR '2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2h- isoindol-2-yl)-' OR 'imid3 cpd' OR '3 
(4 amino 1 oxo 1, 3 dihydro 2h isoindol 2 yl) 2, 6 piperidinedione' OR '3 (4 amino 1, 3 dihydro 1 
oxo 2h isoindol 2 yl) glutarimide' OR '3 (4? aminoisoindoline 1? one) 1 piperidine 2, 6 dione' OR 
'cc 5013' OR cc5013 OR 'cdc 501' OR 'cdc 5013' OR cdc501 OR cdc5013 OR 'enmd 0997' OR 
enmd0997 OR 'imid 3' OR imid3 OR revimid OR revlimid 
17576 
#53 'birinapant'/exp OR birinapant OR 'n, n? [ (6, 6? difluoro 1h, 1?h 2, 2? biindolyl 3, 3? diyl) bis 
[methylene (4 hydroxypyrrolidine 2, 1 diyl) (1 ethyl 2 oxoethylene)]] bis [2 (methylamino) 
propanamide]' OR 'n, n? [ (6, 6? difluoro [1h, 1?h 2, 2? biindole] 3, 3? diyl) bis [methylene (4 
hydroxypyrrolidine 2, 1 diyl) (1 oxobutane 1, 2 diyl)]] bis [2 (methylamino) propanamide]' OR 'n, 
n? [ (6, 6? difluoro [2, 2? bi 1h indole] 3, 3? diyl) bis [methylene (4 hydroxy 2, 1 pyrrolidinediyl) 
(1 ethyl 2 oxo 2, 1 ethanediyl)]] bis [2 (methylamino) propanamide]' OR 'tl 32711' OR tl32711 
222 
#52 'belinostat'/exp OR belinostat OR '3 phenylsulfamoylcinnamohydroxamic acid' OR beleodaq OR 
'n hydroxy 3 [ (3 phenylsulfamoyl) phenyl] 2 propenamide' OR 'n hydroxy 3 [3 (n 
phenylsulfamoyl) phenyl] prop 2 enamide' OR 'pdx 101' OR pdx101 OR 'pxd 101' OR pxd101 OR 
belecodaq 
1373 
#51 'nintedanib'/exp OR nintedanib OR '2, 3 dihydro 3 [ [[4 [methyl [2 (4 methyl 1 piperazinyl) acetyl] 
amino] phenyl] amino] phenylmethylene] 2 oxo 1h indole 6 carboxylic acid methyl ester' OR '2, 
3 dihydro 3 [ [[4 [n methyl 2 (4 methyl 1 piperazinyl) acetamido] phenyl] amino] (phenyl) 
methylidene] 2 oxo 1h indole 6 carboxylic acid methyl ester' OR intedanib OR 'methyl 3 [ [[4 [n 
methyl 2 (4 methylpiperazin 1 yl) acetamido] phenyl] amino] (phenyl) methylidene] 2 oxo 2, 3 
dihydro 1h indole 6 carboxylate' OR 'nintedanib esylate' OR ofev OR vargatef OR bibf1120 OR 
'bibf 1120' 
2610 
129 
 
#50 'selumetinib'/exp OR selumetinib OR '5 (4 bromo 2 chloroanilino) 4 fluoro 1 methyl 1h 
benzimidazole 6 carbohydroxamic acid 2 hydroxyethyl ester' OR '5 (4 bromo 2 
chlorophenylamino) 4 fluoro 1 methyl 1h benzimidazole 6 carbohydroxamic acid 2 hydroxyethyl 
ester' OR '5 [ (4 bromo 2 chlorophenyl) amino] 4 fluoro n (2 hydroxyethoxy) 1 methyl 1h 
benzimidazole 6 carboxamide' OR 'arry 142886' OR arry142886 OR 'azd 6244' OR azd6244 OR 
'selumetinib sulfate' OR 'selumetinib sulphate' 
2791 
#49 'aflibercept'/exp OR aflibercept OR 'vegf trap - regeneron' OR 'vegf trap-eye' OR eylea OR zaltrap 
OR ave0005 OR 'ave 0005' OR ave005 OR 'ave 005' OR 'vascular endothelial growth factor trap' 
OR 'vasculotropin trap' OR 'vegf trap' OR 'ziv aflibercept' 
5301 
#48 'vandetanib'/exp OR vandetanib OR 'n-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-
methylpiperidin-4-yl)methoxy)quinazolin-4-amine' OR 'azd 6474' OR azd6474 OR caprelsa OR 'n 
(4 bromo 2 fluorophenyl) 6 methoxy 7 (1 methyl 4 piperidinylmethoxy) 4 quinazolinamine' OR 
'n (4 bromo 2 fluorophenyl) 6 methoxy 7 (1 methylpiperidin 4 ylmethoxy) quinazolin 4 amine' 
OR vandetinib OR zactima OR 'zd 6474' OR zd6474 
4442 
#47 'prexasertib'/exp OR prexasertib OR '5 [ [5 [2 (3 aminopropoxy) 6 methoxyphenyl] 1h pyrazol 3 
yl] amino] 2 pyrazinecarbonitrile' OR '5 [ [5 [2 (3 aminopropoxy) 6 methoxyphenyl] 1h pyrazol 3 
yl] amino] pyrazine 2 carbonitrile' OR 'ly 2606368' OR ly2606368 
147 
#46 'trabectedin'/exp OR trabectedin OR 'nsc 684766' OR 'ecteinascidin 743' OR 'et 743' OR et743 
OR yondelis 
2425 
#45 'gimatecan'/exp OR '7-t-butoxyiminomethylcamptothecin' OR '7-t-butoxyiminomethyl-
camptothecin' OR gimatecan OR '7 tert butoxyiminomethylcamptothecin' OR 'cpt 184' OR 
cpt184 OR 'lbq 707' OR lbq707 OR 'st 1481' OR st1481 
144 
#44 'dasatinib'/exp OR dasatinib OR 'n-(2-chloro-6-methylphenyl)-2-(6-(4-(2-
hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide' OR '(18f)-
n-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-
ylamino)thiazole-5-carboxamide' OR '354825, bms' OR 'bms 354825' OR 'bms 354825 03' OR 
'bms 354825-03' OR 'bms 35482503' OR bms354825 OR 'bms354825 03' OR bms35482503 OR 
'dasatinib hydrate' OR 'n (2 chloro 6 methylphenyl) 2 [6 [4 (2 hydroxyethyl) 1 piperazinyl] 2 
methyl 4 pyrimidinylamino] 5 thiazolecarboxamide' OR 'n (2 chloro 6 methylphenyl) 2 [6 [4 (2 
hydroxyethyl) piperazin 1 yl] 2 methylpyrimidin 4 ylamino] thiazole 5 carboxamide' OR 'n (2 
chloro 6 methylphenyl) 2 [ [6 [4 (2 hydroxyethyl) 1 piperazinyl] 2 methyl 4 pyrimidinyl] amino] 5 
thiazolecarboxamide' OR 'n (2 chloro 6 methylphenyl) 2 [ [6 [4 (2 hydroxyethyl) piperazin 1 yl] 2 
methylpyrimidin 4 yl] amino] thiazole 5 carboxamide' OR sprycel 
12579 
#43 'ixabepilone'/exp OR ixabepilone OR '7, 11 dihydroxy 8, 8, 10, 12, 16 pentamethyl 3 [1 methyl 2 
(2 methyl 4 thiazolyl) ethenyl] 17 oxa 4 azabicyclo [14.1.0] heptadecane 5, 9 dione' OR 
'azaepothilone b' OR 'bms 247550' OR 'bms 247550 1' OR 'bms 247550-1' OR bms247550 OR 
'bms247550 1' OR ixempra OR 'ixempra kit' OR 'nsc 710428' OR nsc710428 
1749 
#42 'perifosine'/exp OR perifosine OR 'octadecyl-(1,1-dimethyl-4-piperidylio)phosphate' OR '4 [ 
[hydroxy (octadecyloxy) phosphinyl] oxy] 1, 1 dimethylpiperidinium' OR 'd 21266' OR d21266 
OR 'krx 0401' OR krx0401 OR 'nka 17' OR nka17 OR 'octadecyl (1, 1 dimethylpiperidinio 4 yl) 
phosphate' 
1274 
#41 'rivoceranib'/exp OR rivoceranib OR aitan OR apatinib OR 'apatinib mesilate' OR 'apatinib 
mesylate' OR 'apatinib methanesulfonate' OR 'n [4 (1 cyanocyclopentyl) phenyl] 2 (4 
pyridinylmethyl) amino 3 pyridinecarboxamide' OR 'n [4 (1 cyanocyclopentyl) phenyl] 2 [ [(4 
pyridinyl) methyl] amino] 3 pyridinecarboxamide' OR 'n [4 (1 cyanocyclopentyl) phenyl] 2 [ 
[(pyridin 4 yl) methyl] amino] pyridine 3 carboxamide' OR 'rivoceranib mesilate' OR 'rivoceranib 
mesylate' OR 'rivoceranib methanesulfonate' OR 'yn 968d1' OR yn968d1 
684 
#40 'volasertib'/exp OR volasertib OR 'bi 6727' OR bi6727 OR 'n [4 [4 (cyclopropylmethyl) 1 
piperazinyl] cyclohexyl] 4 [ (7 ethyl 5, 6, 7, 8 tetrahydro 5 methyl 8 (1 methylethyl) 6 oxo 2 
pteridinyl) amino] 3 methoxybenzamide' OR 'n [4 [4 (cyclopropylmethyl) 1 piperazinyl] 
cyclohexyl] 4 [ (7 ethyl 5, 6, 7, 8 tetrahydro 8 isopropyl 5 methyl 6 oxo 2 pteridinyl) amino] 3 
methoxybenzamide' OR 'n [4 [4 (cyclopropylmethyl) piperazin 1 yl] cyclohexyl] 4 [ [7 ethyl 5 
421 
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methyl 6 oxo 8 (propan 2 yl) 5, 6, 7, 8 tetrahydropteridin 2 yl] amino] 3 methoxybenzamide' OR 
'n [4 [4 (cyclopropylmethyl) piperazin 1 yl] cyclohexyl] 4 [ [7 ethyl 5 methyl 8 (1 methylethyl) 6 
oxo 5, 6, 7, 8 tetrahydropteridin 2 yl] amino] 3 methoxybenzamide' OR 'volasertib hydrochloride' 
OR 'volasertib trihydrochloride' 
#39 'temsirolimus'/exp OR temsirolimus OR 'rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-
methylpropanoate)' OR '42 o [2, 2 bis (hydroxymethyl) propionyl] rapamycin' OR 'cci 779' OR 
cci779 OR 'cell cycle inhibitor 779' OR 'nsc 683864' OR nsc683864 OR 'rapamycin 2, 2 bis 
(hydroxymethyl) propionate' OR 'rapamycin 42 [2, 2 bis (hydroxymethyl) propionate]' OR torisel 
OR 'way-cci 779' 
7877 
#38 'imatinib'/exp OR 'mesylate, imatinib' OR 'imatinib methanesulfonate' OR 'methanesulfonate, 
imatinib' OR imatinib OR 'alpha-(4-methyl-1-piperazinyl)-3?-((4-(3-pyridyl)-2-
pyrimidinyl)amino)-p-tolu-p-toluidide' OR '2 [2 methyl 5 [4 (4 methyl 1 piperazinylmethyl) 
benzamido] anilino] 4 (3 pyridyl) pyrimidine' OR '4 (4 methylpiperazin 1 ylmethyl) n [4 methyl 3 
[4 (3 pyridyl) pyrimidin 2 ylamino] phenyl] benzamide' OR '4 [ (4 methyl 1 piperazinyl) methyl] n 
[4 methyl 3 [ [4 (3 pyridinyl) 2 pyrimidinyl] amino] phenyl] benzamide' OR 'alpha (4 methyl 1 
piperazinyl) 3? [ [4 (3 pyridyl) 2 pyrimidinyl] amino] para tolu para toluidide' OR 'cgp 57148' OR 
'cgp 57148b' OR cgp57148 OR cgp57148b OR gleevac OR gleevec OR glivec OR glivic OR 'imatinib 
mesilate' OR 'imatinib mesylate' OR ruvise OR 'signal transduction inhibitor 571' OR 'st 1571' OR 
st1571 OR 'sti 571' OR sti571 
41122 
#37 'alisertib'/exp OR alisertib OR '4 [ [9 chloro 7 (2 fluoro 6 methoxyphenyl) 5h pyrimido [5, 4 d] [2] 
benzazepin 2 yl] amino] 2 methoxybenzoic acid' OR 'alisertib sodium' OR 'mln 8237' OR 'mln 
8237 004' OR 'mln 8237-004' OR mln8237 OR 'mln8237 004' 
985 
#36 'cisplatin'/exp OR 'liposomal cisplatin' OR 'spi 077' OR spi077 OR 'spi 77' OR 'stealth liposomal 
cisplatin' OR 'cisplatin liposomal' OR (cisplatin AND (liposomes OR liposomal)) 
171244 
#35 'lurbinectedin'/exp OR lurbinectedin OR '8, 14 dihydroxy 6?, 9 dimethoxy 4, 10, 23 trimethyl 19 
oxo 2?, 3?, 4?, 6, 7, 9?, 12, 13, 14, 16 decahydro 6ah spiro [7, 13 azano 6, 16 
(epithiopropanooxymethano) [1, 3] dioxolo [7, 8] isoquinolino [3, 2 b] [3] benzazocine 20, 1? 
pyrido [3, 4 b] indol] 5 yl acetate' OR 'pm 01183' OR 'pm 1183' OR pm01183 OR pm1183 
151 
#34 'dalantercept'/exp OR 'alk1-fc fusion protein, human' OR dalantercept OR 'ace 041' OR ace041 79 
#33 'olaparib'/exp OR olaparib OR azd221 OR '1 (cyclopropylcarbonyl) 4 [2 fluoro 5 [ (4 oxo 3, 4 
dihydrophthalazin 1 yl) methyl] benzoyl] piperazine' OR '4 [3 (4 cyclopropanecarbonylpiperazine 
1 carbonyl) 4 fluorobenzyl] 2h phthalazin 1 one' OR '4 [ [3 [ [4 (cyclopropylcarbonyl) 1 
piperazinyl] carbonyl] 4 fluorophenyl] methyl] 1 (2h) phthalazinone' OR '4 [ [3 [ [4 
(cyclopropylcarbonyl) piperazin 1 yl] carbonyl] 4 fluorophenyl] methyl] phthalazin 1 (2h) one' 
OR 'azd 2281' OR azd2281 OR 'ku 0059436' OR 'ku 59436' OR ku0059436 OR ku59436 OR 
lynparza 
3895 
#32 'doxorubicin'/exp OR doxorubicin OR ribodoxo OR 'doxo cell' OR 'urokit doxo-cell' OR 'urokit 
doxo cell' OR 'doxorubicina ferrer farm' OR 'doxorubicina funk' OR 'doxorubicina tedec' OR 
'doxorubicine baxter' OR doxotec OR onkodox OR '14 hydroxydaunomycin' OR '14 
hydroxydaunorubicin' OR a.d.mycin OR adriablastin OR adriablastina OR 'adriablastina r.d.' OR 
adriablastine OR adriacin OR adriamicina OR adriamicine OR adriamycin OR 'adriamycin 
hydrochloride' OR 'adriamycin p.f.s.' OR 'adriamycin pfs' OR 'adriamycin r.d.f.' OR 'adriamycin 
rd' OR 'adriamycin rdf' OR adriamycina OR adriblastin OR adriblastina OR 'adriblastina cs' OR 
'adriblastina pfs' OR adriblastine OR adrim OR adrimedac OR adrubicin OR amminac OR caelix 
OR caelyx OR 'caelyx/doxil' OR carcinocin OR dexorubicin OR 'dox sl' OR doxil OR 'doxil 
(liposomal)' OR doxolem OR 'doxor lyo' OR 'doxorubicin hydrochloride' OR 'doxorubicin meiji' 
OR 'doxorubicin, liposomal' OR doxorubicine OR doxorubin OR evacet OR farmiblastina OR 'fi 
106' OR fi106 OR ifadox OR lipodox OR 'liposomal doxorubicin' OR 'mcc 465' OR mcc465 OR 
myocet OR 'nsc 123127' OR nsc123127 OR 'pegylated liposomal doxorubicin' OR 'polyethylene 
glycol-coated liposomal doxorubicin' OR rastocin OR resmycin OR 'rp 25253' OR rp25253 OR 
rubex OR rubidox OR sarcodoxome OR 'tlc d 99' 
186007 
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#31 '4 (8 cyclopentyl 7 ethyl 5,6,7,8 tetrahydro 5 methyl 6 oxo 2 pteridinylamino) 3 methoxy n (1 
methyl 4 piperidinyl)benzamide'/exp OR '4 (8 cyclopentyl 7 ethyl 5,6,7,8 tetrahydro 5 methyl 6 
oxo 2 pteridinylamino) 3 methoxy n (1 methyl 4 piperidinyl)benzamide' OR bi2536 OR 'bi 2536' 
512 
#30 'bendamustine'/exp OR 'hydrochloride, bendamustine' OR bendamustine OR bendamustin OR 
'4 [5 [bis (2 chloroethyl) amino] 1 methylbenzimidazol 2 yl] butyric acid' OR '5 [bis (2 chloroethyl) 
amino] 1 methyl 2 benzimidazolebutyric acid' OR 'bendamustine hydrochloride' OR bendeka OR 
'cimet 3393' OR cytostasan OR 'cytostasan r' OR cytostasane OR 'imet 3393' OR levact OR 
ribomustin OR ribovact OR treanda OR 'zimet 3393' OR zimet3393 
5940 
#29 'eribulin'/exp OR eribulin OR nsc707389 OR 'nsc 707389' OR 'b 1793' OR 'b-1793' OR 'b 1939' OR 
'eribulin monomethanesulfonate' OR 'eribulin (as mesylate)' OR 'e 7389' OR e7389 OR 'er 
086526' OR 'er 86526' OR er086526 OR er86526 OR 'eribulin mesilate' OR 'eribulin mesylate' OR 
halaven 
2098 
#28 'danusertib'/exp OR danusertib OR '4 (4 methyl 1 piperazinyl) n [1, 4, 5, 6 tetrahydro 5 (2 
methoxy 2 phenylacetyl) pyrrolo [3, 4 c] pyrazol 3 yl] benzamide' OR 'n [5 (2 methoxy 2 
phenylacetyl) 1, 4, 5, 6 tetrahydropyrrolo [3, 4 c] pyrazol 3 yl] 4 (4 methylpiperazin 1 yl) 
benzamide' OR 'pha 739358' OR pha739358 
355 
#27 'zoptarelin doxorubicin'/exp OR 'lhrh, lysine(6)-doxorubicin' OR 'luteinizing hormone-releasing 
factor (pig), 6-(n6-(5-(2-(4- ((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)- 
1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11- dioxo-2-naphthacenyl)-2-
oxoethoxy)-1,5-dioxopentyl)-d- lysine)-, (2s-cis)-' OR 'zoptarelin doxorubicin' OR 'lys(6)-lhrh-
doxorubicin' OR 'aezs 108' OR aezs108 OR 'an 152' OR an152 OR 'd 81858' OR d81858 OR 
'doxorubicin lhrh [6 dextro lysine]' OR 'gonadorelin [6 dextro lysine] doxorubicin' OR 'lhrh [6 
dextro lysine] doxorubicin' OR 'zen 008' OR zen008 OR 'zopatrelin doxorubicin acetate' 
155 
#26 'sorafenib'/exp OR sorafenib OR nexavar OR 'sorafenib n-oxide' OR 'sorafenib n oxide' OR 'bay 
673472' OR 'bay 545-9085' OR 'bay 5459085' OR 'bay 545 9085' OR bay5459085 OR 'sorafenib 
tosylate' OR '4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic 
acid methyamide-4-methylbenzenesulfonate' OR '4 [4 [3 [4 chloro 3 (trifluoromethyl) phenyl] 
ureido] phenoxy] n methyl 2 pyridinecarboxamide' OR 'bay 43 9006' OR 'bay 43-9006' OR 'bay 
439006' OR bay43) AND 9006 OR 'bay43 9006' OR bay439006 OR nexavar OR 'sorafenib tosylate' 
3522 
#25 'cabozantinib'/exp OR cabozantinib OR 'xl184 cpd' OR 'bms 907351' OR bms907351 OR 
cabometyx OR 'cabozantinib malate' OR 'cabozantinib s malate' OR 'cabozantinib s-malate' OR 
cometriq OR 'cyclopropane 1, 1 dicarboxylic acid [4 (6, 7 dimethoxyquinolin 4 yloxy) phenyl] 
amide (4 fluorophenyl) amide' OR 'n [4 (6, 7 dimethoxy 4 quinolinyloxy) phenyl] n? (4 
fluorophenyl) 1, 1 cyclopropanedicarboxamide' OR 'n [4 [ (6, 7 dimethoxyquinolin 4 yl) oxy] 
phenyl] n? (4 fluorophenyl) cyclopropane 1, 1 dicarboxamide' OR 'xl 184' OR xl184 
3049 
#24 'pazopanib'/exp OR pazopanib OR gw780604 OR 'gw 780604' OR '5 [ [4 [ (2, 3 dimethyl 2h indazol 
6 yl) methylamino] 2 pyrimidinyl] amino] 2 methylbenzenesulfonamide' OR 'armala' OR 'gw 
786034' OR 'gw 786034b' OR 'gw 786034x' OR gw786034 OR gw786034b OR gw786034x OR 
'pazopanib hydrochloride' OR 'sb 710468' OR 'sb 710468a' OR sb710468 OR sb710468a OR 
votrient 
7043 
#23 'sagopilone'/exp OR sagopilone OR 'de 03757' OR 'epo 477' OR 'sh y 03757' OR 'bay 86 5302' OR 
'sh y03757' OR 'sh y03757a' OR shy03757 OR shy03757a OR 'zk 219477' OR 'zk epo' OR 'zk 
epothilone' OR zk219477 
187 
#22 'topotecan'/exp OR topotecan OR '9-dimethylaminomethyl-10-hydroxycamptothecin' OR 
'hydrochloride, topotecan' OR 'nogitecan hydrochloride' OR 'hydrochloride, nogitecan' OR 
'topotecan monohydrochloride, (s)-isomer' OR 'sk and f-104864-a' OR 'sk and f 104864 a' OR 'sk 
and f104864a' OR hycamtamine OR '9 dimethylaminomethyl 10 hydroxycamptothecin' OR 'e 
89001' OR e89001 OR evotopin OR hycamptamine OR hycamtin OR lutecan OR 'nsc 609699' OR 
nsc609699 OR oncotecan OR potactasol OR ribocamtin OR 'skf 104864' OR 'skf 104864 a' OR 'skf 
104864a' OR 'skf s 104864a' OR 'skf s104864a' OR skf104864 OR skf104864a OR topocan OR 
topoliquid OR 'topotecan hydrochloride' OR topotecane OR topotecano OR topotekan OR 
topotel OR topovin 
11475 
132 
 
#21 'n (6,7 dihydro 6 oxo 5h dibenz[b,d]azepin 7 yl) 2,2 dimethyl n` (2,2,3,3,3 
pentafluoropropyl)propanediamide'/exp OR 'n (6,7 dihydro 6 oxo 5h dibenz[b,d]azepin 7 yl) 2,2 
dimethyl n` (2,2,3,3,3 pentafluoropropyl)propanediamide' OR ro4929097 OR 'ro 4929097' 
280 
#20 'epothilone b'/exp OR 'epothilone b' OR patupilone OR 'epothilon b' OR 'epo 906' OR epo906 1196 
#19 peptide AND 'a6' OR ('urokinase plasminogen activator' AND '136-143') OR 'urokinase derived 
peptide' OR 'urokinase-derived peptide' OR 'ac lys pro ser ser pro pro glu glu nh2' OR 'ac 
kpssppee nh2' OR 'acetyl-lysyl-prolyl-seryl-seryl-prolyl-prolyl-glutamyl-glutamic acid amide' 
378 
#18 'tasquinimod'/exp OR tasquinimod OR '4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-((4-
trifluoromethyl)phenyl)-1,2-dihydroquinoline-3-carboxamide' OR '4 hydroxy 5 methoxy n, 1 
dimethyl 2 oxo n [4 (trifluoromethyl) phenyl] 1, 2 dihydroquinoline 3 carboxamide' OR 'abr 
215050' OR abr215050 
221 
#17 'veliparib'/exp OR veliparib OR '2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-
carboxamide' OR '2-(2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide' OR '2 (2 methyl 
2 pyrrolidinyl) 1h benzimidazole 4 carboxamide' OR '2 (2 methylpyrrolidin 2 yl) 1h benzimidazole 
4 carboxamide' OR 'abt 888' OR abt888 
1828 
#16 'sunitinib'/exp OR sunitinib OR '5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-
1h-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide' OR '5 (5 fluoro 1, 2 dihydro 2 oxo 3 
indolylidenemethyl) 2, 4 dimethyl 1h pyrrole 3 carboxylic acid (2 diethylaminoethyl) amide' OR 
'5 (5 fluoro 2 oxo 1, 2 dihydroindol 3 ylidenemethyl) 2, 4 dimethyl 1h pyrrole 3 carboxylic acid 
(2 diethylaminoethyl) amide' OR 'n [2 (diethylamino) ethyl] 5 [ (5 fluoro 1, 2 dihydro 2 oxo 3h 
indol 3 ylidene) methyl] 2, 4 dimethyl 1h pyrrole 3 carboxamide' OR 'pha 2909040ad' OR 
pha2909040ad OR 'su 010398' OR 'su 011248' OR 'su 10398' OR 'su 11248' OR su010398 OR 
su011248 OR su10398 OR su11248 OR 'sunitinib malate' OR 'suo 11248' OR suo11248 OR sutent 
21503 
#15 'paclitaxel'/exp OR '130-nm albumin-bound paclitaxel' OR (albumin AND paclitaxel) OR 
'paclitaxel, albumin-bound' OR 'protein-bound paclitaxel' OR 'paclitaxel, protein-bound' OR 
'protein bound paclitaxel' OR 'abi 007' OR abi007 OR abraxane OR 'albumin bound paclitaxel' 
OR 'albumin-bound paclitaxel' OR anzatax OR apealea OR asotax OR biotax OR 'bms 181339' OR 
bms181339 OR 'bmy 45622' OR bmy45622 OR bristaxol OR britaxol OR coroxane OR 'dts 301' 
OR dts301 OR 'endotag 1' OR formoxol OR genexol OR 'genexol pm' OR hunxol OR ifaxol OR 
infinnium OR intaxel OR 'mbt 0206' OR mbt0206 OR medixel OR mitotax OR 'nab paclitaxel' OR 
'nanoparticle albumin bound paclitaxel' OR 'nsc 125973' OR 'nsc 673089' OR nsc125973 OR 
nsc673089 OR 'oas pac 100' OR oaspac100 OR oncogel OR onxol OR pacitaxel OR 'paclitaxel nab' 
OR pacxel OR padexol OR parexel OR paxceed OR paxene OR paxus OR praxel OR 'sb 05 
(terpenoid)' OR 'sb05 (terpenoid)' OR taxocris OR taxol OR 'taxus (drug)' OR taycovit OR 
yewtaxan 
101187 
#14 'motesanib'/exp OR motesanib OR 'amg 706' OR amg706 OR 'motesanib diphosphate' OR 'n (2, 
3 dihydro 3, 3 dimethyl 6 indolyl) 2 (4 pyridinylmethylamino) 3 pyridinecarboxamide' OR 'n (3, 3 
dimethyl 2, 3 dihydro 1h indol 6 yl) 2 (pyridin 4 ylmethylamino) pyridine 3 carboxamide' OR 'n 
(3, 3 dimethyl 6 indolinyl) 2 (4 pyridinylmethylamino) nicotinamide' 
967 
#13 'lapatinib'/exp OR lapatinib OR 'n-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-
methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine' OR gw282974x OR 'gw 
282974x' OR '4 [3 chloro 4 (3 fluorobenzyloxy) anilino] 6 [5 [2 (methylsulfonyl) 
ethylaminomethyl] 2 furyl] quinazoline' OR 'gw 2016' OR 'gw 572016' OR 'gw 572016f' OR 
gw2016 OR gw572016 OR gw572016f OR 'lapatinib ditosylate' OR 'lapatinib ditosylate 
monohydrate' OR 'lapatinib tosylate' OR 'n [3 chloro 4 [ (3 fluorobenzyl) oxy] phenyl] 6 [5 [ [[2 
(methylsulfonyl) ethyl] amino] methyl] furan 2 yl] quinazolin 4 amine bis (4 
methylbenzenesulfonate)' OR tykerb OR tyverb 
11411 
#12 'asparaginase'/exp OR asparaginase OR 'monomethoxypolyethylene glycol-conjugated 
asparaginase' OR 'peg(2)-asp' OR '2,4-bis(2-methoxypolyethyleneglycol)-6-chloro-s-triazine-
conjugated l-asparaginase' OR 'asparaginase 2' OR 'asparaginase a' OR 'asparaginase ag' OR 
'asparaginase b' OR 'asparaginase erwinia chrysanthemi' OR 'asparagine amidohydrolase' OR 
asparginase OR aspariginase OR colaspase OR collaspase OR crasnitin OR crisantaspase OR 'e.c. 
15632 
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3.5.1.1' OR elaspar OR elspar OR erwinase OR erwinaze OR 'ery 001' OR 'ery asp' OR ery001 OR 
eryasp OR eryaspase OR 'fb b 6366' OR 'fb b6366' OR fbb6366 OR graspa OR kidrolase OR 
krasnitin OR 'l asparaginase' OR 'l asparaginase a' OR 'l asparagine amidohydrolase' OR 'l 
asparginase' OR laspar OR 'levo asparaginase' OR 'levo asparagine amidohydrolase' OR 'nsc 
109229' OR nsc109229 OR paronal OR 'asparagine deaminase' OR 'deaminase, asparagine' OR 
'asparaginase ii' OR leunase OR 'asparaginase medac' OR 'medac, asparaginase' 
#11 'rucaparib'/exp OR rucaparib OR '8 fluoro 1, 3, 4, 5 tetrahydro 2 [4 (methylaminomethyl) phenyl] 
6h pyrrolo [4, 3, 2 ef] [2] benzazepin 6 one' OR '8 fluoro 1, 3, 4, 5 tetrahydro 2 [4 [ (methylamino) 
methyl] phenyl] 6h azepino [5, 4, 3 cd] indol 6 one' OR '8 fluoro 2 [4 [ (methylamino) methyl] 
phenyl] 1, 3, 4, 5 tetrahydro 6h azepino [5, 4, 3 cd] indol 6 one' OR '8 fluoro 2 [4 [ (methylamino) 
methyl] phenyl] 1, 3, 4, 5 tetrahydro 6h pyrrolo [4, 3, 2 ef] [2] benzazepin 6 one' OR '8 fluoro 3, 
4 dihydro 2 [4 (methylaminomethyl) phenyl] pyrrolo [3, 4, 5 e, f] [2] benzazepin 6 (5h) one' OR 
'8 fluoro 3, 4 dihydro 2 [4 (methylaminomethyl) phenyl] pyrrolo [4, 3, 2 ef] [2] benzazepin 6 (5h) 
one' OR 'ag 014699' OR 'ag 14447' OR 'ag 14699' OR ag014699 OR ag14447 OR ag14699 OR 'co 
338' OR co338 OR 'pf 01367338' OR 'pf 1367338' OR 'pf 1367338 bw' OR pf01367338 OR 
pf1367338 OR pf1367338bw OR rubraca OR 'rucaparib camphorsulfonate' OR 'rucaparib 
camsilate' OR 'rucaparib camsylate' OR 'rucaparib phosphate' 
1035 
#10 'elacytarabine'/exp OR '5?-oleoyl cytarabine' OR '5?-oleyl-ara-c' OR '5?-oleoyl cytosine 
arabinoside' OR elacytarabine OR '4 amino 1 [5 o (octadec 9 enoyl) beta dextro 
arabinofuranosyl] pyrimidin 2 (1h) one' OR '5? o (9?? octadecenoyl) 1 beta dextro 
arabinofuranosylcytosine' OR '5? o (trans 9?? octadecenoyl) 1 beta d arabinofuranosylcytosine' 
OR 'cp 4055' OR cp4055 OR 'cytarabine 5? elaidic acid ester' OR elacyt 
106 
#9 'iniparib'/exp OR iniparib OR '4 iodo 3 nitrobenzamide' OR 'bsi 201' OR bsi201 OR 'sar 240550' 
OR sar240550 
749 
#8 'cediranib'/exp OR cediranib OR '4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-(3-
(pyrrolidin-1-yl)propoxy)quinazoline' OR '4 (4 fluoro 2 methyl 5 indolyloxy) 6 methoxy 7 [3 (1 
pyrrolidinyl) propoxy] quinazoline' OR '4 [ (4 fluoro 2 methyl 1h indol 5 yl) oxy] 6 methoxy 7 [3 
(pyrrolidin 1 yl) propoxy] quinazoline' OR 'azd 2171' OR azd2171 OR 'cediranib maleate' OR 
recentin OR zemfirza 
2688 
#7 'irofulven'/exp OR irofulven OR 'hmaf cpd' OR '6-(hydroxymethyl)acylfulvene' OR mgi.114 OR '6 
hydroxymethylacylfulvene' OR '6? hydroxy 3? hydroxymethyl 2?, 4?, 6? trimethylspiro 
[cyclopropane 1, 5? 5h inden] 7? (6?h) one' OR hmaf OR hydroxymethylacylfulvene OR 
irofulvene OR 'mgi 114' OR mgi114 OR 'nsc 683863' OR nsc683863 
226 
#6 'etirinotecan pegol'/exp OR etirinotecan OR 'etirinotecan pegol tetrahydrochloride' OR 
'etirinotecan pegol tetratriflutate' OR 'nktr 102' OR nktr102 OR onzeald 
138 
#5 'enzastaurin'/exp OR enzastaurin OR ly317615.hcl OR '3 (1 methyl 1h indol 3 yl) 4 [1 [1 (pyridin 
2 ylmethyl) piperidin 4 yl] 1h indol 3 yl] 1h pyrrole 2, 5 dione' OR '3 (1 methyl 1h indol 3 yl) 4 [1 
[1 (pyridin 2 ylmethyl) piperidin 4 yl] 1h indol 3 yl] pyrrole 2, 5 dione' OR '3 (1 methyl 3 indolyl) 
4 [1 [1 (2 pyridinylmethyl) 4 piperidinyl] 3 indolyl] 2, 5 pyrroledione' OR 'enzastaurin 
hydrochloride' OR 'ly 317615' OR ly317615 
1035 
#4 'enmd 2076'/exp OR 'enmd 2076' OR enmd2076 115 
#3 'rat'/exp OR rat OR rats OR rattus OR 'mouse'/exp OR mouse OR mice OR mus OR murine OR 
xenograft OR xenografts OR heterograft OR heterografts OR xenogeneic OR xenogenic OR 
heterotransplant OR xenotransplant OR allograft OR allografts OR homograft OR homografts OR 
allogeneic OR allogenic OR allotransplant OR homotransplant OR alloplastic OR syngeneic OR 
syngenic OR isogeneic OR isogenic OR syngraft OR syngrafts OR 'syn graft' OR 'syn grafts' OR 
isograft OR isografts OR 'iso graft' OR 'iso grafts' OR 'iso transplant' OR isotransplant OR 
'genetically engineered mouse strain'/exp OR 'genetically engineered rat strain'/exp OR 
'genetically modified' OR 'genetically engineered' OR 'genetically manipulated' OR 'genetically-
modified' OR 'genetically-engineered' OR 'genetically-manipulated' OR transgenic OR transgene 
4110903 
#2 'drug screening'/exp 172453 
134 
 
#1 'ovary tumor'/exp OR ovarian OR ovary 365747 
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Appendix B 
 Repetition and external validity   
α1. Is the same experiment repeated more than once by a single lab? Yes No 
                       N° of repetition ______ 
                      Reasons for repetition ______ 
α2. N° of different species in which the EOC experiment has been repeated  N° _____ 
α3. N° of different cancer models in which the EOC experiment has been repeated N° _____ 
α4.  N° of participating laboratories     Monolab Multilab 
 Internal validity 
β1. Is an internal control group used?     Yes No 
β1 a. Are animals randomly allocated to treatments?   Yes No     Unknown 
      Alternative method to randomization ____________________________ 
β1 b. If randomization is used, is the randomization method stated? Yes No 
Randomization method ____________________________________ 
β1 c. If randomization is used, is allocation concealment employed? Yes No     Unknown 
β1 d. Are the animals randomly housed within the animal room? Yes No     Unknown 
β1 e. Are there equal numbers per treatment group?   Yes No     Unknown 
β1 f. If not, is this justified?       Yes No  Not applicable 
         Specify justification ______________________________________ 
β2. Is the experimental unit clearly identified?    Yes No 
                 Specify experimental unit ____________                                                         
      Suspicious cause of pseudo-replication ____________ 
β3. Role of CC monotherapy arm     Active Control  Both  
 Statistical design 
γ1. Is an active control group used?   Yes No 
γ2. Number of design factors       N° _____________________ 
γ3. Number of treatment (design) groups    N° _____________________ 
γ4. Is a factorial design used?    Yes No 
γ5. Is dose-response (i.e. > 3 doses) evaluated?  Yes No 
γ6. Is blocking used?     Yes No Unknown 
γ7. Type of experiment          Between units Within units Both 
 
136 
 
 Sample size 
δ1. Is the sample size justified?      Yes No 
δ1 a. If yes, specify method  common sense  Yes No 
power analysis  Yes No 
resource equation  Yes No 
      other    _____________________ 
δ2. Total number of enrolled animals per arm (methods section)          Exact Estimate Unknown 
                            specify N° __________________ 
 Outcomes and their assessment 
ε1. Can the primary outcomes of antitumor activity clearly be identified? Yes No 
ε2. N°           Name       Definition 
Primary   
1   
2   
3   
4   
5   
 
ε3. Is the antitumor activity endpoint (i.e. event) clearly defined?  Yes No 
     Specify definition  ___________________________________________________________ 
ε4. Are the competing events (compEv) clearly defined?   Yes No 
     Specify compEv n.1  __________________________________________________________ 
       compEv n.2  __________________________________________________________ 
       compEv n.3  __________________________________________________________ 
ε5. Outcome assessment 
ε5 a. Are the caregivers and/or investigators blinded from knowledge of which intervention 
each animal received during the experiment?   Yes No Unknown 
ε5 b. Are animals selected at random for outcome assessment? Yes No Unknown 
ε5 c. Is the outcome assessor blinded?     Yes No Unknown 
 Statistical analysis 
ζ1. Are inferential methods used to demonstrate antitumor activity?  Yes No 
ζ1 a. Hypothesis test        Yes No 
method n°1 ________________________________________________________________ 
method n°2 ________________________________________________________________ 
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method n°3 ________________________________________________________________ 
ζ1 b. Estimation         Yes No 
method n°1 ________________________________________________________________ 
method n°2 ________________________________________________________________ 
method n°3 ________________________________________________________________ 
ζ2. Are descriptive methods used to demonstrate antitumor activity? Yes No 
method n°1 ________________________________________________________________ 
method n°2 ________________________________________________________________ 
method n°3 ________________________________________________________________ 
ζ3. Are methods for correction of multiple comparison used?             Yes   No  Not applicable 
method n°1 ________________________________________________________________ 
method n°2 ________________________________________________________________ 
method n°3 ________________________________________________________________ 
ζ4. Are statistical assumptions used to analyze tumor growth data justified?  
Yes  No  Not applicable 
method n°1 ________________________________________________________________ 
method n°2 ________________________________________________________________ 
method n°3 ________________________________________________________________ 
 Attrition bias about tumor growth curves 
η1. Number of animals assigned to each treatment arm (results section) 
        Exact Estimate Unknown 
                            specify N° _____________ 
η2. Are there animals assigned to each treatment arm and excluded from statistical analysis? 
Yes No Unknown 
η2 a. If yes, are reasons for exclusion reported?  Yes No Not applicable 
                  Specify reasons for exclusion ________________________________________________ 
η3. Are there animals at risk progressively reported in the plot of tumor growth curves? 
Yes No Not applicable 
η4. Is the number of animals with right-censored data clearly reported? 
Yes No 
η5. For each animal, is it clearly reported which event determined the end of follow-up? 
Yes No 
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η6. Is the length of follow-up clearly defined?   Yes No 
Specify definition ____________________________________________________________ 
 Miscellanea 
θ1.  State any important concerns about statistical design and analysis not covered by other 
sections in the checklist _______________________________________________________ 
θ2.  Was any author a member of a department of statistics or epidemiology? Yes No 
θ3.  Was mentioned the use of a statistical software for data analysis?  Yes No 
Specify statistical software ____________ 
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Appendix C 
List of eligible clinical trials 
o Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, 
Steinberg SM, Kohn EC. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no 
clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of 
VEGFR2. Clin Cancer Res. 2010 Jan 15;16(2):664-72 
o Aoki D, Katsumata N, Nakanishi T, Kigawa J, Fujiwara K, Takehara K, Kamiura S, Hiura M, Hatae 
M, Sugiyama T, Ochiai K, Noda K. A phase II clinical trial of topotecan in Japanese patients with 
relapsed ovarian carcinoma. Jpn J Clin Oncol. 2011 Mar;41(3):320-7 
o Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel 
JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-
ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent 
ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):245-51 
o Baker AF, Roe DJ, Laughren C, Cohen JL, Wright HM, Clouser MC, Cui H, Alberts DS, Chambers SK. 
Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer. 
Invest New Drugs. 2013 Feb;31(1):160-6 
o Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg 
A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, 
Wagner U. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized 
multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and 
effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol. 
2012 Sep;23(9):2265-71 
o Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin 
AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating 
tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary 
peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 
Oct;123(1):19-26 
o Bell-McGuinn KM1, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, 
Sabbatini P, Aghajanian C. A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or 
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Appendix E 
SAS MACRO programs 
* ------------------------------------------------------------------------------------------------------------------------------ * 
* Program......: POWER.SAS               * 
* Scope………..: Calculating asymptotic power of the family of statistical tests        * 
* Version……..: 1.0                * 
* Author………: Luca Porcu               * 
* Data created: 20AUG2019               * 
* Project: new statistical framework to analyze tumor growth curves         * 
 * Warning: slopes in different intervals in the same animal are distributed independently.          *      
*                   This assumption does not usually hold for real cases          * 
* Example: %POWER(delta= 0.04,               * 
*    sigma= 0.06,              * 
*    m= 10,               * 
*   n= 10,               * 
*   k= 5)               * 
* ------------------------------------------------------------------------------------------------------------------------------ * 
%MACRO POWER( 
delta=,            /*Absolute effect size*/ 
sigma=,                       /*Slopes’ standard deviation*/ 
m=,                   /*Number of animals in the active arm*/ 
n=,                 /*Number of animals in the control arm*/ 
k=,                      /*Number of time intervals*/ 
alpha=                            /*Type I error*/ 
); 
Data power; 
delta = &delta.; 
sigma = &sigma.; 
m=&m.; 
n=&n.; 
k=&k.; 
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*** Expectation and variance of the Mann-Whitney statistics under the null hypothesis. No ties are 
present. Slopes in different intervals in the same animal are assumed to be distributed 
independently;  
E0 = k*(1/2)*(m*n); 
Var0 = k*(1/12)*(m*n)*(m+n+1); 
*** Expectation and variance of the Mann-Whitney statistics under the alternative hypothesis (i.e. 
additive treatment effect). No ties are present. Slopes in different intervals in the same animal are 
assumed to be distributed independently. Refer to the Lehmann’s book (2006), pp. 71-72 for proofs 
of the following formulas;  
ES = delta/sigma; 
p1 = probnorm(ES/sqrt(2)); 
*** Because of the symmetry of the normal distribution p2 and p3 are equal; 
p2 = probbnrm(ES/sqrt(2),ES/sqrt(2),0.5); 
p3 = probbnrm(ES/sqrt(2),ES/sqrt(2),0.5); 
  E1 = k*(m*n)*p1; 
     Var1 = k*((m*n)*p1*(1-p1)+m*n*(n-1)*(p2-p1**2)+m*n*(m-1)*(p3-p1**2)); 
*** Asymptotic power calculation; 
 cut=E0+(probit(1-(&alpha./2)))*sqrt(Var0); 
*** A continuity correction was introduced in asymptotic power calculation; 
 power=1-probnorm((cut-(0.5+E1))/sqrt(Var1)); 
 run; 
Proc print Data=power; 
Run; 
%MEND; 
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* ------------------------------------------------------------------------------------------------------------------------------ * 
* Program......: MW_PASYMP.SAS              * 
* Scope………..: Computing asymptotic p-value                * 
* Version……..: 1.0                * 
* Author………: Luca Porcu               * 
* Data created: 22AUG2019               * 
* Project: new statistical framework to analyze tumor growth curves         * 
* Warning: slopes in different intervals in the same animal are distributed independently.          *      
*                   This assumption does not usually hold for real cases          * 
* Example: %MW_PASYMP (treatment= Doxorubicin,           * 
*                 control= Vehicle,            * 
*    interval= time1 time2 time3 time4 time5,         * 
*                 dSet= dSet)             * 
* ------------------------------------------------------------------------------------------------------------------------------ * 
%MACRO MW_PASYMP( 
treatment=,                                  /*Treatment compared to the control arm*/ 
control=,                                         /*Control arm*/ 
interval=,              /*Names of tumor volume variables, at different time points*/ 
dSet=                          /*Name of the SAS dataset*/ 
); 
*** The "MW" dataset is initialized. It will contain the Mann-Whitney statistics and its asymptotic 
expectation and variance, at each time point;  
Data MW; 
 length time $ 250; 
 time = ""; 
 if 0 = 1; 
 run; 
%LET count=1; 
%DO %WHILE(%SCAN(&interval.,&count.,%str( )) ne %str( )); 
%Let time=%SCAN(&interval.,&count.,%str( )); 
*** Calculation of the number of slopes at each time interval in the active and control arm; 
Proc sql noprint; 
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 select count(&time.) 
  into :Ctr 
  from &dset. 
  where arm = "&Control." and &time. ne .; 
 select count(&time.) 
  into :Trt 
  from &dset. 
  where arm = "&Treatment." and &time. ne .; 
  quit; 
*** Calculation of the Mann-Whitney statistics at each time interval. No ties are present; 
%IF %EVAL(&Ctr. > 0 AND &Trt. > 0) %THEN %DO; 
Proc transpose Data=&dset. out=MWset(drop= _name_) prefix=Trt; 
 var &time.; 
 where arm = "&Treatment." and &time. ne .; 
 run; 
Proc sql; 
 create table auxMW1 as 
 select a.&time. as Ctr, b.* 
  from &dset. as a, MWset as b 
  where a.arm = "&Control."; 
  quit; 
%LET dimens = Trt%LEFT(&Trt.); 
Data auxMW2 (drop= i); 
 set auxMW1; 
 array rango (1:&Trt.) Trt1-&dimens.; 
 MW = 0; 
 do i=1 to &Trt.; 
 if Ctr > rango(i) then MW = MW + 1; 
 end; 
 run; 
Proc sql; 
 create table auxMW3 as 
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  select sum(MW) as MW 
   from auxMW2; 
   quit; 
*** Expectation and variance of the Mann-Whitney statistics under the null hypothesis at each time 
interval. No ties are present; 
Data MW&time.; 
 length time $ 250; 
 set auxMW3; 
 time = "&time."; 
 expMW = (1/2)*(%EVAL(&Ctr.*&Trt.)); 
 varMW = (1/12)*(%EVAL(&Ctr.*&Trt.)*%EVAL(&Ctr.+&Trt.+1)); 
 run; 
Data MW; 
 set MW MW&time.; 
 O_E = MW - expMW; 
 run; 
%END; 
%LET count=%EVAL(&count.+1); 
%END; 
Data _NULL_; 
 set MW end= last; 
 if last then call symput('clock',time); 
 run; 
*** The "PValue" dataset is built. It contains the Mann-Whitney statistics and its asymptotic 
expectation and variance over all time points;  
Proc sql; 
 create table auxPValue as 
select sum(O_E) as OminusE, sum(MW) as MWobs, sum(expMW) as MWexp, sum(varMW) 
as MWvariance 
  from MW; 
  quit; 
Data PValue; 
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 set auxPValue; 
 time = "&clock."; 
 chi2 = (OminusE**2)/MWvariance; 
 PValue = 1-probchi(chi2,1); 
 format PValue pvalue5.3; 
 run; 
Proc print Data=PValue; 
label MWobs = "Observed Mann-Whitney statistics" 
   MWexp = "Expected Mann-Whitney statistics" 
   OminusE = "Observed minus expected Mann-Whitney statistics" 
   MWvariance = "Asymptotic variance of the Mann-Whitney statistics" 
   chi2 = "Chi-square (1 d.f.)" 
   PValue = "Asymptotic p-value" 
   time = "Last time point in which it was possible to compare control and treatment arms"; 
run; 
%MEND; 
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* ------------------------------------------------------------------------------------------------------------------------------ * 
* Program......: MW_PEXACT.SAS              * 
* Scope………..: Calculating exact p-value                  * 
* Version……..: 1.0                * 
* Author………: Luca Porcu               * 
* Data created: 30AUG2019               * 
* Project: new statistical framework to analyze tumor growth curves         * 
* Example: %MW_ PEXACT (treatment= Doxorubicin,           * 
*                 control= Vehicle,            * 
*    interval= time1 time2 time3 time4 time5,         * 
*                 dSet= dSet,             * 
*    nSimul= 500,             * 
*    seed= 10)             * 
* ------------------------------------------------------------------------------------------------------------------------------ * 
%MACRO MW_PEXACT( 
treatment=,                                    /*Treatment compared to the control arm*/ 
control=,                                         /*Control arm*/ 
interval=,              /*Names of tumor volume variables, at different time points*/ 
dSet=,                     /*Name of the dataset*/ 
nSimul=,                            /*Number of simulations*/ 
seed=       /*Random seed used to initialize SAS pseudorandom number generator*/ 
); 
*** 1st step: calculation of the Mann-Whitney statistics over all time points; 
Data MW; 
 length time $ 250; 
 time = ""; 
 if 0 = 1; 
 run; 
%LET count=1; 
%LET countReal=1; 
%DO %WHILE(%SCAN(&interval.,&count.,%str( )) ne %str( )); 
%Let time=%SCAN(&interval.,&count.,%str( )); 
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Proc sql noprint; 
 select count(&time.) 
  into :Ctr 
  from &dset. 
  where arm = "&Control." and &time. ne .; 
 select count(&time.) 
  into :Trt 
  from &dset. 
  where arm = "&Treatment." and &time. ne .; 
  quit; 
*** The number of observations assigned to the control arm are calculated. This number will be 
used for each resampling SAS dataset; 
%IF &count.=1 %THEN %DO;  
Proc sql noprint; 
 select count(&time.) 
  into :nObs 
  from &dset. 
  where arm = "&Control."; 
        %END; 
%IF %EVAL(&Ctr. > 0 AND &Trt. > 0) %THEN %DO; 
Proc transpose Data=&dset. out=MWset(drop= _name_) prefix=Trt; 
 var &time.; 
 where arm = "&Treatment." and &time. ne .; 
 run; 
Proc sql; 
 create table auxMW1 as 
 select a.&time. as Ctr, b.* 
  from &dset. as a, MWset as b 
  where a.arm = "&Control."; 
  quit; 
%LET dimens = Trt%LEFT(&Trt.); 
Data auxMW2 (drop= i); 
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 set auxMW1; 
 array rango (1:&Trt.) Trt1-&dimens.; 
 MW = 0; 
 do i=1 to &Trt.; 
 if Ctr > rango(i) then MW = MW + 1; 
 end; 
 run; 
Proc sql; 
 create table auxMW3 as 
  select sum(MW) as MW 
   from auxMW2; 
   quit; 
Data MW&time.; 
 length time $ 250; 
 set auxMW3; 
 time = "&time."; 
 run; 
Data MW; 
 set MW MW&time.; 
 run; 
%LET countReal=%EVAL(&countReal.+1); 
%END; 
%LET count=%EVAL(&count.+1); 
%END; 
*** The Mann-Whitney statistics is calculated; 
Proc sql noprint; 
 create table statObs as 
 select sum(MW) as statObs 
  from MW; 
  quit; 
*** 2nd step: calculation of the exact Mann-Whitney distribution over all time points; 
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*** The "PValueExt" dataset is initialized. It will contain the exact distribution of the Mann-Whitney 
statistics under the null hypothesis; 
Data PValueExt; 
 if 0 = 1; 
 run; 
%DO j=1 %TO %EVAL(&nSimul.); 
*** The "MW" dataset is initialized again. It will contain the observed Mann-Whitney statistics in 
each resampling dataset;  
Data MW; 
 if 0 = 1; 
 run; 
%Let root=%EVAL(&seed.+&j.); 
proc surveyselect data=&dset. 
   method=srs n=&nObs. out=SampleSRS noprint seed=&root.; 
   where arm in ("&Control.","&Treatment."); 
run; 
Proc sql noprint; 
 select quote(subject) 
  into :IDrandom separated by ',' 
  from SampleSRS; 
  quit; 
Data Sample; 
 set &dset. (where= (arm in("&Control.","&Treatment."))); 
 if subject in(&IDrandom.) then arm = "&Control."; 
 else arm = "&Treatment."; 
 run; 
%LET countExt=1; 
%DO %WHILE(%EVAL(&countExt. < &countReal.)); 
%Let time=%SCAN(&interval.,&countExt.,%str( )); 
Proc sql noprint; 
 select count(&time.) 
  into :Ctr 
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  from sample 
  where arm = "&Control." and &time. ne .; 
 select count(&time.) 
  into :Trt 
  from sample 
  where arm = "&Treatment." and &time. ne .; 
  quit; 
%IF %EVAL(&Ctr. > 0 AND &Trt. > 0) %THEN %DO; 
Proc transpose Data=sample out=MWset(drop= _name_) prefix=Trt; 
 var &time.; 
 where arm = "&Treatment." and &time. ne .; 
 run; 
Proc sql; 
 create table auxMW1 as 
 select a.&time. as Ctr, b.* 
  from sample as a, MWset as b 
  where a.arm = "&Control."; 
  quit; 
%LET dimens = Trt%LEFT(&Trt.); 
Data auxMW2 (drop= i); 
 set auxMW1; 
 array rango (1:&Trt.) Trt1-&dimens.; 
 MW = 0; 
 do i=1 to &Trt.; 
 if Ctr > rango(i) then MW = MW + 1; 
 end; 
 run; 
Proc sql; 
 create table auxMW3&j. as 
  select sum(MW) as MW 
   from auxMW2; 
   quit; 
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Data MW&time.; 
 length time $ 250; 
 set auxMW3&j.; 
 time = "&time."; 
 run; 
Data MW; 
 set MW MW&time.; 
run; 
%END; 
%LET countExt=%EVAL(&countExt.+1); 
%END; 
Proc sql; 
 create table auxPValueExt&j. as 
 select sum(MW) as stat 
  from MW; 
  quit; 
Data PValueExt; 
 set PValueExt auxPValueExt&j.; 
 run; 
%END; 
Proc sql; 
 create table distrib1 as 
 select a.stat, b.statObs 
  from PValueExt as a, statObs as b; 
*** Expected value and variance of exact Mann-Whitney distribution are stored in “distrib2” table; 
 create table distrib2 as 
  select mean(stat) as expected, var(stat) as varDistrib 
   from distrib1; 
 create table distrib3 as 
 select a.*, b.expected, b.varDistrib 
  from distrib1 as a, distrib2 as b; 
  quit; 
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Data distrib; 
 set distrib3; 
 absDelta=abs(stat-expected); 
 absObs=abs(statObs-expected); 
 run; 
*** 3rd step: exact p-value is calculated; 
Proc sql; 
 create table PValue as  
 select (count(*)) as freq, (calculated freq) / &nSimul. as probMW format=pvalue5.3 
  from distrib 
  where absDelta >= absObs; 
  quit; 
Data exactDistrib; 
 merge PValue distrib2; 
 run; 
Proc print Data=exactDistrib label; 
var expected varDistrib probMW; 
label expected = "Exact expected value" 
      varDistrib = "Exact variance" 
      probMW = "Exact p-value"; 
run; 
%MEND; 
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* ------------------------------------------------------------------------------------------------------------------------------ * 
* Program......: MW_ESTIM.SAS              * 
* Scope………..: Estimating credibility intervals of the additive treatment effect        * 
* Version……..: 1.0                * 
* Author………: Luca Porcu               * 
* Data created: 02SEP2019               * 
* Project: new statistical framework to analyze tumor growth curves         * 
* Example: %MW_ ESTIM (treatment= Doxorubicin,           * 
*                 control= Vehicle,            * 
*    interval= time1 time2 time3 time4 time5,         * 
*                 dSet= dSet,             * 
*    nSimul= 500,             * 
*    seed= 10,             * 
*    alpha= 0.05)             * 
* ------------------------------------------------------------------------------------------------------------------------------ * 
%MACRO MW_ ESTIM( 
treatment=,                          /*Treatment to be compared to the control arm*/ 
control=,                                         /*Control arm*/ 
interval=,              /*Names of tumor volume variables, at different time points*/ 
dSet=,                     /*Name of the dataset*/ 
nSimul=,                            /*Number of simulations*/ 
seed=,       /*Random seed used to initialize SAS pseudorandom number generator*/ 
alpha=                                                /*Probability not covered by the credible interval*/ 
); 
*** The "Delta" dataset is initialized. It will contain the set of slope differences between control and 
treatment arms;  
Data Delta; 
 length time $ 250; 
 time = ""; 
 if 0 = 1; 
 run; 
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*** The "MWexact" dataset is initialized. It will contain the exact distribution of the Mann-Whitney 
statistics under null hypothesis; 
Data MWexact; 
 length time $ 250; 
 time = ""; 
 if 0 = 1; 
 run; 
%LET count=1; 
%LET Pts=0; 
%DO %WHILE(%SCAN(&interval.,&count.,%str( )) ne %str( )); 
*** The number of observations at time &time. are calculated in control and treatment arms; 
%Let time=%SCAN(&interval.,&count.,%str( )); 
Proc sql noprint; 
 select count(&time.) 
  into :Ctr 
  from &dSet. 
  where arm = "&Control." and &time. ne .; 
 select count(&time.) 
  into :Trt 
  from &dset. 
  where arm = "&Treatment." and &time. ne .; 
  quit; 
%IF %EVAL(&Trt. > &Pts.) %THEN %DO; %LET Pts=&Trt.; %END; 
%IF %EVAL(&Ctr. > 0 AND &Trt. > 0) %THEN %DO; 
*** The "Delta" dataset is built; 
*** Each observation contains one value of the control arm and all available values of the treatment 
arm, at each time &time. In the "Delta" dataset differences between control and treatment values 
are calculated and stored; 
Proc transpose Data=&dset. out=wilc(drop= _name_) prefix=Trt; 
 var &time.; 
 where arm = "&Treatment." and &time. ne .; 
 run; 
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Proc sql; 
 create table Delta&time. as 
 select a.&time. as Ctr, b.* 
  from &dset. as a, wilc as b 
  where a.arm = "&Control."; 
  quit; 
Data Delta&time.; 
 set Delta&time.; 
 time = "&time."; 
 run; 
*** The exact distribution of the Mann-Whitney statistics under null hypothesis is calculated by 
resampling techniques; 
%DO j=1 %TO %EVAL(&nSimul.); 
%Let root=%EVAL(&seed.+&j.); 
proc surveyselect data=&dset. 
   method=srs n=&Ctr. out=SampleSRS noprint seed=&root.; 
   where arm in ("&Control.","&Treatment."); 
run; 
Proc sql noprint; 
 select quote(subject) 
  into :IDrandom separated by ',' 
  from SampleSRS; 
  quit; 
Data Sample; 
 set &dset. (where= (arm in("&Control.","&Treatment."))); 
 if subject in(&IDrandom.) then arm = "&Control."; 
 else arm = "&Treatment."; 
 run; 
Proc transpose Data=Sample out=MWset(drop= _name_) prefix=Trt; 
 var &time.; 
 where arm = "&Treatment." and &time. ne .; 
 run; 
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Proc sql; 
 create table auxMW1 as 
 select a.&time. as Ctr, b.* 
  from sample as a, MWset as b 
  where a.arm = "&Control."; 
  quit; 
%LET dimens = Trt%LEFT(&Trt.); 
Data auxMW2 (drop= i); 
 set auxMW1; 
 array rango (1:&Trt.) Trt1-&dimens.; 
 MW = 0; 
 do i=1 to &Trt.; 
 if Ctr > rango(i) then MW = MW + 1; 
 end; 
 run; 
Proc sql; 
 create table auxMW3&j. as 
  select sum(MW) as MWobs 
   from auxMW2; 
   quit; 
Data MWaux; 
 length time $ 250; 
 set auxMW3&j.; 
 time = "&time."; 
 run; 
Data MW&time.; 
 set MW&time. MWaux; 
 run; 
%END; 
Data MWexact; 
 set MWexact MW&time.; 
 run; 
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Data Delta; 
 set Delta Delta&time.; 
 run; 
%END; 
%LET count=%EVAL(&count.+1); 
%END; 
*** Slope differences between control and treatment arm are calculated at each time; 
Data Delta (drop= i); 
 set Delta; 
    array Trt (1:&Pts) Trt1-Trt&Pts.; 
    array diff (1:&Pts) Delta1-Delta&Pts.; 
 do i=1 to &Pts.; 
  if Trt(i) ne . then diff(i) = Trt(i)-Ctr; 
 end; 
 run; 
*** Slope differences between control and treatment arm are ordered by time and value; 
Data Ranking; 
 set Delta; 
    array diff (1:&Pts) Delta1-Delta&Pts.; 
 do i=1 to &Pts.; 
  Delta = diff(i); 
  if Delta ne . then do; keep time delta; output Ranking; end; 
 end; 
 run; 
Proc sort Data=Ranking; 
 by time delta; 
 run; 
Data Ranking; 
 retain rankDelta 1;  
 set Ranking; 
 by time; 
 if first.time then rankDelta = 1; 
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 else rankDelta = sum(rankDelta,1); 
 run; 
*** The probability distribution of the Mann-Whitney statistics under null hypothesis is calculated 
and stored in “ditrib” dataset; 
Proc sql; 
 create table ditrib as 
 select (count(MWobs)) as freq, (calculated freq) / &nSimul. as probMW, MWobs, time 
  from MWexact 
  group by time, MWobs 
  order by time, MWobs; 
  quit; 
*** The cumulative distribution of the Mann-Whitney statistics under null hypothesis is calculated 
and stored in “rankMW” dataset; 
Data rankMW; 
 retain cumProb rankMW; 
 set ditrib; 
 by time; 
 if first.time then do; rankMW = 1; cumProb = ProbMW; end; 
 else do; rankMW = sum(rankMW,1); cumProb = sum(cumProb,ProbMW); end; 
 run; 
*** Useful percentiles of the Mann-Whitney statistics under null hypothesis are calculated and 
stored in “posMW” dataset; 
Data posMW; 
 set rankMW; 
 by time; 
 if cumProb <= &alpha./2 then low = 1; else low = 0; 
 if 1-cumProb <= &alpha./2 then upp = 1; else upp = 0; 
 run; 
*** Theorem 5.5.2.1 is applied in the following SAS statements; 
Proc sql; 
 create table lowCI as 
 select max(MWobs) as lowCI, time 
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  from posMW 
  where low=1 
  group by time; 
 create table uppCI as 
 select min(MWobs) as uppCI, time 
  from posMW 
  where upp=1 
  group by time; 
 create table CI as 
  select a.time, a.lowCI, b.uppCI 
   from lowCI as a left join uppCI as b 
   on a.time=b.time 
   order by time; 
  quit; 
Proc sql; 
 create table Selection as  
 select a.*, b.lowCI, b.uppCI 
  from Ranking as a left join CI as b 
  on a.time=b.time 
  order by time, rankDelta; 
  quit; 
*** Credibility intervals of the additive effect are calculated by time interval; 
Data CredibilityInt; 
 length typeCI $ 3; 
 set Selection; 
 if rankDelta = lowCI then do; 
        typeCI = 'Low'; 
        CI = Delta; 
        keep time typeCI Delta; 
         output CredibilityInt; 
         end; 
 if rankDelta = uppCI then do; 
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        typeCI = 'Upp'; 
        CI = Delta; 
        keep time typeCI Delta; 
         output CredibilityInt; 
         end; 
 run; 
Proc sort Data=CredibilityInt; 
 by time typeCI; 
 run; 
Proc transpose Data=CredibilityInt out=ListOfValues (drop= _NAME_); 
 by time; 
 var Delta; 
 id typeCI; 
run; 
*** Output variables: time interval, lower estimate of the credibility interval, upper estimate of the 
credible interval; 
Proc sql; 
 select time, Low, Upp 
  from ListOfValues 
  order by time; 
  quit; 
%MEND; 
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Appendix F 
Tumor volumes (mm3) measured during the in vivo experiment with ML017/ET myxoid liposarcoma PDX 
    Days from treatment start 
Arm ID 0 4 7 12 15 18 21 26 29 34 36 40 43 46 
Vehicle 1 342,8 403,2 693,2 1004,2 1422,6 1933,0 2244,8 
       
Vehicle 2 203,0 253,5 267,4 346,2 501,4 688,3 946,4 
       
Vehicle 3 316,5 437,8 563,1 983,6 1150,5 1467,2 1880,8 
       
Vehicle 4 296,9 466,3 642,9 1102,8 1403,1 2011,2 2633,9 
       
Vehicle 5 269,7 351,3 496,7 720,0 1074,2 1317,9 1351,3 
       
Vehicle 6 191,4 316,0 431,5 848,2 1412,9 2064,9 2505,8 
       
Vehicle 7 280,5 557,6 736,7 1256,1 1522,6 1948,0 2548,4 
       
Vehicle 8 215,6 320,6 468,0 779,5 1085,4 1500,8 2113,3 
       
Vehicle 9 163,2 274,8 346,8 577,1 779,6 943,3 1248,6 
       
Vehicle 10 311,7 481,4 770,6 1301,7 2193,5 2862,9 3899,9 
       
Vehicle 11 150,3 127,7 141,3 200,4 244,9 267,8 400,9 
       
Vehicle 12 211,0 287,1 622,7 967,9 838,0 604,8 564,0 
       
Pioglitazone 13 395,2 695,4 870,7 2060,4 2543,0 3098,3 3753,2 
       
Pioglitazone 14 320,9 460,4 731,1 1311,5 1734,9 1923,8 2369,9 
       
Pioglitazone 15 105,3 190,2 254,0 514,1 636,2 875,9 1204,4 
       
Pioglitazone 16 318,1 485,4 1013,9 1235,0 1505,0 1657,3 1955,5 
       
180 
 
  Days from treatment start 
Arm ID 0 4 7 12 15 18 21 26 29 34 36 40 43 46 
Pioglitazone 17 142,2 176,7 232,1 256,7 396,0 388,4 415,5 
       
Pioglitazone 18 315,3 704,1 1300,9 1563,2 1712,3 1572,0 1592,3 
       
Pioglitazone 19 279,8 484,1 708,1 1154,4 1346,7 1378,5 1318,9 
       
Pioglitazone 20 184,8 354,8 547,0 768,0 890,0 935,4 1049,7 
       
Pioglitazone 21 162,7 255,3 504,3 683,5 914,2 991,0 1120,9 
       
Pioglitazone 22 254,3 393,9 716,9 997,2 1467,3 1701,1 2135,9 
       
Pioglitazone 23 227,6 368,5 616,8 1015,4 1089,4 1240,9 1455,0 
       
Trabectedin 24 119,4 131,0 193,5 198,1 232,1 165,3 211,1 252,7 313,0 
     
Trabectedin 25 342,4 396,6 523,7 648,5 720,8 675,5 817,7 989,4 1013,3 
     
Trabectedin 26 305,8 499,8 679,4 1133,5 1148,3 1367,7 2359,4 3826,2 4613,0 
     
Trabectedin 27 191,3 228,3 276,9 260,5 330,9 428,4 543,3 671,3 931,7 
     
Trabectedin 28 321,5 325,3 401,5 564,6 790,6 884,8 1259,8 1902,1 2495,9 
     
Trabectedin 29 275,5 483,8 610,1 771,8 887,4 949,3 1107,5 1076,9 1441,0 
     
Trabectedin 30 264,5 305,3 311,2 510,3 695,7 515,9 695,2 862,8 789,7 
     
Trabectedin 31 203,6 225,6 380,3 401,3 572,2 585,5 978,0 1679,6 2296,1 
     
Trabectedin 32 182,2 257,2 318,2 377,9 496,4 531,7 720,8 808,9 1186,5 
     
Trabectedin 33 277,5 370,4 561,8 579,5 747,6 818,4 1276,5 1428,5 1937,9 
     
Trabectedin 34 213,8 317,9 523,8 630,5 886,4 1151,7 1545,5 2113,4 3145,8 
     
Trab + Pio 35 107,7 156,8 256,8 276,4 295,2 273,7 342,0 402,2 433,9 555,6 559,0 578,1 679,8 732,9 
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  Days from treatment start 
Arm ID 0 4 7 12 15 18 21 26 29 34 36 40 43 46 
Trab + Pio 36 384,8 460,1 631,1 792,8 805,6 843,3 817,8 860,0 889,4 1003,4 1183,9 1420,4 1861,2 2022,9 
Trab + Pio 37 330,2 522,6 702,5 1068,6 1233,8 1034,7 1209,3 1383,6 1390,7 1601,3 1567,6 1724,6 2027,8 2258,1 
Trab + Pio 38 281,8 304,0 487,3 701,8 721,0 835,5 854,5 894,8 983,2 1121,8 1140,7 1367,1 1576,9 1849,5 
Trab + Pio 39 251,2 306,9 339,1 344,3 369,6 348,4 379,2 291,9 346,6 434,4 423,9 449,3 560,6 616,2 
Trab + Pio 40 185,6 190,7 485,7 706,9 842,3 771,6 929,5 1108,8 1207,5 1488,7 1670,4 2066,0 2246,9 2760,1 
Trab + Pio 41 241,8 253,1 525,5 700,5 937,5 900,7 971,9 1170,2 1385,5 1496,1 1972,4 2553,1 2794,6 3383,7 
Trab + Pio 42 133,9 143,1 264,2 309,8 366,7 438,3 471,6 538,9 544,3 558,1 697,7 690,6 904,9 953,0 
Trab + Pio 43 314,7 296,8 566,8 688,5 737,1 776,8 893,1 894,4 1123,0 1244,7 1294,8 1299,2 1602,0 1473,9 
Trab + Pio 44 244,3 314,3 524,6 673,0 708,7 672,6 789,9 901,5 1103,4 1291,3 1436,9 1852,9 2249,9 2185,6 
Trab + Pio 45 225,2 348,7 555,8 669,2 686,0 742,4 812,1 1028,2 1168,4 1123,6 1306,4 1464,6 1699,4 2122,2 
 
 
 
